❌

Normal view

The US has officially lost control of measles

17 November 2026 at 17:40
A healthcare worker takes down signs at a Maryland vaccine clinic.
A healthcare worker takes down signs at a Maryland vaccine clinic. | Sarah L. Voisin/The Washington Post via Getty Images

This year, the United States has recorded more measles cases — 5,739 as of Tuesday, November 17 — than in the past 25 years combined. There are active outbreaks in New York, Pennsylvania, and across the Midwest. At least eight people have died with measles infections in the US.

None of this is supposed to happen in the 21st century. In 2000, the United States declared that measles had been eliminated. For years, the extremely rare cases the US saw were from people who contracted the virus in another country and brought it back to America; we didn’t have to worry about measles spreading naturally in our communities.

But that’s no longer true. The Pan American Health Organization, which works with the countries in the Western Hemisphere on ongoing public health threats as well as emergency response, made it official Monday after the annual meeting of its measles and rubella elimination commission: The United States’ measles elimination status has been revoked. The virus is once again endemic in America.

It is an international embarrassment for a country that until very recently was the world’s unquestioned global health leader. And for doctors here in the US who have been practicing for decades, it’s an almost-unthinkable development, putting American lives needlessly at risk. The death of a 7-month-old baby in New York state, who was too young to be vaccinated, has made the consequences of the country’s collective failure hauntingly clear. 

“It’s very, very, very surreal,” Dr. Barbara Keber, a family physician in Long Island, New York, told me last week. She’s been practicing medicine for 45 years and is old enough to have gotten measles herself when she was a child. But it was never something she’d had to deal with during her professional career — until now.

“When I had it, my sister had it, my best friend had it — that’s how I saw measles,” she said. “Then it disappeared, and I never saw it as a practicing physician until more recently.”

The reversal has been dramatic. In 2024, there were just a couple hundred measles cases in the US, nothing out of the ordinary. But last year, there were more than 2,000 measles cases and three deaths, and then both of those figures more than doubled in 2026. This year started with a brutal outbreak in South Carolina, and it is winding down with Pennsylvania in crisis and New York state reporting its first measles death in more than 30 years.

It’s impossible to talk about the recent rise of measles without talking about vaccine skepticism. Fears that childhood immunizations cause autism have been growing for years (reminder: they don’t), and the rise of US health secretary Robert F. Kennedy Jr. and a vast network of anti-science activists and politicians has led to widespread distrust in medical science and doctors since the pandemic began. As a result, fewer and fewer American kids are being given their measles shots. Nationwide, the measles vaccination rate is 92.4 percent among kindergarteners, down from 95 percent before the pandemic, which is the threshold public health experts say is necessary to stop the virus from spreading locally. And in some places, the decline has been more severe: In one Texas school district where measles ran wild last year, less than 50 percent of schoolchildren were vaccinated.

Over the past two years, I have spoken with doctors working on the front lines of these outbreaks to better understand what it’s like to face measles, often for the first time, and what they hear from their patients in the midst of an outbreak. I’ve taken away three lessons from those conversations, which serve as both an explanation of how we got here and a guide for what to expect as we try to find our way out of this crisis.

1. Small communities can be the kindling for measles outbreaks

One clear pattern has emerged across the recent outbreaks: They are often sparked in insular communities where anti-vaccine attitudes — sometimes the result of sincerely held religious reliefs — are widespread.

In New York and Pennsylvania right now, for example, measles has taken hold in Amish and Mennonite communities. Last year’s outbreak in Texas started in a Mennonite community as well. A charter school in South Carolina where less than 20 percent of kids were vaccinated against measles was the epicenter of that state’s outbreak. This is a pattern that predates our current measles explosion: When New York endured an isolated outbreak in 2019, it was concentrated in the Hasidic Jewish communities north of New York City.

Even in states like New York, where state officials have actually tried to strengthen school vaccine requirements, some parents in these communities have opted to homeschool their kids; they don’t have to follow those mandates. And when they do go out into the world, where more children may be vaccinated on average, they are increasingly likely to encounter another kid who is also unvaccinated as more families overall opt out of those shots.

That’s the recipe for these massive outbreaks: A lot of unvaccinated kids in one group get infected and then, as they move around the community, they come into contact with those other kids, who are also unprotected.

“These are groups that we have to work very carefully with because they have their religious beliefs. When you speak to them about vaccines, they’re just going to tell you no,” Keber told me. “But the issue there then becomes, well, they might not be being exposed during the school day, but they go and play baseball and they do dance and they do other activities where they’re mixing with other kids.”

In some of these communities, skepticism has remained stubbornly high even in the aftermath of an outbreak. But some people do take the threat of measles more seriously after people get sick around them. Keber told me that fear is not really the most effective message for convincing previously skeptical people to get themselves or their children vaccinated; relationship building over time — even if it takes a couple of conversations — is more effective.

“We’re not trying to scare people. That doesn’t really help anything,” Keber said. “If they get to trust the physician, that’s the biggest bang for the buck. This is somebody that you trust with the health of yourself and your family.”

2. Doctors are still figuring out how to deal with measles in the wild

Measles may be one of the most well-known diseases given its high infectiousness and signature rashes, but because it had been eliminated for so long, many doctors have had only an academic understanding of the virus — at least until these past few years.

“Almost no physicians that are currently practicing medicine have ever seen measles,” Keber said.

When I spoke last year to Dr. Ada Stewart, a family physician in Columbia, South Carolina, who has been practicing medicine for more than 20 years, she told me the same thing. At the time, she and her colleagues were reviewing their old medical school materials to make sure they knew all the signs and symptoms.

“We learned those things in medical school, but we never saw it,” Steward said. “We never had to worry about seeing it.”

When both doctors and patients are a step behind because they’re unfamiliar with measles, the virus can flourish. As Keber told me, somebody who’s not immune to measles has a 90 percent chance of catching it if they are exposed. And people can be contagious up to four days before the telltale skin rashes appear.

The early symptoms can resemble lots of other conditions: high fever, cough, runny nose, or red, watery eyes. Until very recently, Americans and their doctors didn’t have to worry whether those might be signs of a measles infection. But now they do.

“That makes it a little more dangerous than some other things where you know right away if somebody’s sick,” Keber said.

3. It’s going to take a long time to get measles under control

One of the observations that has stuck with me most came from Dr. Andrew Carroll, a family physician in Chandler, Arizona, a suburb outside of Phoenix. He told me there were two groups of people who seemed most fearful about measles when it began to spread locally: The older generation, who remembered what the disease was like, and the youngest patients for whom it was an entirely foreign and frightening pathogen. 

The people in the middle, who grew up at the time the US was successfully stamping out measles and knew it only as a public health victory, were less bothered. It is one of the great dilemmas in public health: When you eradicate a disease, people become less concerned about it — and that can create the conditions for its return. We’re seeing that with measles: a swath new parents, for whom the virus was never a serious worry, are choosing not to vaccinate their own children, and that has helped the virus to surge back.

“It only takes one generation to forget the progress we’ve made on certain things — and one of those is measles,” Carroll told me. “Twenty-five years ago, we were a measles-free nation. Now we’re back one generation later because we forgot how terrible it was.”

And that may mean that, ultimately, it will take another generation coming of age and having their own kids — who, having been chastened by the outbreaks we’re experiencing right now, help vaccination rates recover to the point that we can eliminate measles a second time. 

“We’re going through a cycle, and there will be casualties. There will be needless deaths and illnesses,” Dr. Jason Terk, a pediatrician in north Texas, told me last year. “I think that the only generation that is going to learn from this will be maybe the next one.”

How the 7 healthcare workers who just got elected to Congress plan to fix our broken system

12 November 2026 at 22:45
New members of Congress on Capitol Hill.
Newly elected members of Congress on Capitol Hill. | Andrew Harnik/Getty Images

Last week’s blue tsunami carried a lot of white coats: At least seven newly elected Democrats have medical degrees or nursing careers. Pediatrician Annie Andrews of South Carolina scored one of the most shocking Senate victories of election night for Democrats, while Abdul El-Sayed (who earned a medical degree before working in public health) won the all-important Michigan Senate race. In the House, Democrats will soon welcome pediatrician Richard Pan of California, emergency room physician Amish Shah of Arizona, surgeon Adam Hamawy of New Jersey, emergency nurse Mitchell Berman of Wisconsin, and oncology nurse practitioner Kristina Knickerbocker of Ohio.

Like many Democrats, these candidates campaigned on lowering costs, expanding health coverage, and confronting the drugmakers and healthcare corporations that they accuse of putting profits ahead of patients. They have endorsed big ideas to make healthcare better, from a public insurance option to Medicare-for-all, alongside targeted changes to drug prices and health insurance denials.

With President Donald Trump still in the White House, Democrats’ healthcare agenda faces obvious obstacles in the short term. But I spoke with Pan and Shah this week to learn how they hope to influence the healthcare conversation in Washington going forward. 

They may be politicians, but they have seen America’s broken healthcare up close. They’re hoping to help some of their new colleagues, who may not have those same experiences and may be prone to thinking of policy issues in abstract terms, understand the urgency and the human toll of our messed-up medical system. And as lawmakers try to come up with solutions to fix those problems, they’ll be there to make sure those policies actually make sense in practice.

“For us, these policy discussions are not abstract,” Pan said. “As a practicing physician, I know what it’s like to be on the front lines and have to look a patient in the eye and even tell them that, well, these programs either exist or don’t exist, and we’re not going to be able to get you help. And those are the types of things I have to deal with each time I see a patient.”

What practicing medicine teaches you about politics

The new members will join a small but notable group of providers-turned-politicians: The Congressional Doctors Caucus, founded last year, had six Democratic members before last week’s midterms. Shah, who previously served in the Arizona legislature, told me that he believed his medical career had given him a valuable outlook for thinking about how to serve in political office.

“The core function of practicing medicine is to care for people,” Shah said. “The same should really be true about politics.”

He’s experienced the shocking inequities of US healthcare, and seen its impact on people’s well-being, firsthand. Earlier this year, Shah said, an uninsured woman came into his emergency room department with an allergic reaction. His team treated her successfully. But she was worried about the bill, asking if she might have to pay a $10,000 charge after she was discharged. And Shah told me that he had to be honest with her that she might.

That’s when he learned that his patient was her family’s breadwinner — and that she actually worked in a nearby emergency department. Somebody who helped provide emergency care to others couldn’t afford it herself.

“It’s a tragedy that those of us who actually go out to help others and be part of the team that saves lives can be left without insurance,” Shah said.

Pan, a former California state senator, described a similar experience while treating kids in primary care. He has seen all the ways US health care is lacking: children who don’t get the mental health support they need to excel in school, families that struggle to afford stable housing or find healthy food. His ability to help depended on decisions made well outside his examination room.

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

“These are all things that certainly have potential policy solutions, but it’s not just theoretical,” he told me. “It is very real and tied to very specific patients that I’ve seen.”

But while these experiences have made them eager to change things, the newly elected physicians are also mindful about how proposed changes could disrupt ongoing patient care. Pan said he wants to push his colleagues about both the intended and unintended consequences or new policies: Who will get help? What happens to people whose needs don’t fit neatly into boxes? As any doctor will tell you, every patient is unique.

That’s especially true for people with chronic conditions, he said, who may have spent years finding the right doctors and treatments. Lawmakers have to strike a balance: identifying ideas that will improve the health system in the long term, without jeopardizing the care that people need right now.

Shah said he hopes his experience as a physician can help Congress find a middle ground between the patients demanding reform and the providers who are wary of big changes. After decades in medicine and a stint in the state legislature, he knows the different players and their concerns.

“I speak the language of healthcare,” he said. “I’ve earned the trust of a lot of those stakeholders that I will not take an axe to the system, but rather reform it in a way that really improves it and centers the patient. So that gives me a unique ability to improve this at the congressional level.”

What the new doctors and nurses want to change

These Democratic doctors, like their party’s leaders, have a clear No. 1 priority when they take office next year: reversing the $1 trillion in Medicaid cuts that Republicans passed as part of the One Big Beautiful Bill Act in 2025.

“Given all the damage the Republicans did in the past two years, first we got to triage to stop the bleeding,” Pan told me. He wants to repeal the OBBBA’s Medicaid work requirements, restore the lapsed Affordable Care Act tax credits that helped reduce premiums for millions of Americans, and protect Medicare payments. Those were common themes across these physician-politicians: Andrews, Berman, and El-Sayed endorsed the same policies as part of their campaign platform, while Knickerbocker likewise pledged to protect Medicaid, Medicare, the ACA, and children’s health coverage.

Beyond reversing the Republican cuts, the newcomers want to cover more people, though they have different ideas about how to do it.

“You have these real stories that then drive the legislation, and give you the ideas to solve the problems for people.”

Amish Shah, emergency room physician elected in Arizona

Shah said he supports letting people buy into Medicare. Andrews, Berman, Knickerbocker, and Shah have also endorsed a public option: a government-backed health insurance plan that would compete with private plans. El-Sayed and Hamawy, meanwhile, say they favor Medicare-for-all, guaranteeing comprehensive coverage without premiums or out-of-pocket costs.

“I want to see every United States citizen covered, and I’d like to see the premiums drop,” Shah said.

But even the people who have health insurance often struggle to pay for medical care. Andrews, Berman, El-Sayed, and Hamawy have all proposed expanding the government’s negotiation of prescription drug prices. Andrews and Berman want to extend Medicare’s $35 insulin cap to private insurance. Andrews, Berman, and Hamawy also want to crack down on private equity ownership and consolidation among healthcare providers.

Perhaps unsurprisingly, these doctors were not afraid to get into the weeds of healthcare policy on the campaign trail. Andrews’s detailed plans include limits on some hospital prices and changing Medicare payments so the same service costs the same regardless of where it is performed. Berman’s agenda draws on his own nursing experience: He wants nurses to help set staffing standards, more funding for nursing education, and enhance workplace safety for medical workers, a goal he shares with Shah. In Arizona, Shah worked on protections for healthcare workers, and he wants Congress to focus on the problem too.

Pan also wants to figure out how to restore trust in public health after two years of US Health Secretary Robert F. Kennedy Jr. undermining faith in vaccinations and other medical science. He helped write California laws tightening exemptions from school vaccination requirements; in Congress, he wants stronger oversight of the administration’s healthcare agencies, including probing any possible corruption, and stronger protections for scientific decision-making. He told me that lawmakers may want to consider creating new safeguards into law so future administrations have less latitude to overhaul public health policy.

“The American people need accurate information from their government,” Pan said. “We might want to rethink how to put better guardrails so that someone like an RFK Jr. in the future couldn’t…basically upend everything.”

Andrews and Shah have also placed a lot of emphasis on fixing prior authorizations, one of the most common frustrations for patients and providers alike.

Shah recalled that he once met a Republican constituent who said he was completing prior authorization paperwork on behalf of the doctor treating his son, who had muscular dystrophy, because the doctor’s office was overwhelmed. He was shouldering an absurd administrative burden as a layperson, just so his child could get the care he needed. 

And so, Shah worked on legislation to streamline the prior authorization process. A 2021 law standardized prior authorization forms and limited their length to two pages, excluding supporting medical documentation. He sees his state work as a possible model for federal legislation.

“We really need to start looking at these denials,” he said. He wants more scrutiny of decisions that are later overturned and of automated and increasing AI-driven systems that reject people’s claims without meaningful review.

It’s another example of how these freshman members will be ready to dive into the weeds of fixing healthcare. The question will be whether the new lawmakers can translate their direct experience with patients’ frustrations into changes that make getting healthcare care easier.

“You have these real stories that then drive the legislation,” Shah said, “and give you the ideas to solve the problems for people.”

A million people could gain health insurance in Texas after Democrats’ shocking win

4 November 2026 at 19:25
Gina Hinojosa speaks to supporters.
Gina Hinojosa speaks to supporters as she is announced as the next governor of Texas on election night, November 3, 2026. | Mikala Compton/The Austin American-Statesman via Getty Images

On election night in Texas, the impossible became possible. Democrats won the governor’s seat for the first time since the 1990s and appear to be on their way to securing control of the state House too. Those massive, unexpected wins have now opened the window for a major policy change that has long been closed: expanding Medicaid to more than a million low-income Texans.

The Affordable Care Act offers generous funding for states to expand Medicaid eligibility to 133 percent of the federal poverty level, which is about $21,000 for one person or $44,000 for a family of three. But the Supreme Court ruled in 2012 that states should have a choice about whether or not to accept the expansion. And even though many other GOP-led states decided to adopt it, Texas is one of the 10 that have steadfastly refused to extend Medicaid coverage to many of its poorest citizens — and it’s by far the biggest. KFF estimates that 1.1 million people in Texas would be eligible for Medicaid expansion, including 605,000 who have no other insurance options without it. In resisting expansion over the years, Republicans have argued that the Medicaid program was broken and already too expensive and that uninsured people should instead be able to get coverage by finding a job that offers health benefits. 

New Democratic Gov.-elect Gina Hinojosa pledged to pursue expansion if elected, framing it as a way to help the state’s children. If she can find a way to get the state legislature on board, Medicaid expansion in Texas would be one of the biggest direct consequences of 2026’s blue tsunami. Texas has the highest uninsured rate of any state in the country at 19 percent.

“We expect expansion to be a priority in the next legislative session. It’s a life-saver in the short term and a money-saver in the long term,” Lynn Cowles, director of health and food justice at the advocacy group Every Texan, told me in an email. “We’re excited to work with our next state legislature that convenes in January to make expansion a reality.”

There is still work to do. But Democrats are in the strongest negotiating position they’ve ever had in the Lone Star State. As of Wednesday afternoon, Dems had clinched control of the Texas House for the first time in more than 20 years. That will allow them to force a more serious conversation about expansion.

“You should expect to see Medicaid expansion bills filed on November 9, which is our first day for early bill filing,” said Bee Moorhead, executive director of Texas Impact. “Absolutely, it will be on the table.”

It’s not a guarantee because Republicans retain control of the state Senate. Still, there is some optimism that the sweeping Democratic victories in Texas and across the country could make the GOP more amenable to compromise. 

Democrats will have one important ally in their fight: Texas hospitals, which have long supported expansion. Their political influence and the threat of Trump-approved Medicaid cuts leading to rural hospital closures — a major theme of Hinojosa’s campaign — could put pressure on Republicans to find a middle ground with the Democrats now in power.

But hospital leaders, having seen dreams of Medicaid expansion in Texas fall short before, aren’t declaring victory yet. Until some of the Texas Senate Republicans who have opposed Medicaid expansion in the past announce that they’re now open to a compromise, the GOP’s control of that chamber could be enough to continue blocking Medicaid expansion in Texas for the time being.

“Everything changed last night. But just because everything changed doesn’t mean everything changes,” John Henderson, president and CEO of the Texas Organization of Rural & Community Hospitals, told me. “We’re gonna have a different climate and different priorities in the next session. But some of these really ambitious policies still have obstacles to clear.”

Texans have been waiting for Medicaid expansion for a long time: A 2020 poll found that 69 percent of the state’s voters supported the policy. But Republican leaders, including now-ousted Republican Gov. Greg Abbott, refused to budge.

There is no guarantee that the stunning midterm results will finally break that logjam. It will require deft politicking by the new Democrats in power. But for the first time, there is real reason for hope.

What Democrats could actually do to lower your healthcare costs

5 November 2026 at 16:35
Protesters urge healthcare reform at the US Capitol, one holding a sign reading “Sick of it! Fix health care now”.

Democrats’ massive wins on election night in Congress — and state races across the country — have opened the door for the party to deliver on one of its biggest campaign promises: making people’s healthcare cheaper.

When Democratic House leader Hakeem Jeffries declared victory on Tuesday night, he promised that his new majority would try to undo the massive Medicaid cuts that the GOP Congress approved in 2025. A new class of Democratic senators — including James Talarico in Texas, Abdul El-Sayed in Michigan, and Annie Andrews in South Carolina — are coming to Washington having backed a diverse suite of health policy ideas, from major overhauls like Medicare-for-all to targeted reforms like ending prior authorization for some services.

Change doesn’t come easily, however, and people should keep their expectations in check: President Donald Trump is still in the White House, and that will limit how much policy work gets done in the next two years. 

But that doesn’t mean we’re stuck, either. Everybody recognizes US healthcare is a mess, and lawmakers from both parties have expressed interest in smaller-scale changes that could actually pass in the next few years and get Trump’s signature. Given how massive the Democratic wins were, Republicans in Congress and even Trump himself may have a political incentive to cooperate with the new Democratic majorities: By a 19-point margin, voters said they trusted Democrats more than Republicans to address healthcare costs, according to a KFF analysis of exit poll data. And at the state level, Democrats will have freer rein to do what they want in the near term.

Larry Levitt, executive vice president for health policy at KFF, said he expects Democrats to push through ambitious healthcare bills — such as a repeal of the One Big Beautiful Bill Act’s healthcare provisions — that Trump will veto. “Then the game of chess between Democrats and Trump will begin to figure out what on healthcare can actually get enacted,” he said.

The other looming issue for Democrats will be the 2028 presidential campaign, in which candidates will have to figure out how much to promise if they win full control of the federal government. It could be a messy intra-party fight — or they could use this time to find a consensus that allows them to actually pass a bill in a few years. Will the progressive wing push hard for Medicare-for-all? Can Democrats unite around a public option?

These questions won’t be answered definitively before 2029 — but whether Democrats can start to make headway in bridging their differences or not will go a long way toward determining what’s possible.

There are a lot of balls in the air at once, even as Americans are desperate for relief right now. Here is how US healthcare could actually change at the federal and state level in the short term — and a look ahead at the long-term prospects for more far-reaching reforms.

What Congress could do in the short term on healthcare

Trump’s veto pen will dictate how far Democrats can go in the next two years. But there could be room for compromise. Both parties have serious criticisms of the health system, and, on some narrow problems, the two sides are actually pretty aligned on a need to do something. Those issues are the best bets for action in the next two years.

1) Reforms for Medicare payments

One top target would be limited Medicare payment reforms. Medicare is the single biggest healthcare program in the US, and even smaller-scale changes could help reduce premiums and out-of-pocket costs for millions of American seniors, while saving taxpayers money.

Here’s one opportunity for change: Under the current Medicare payment system, the price of a procedure is based in part on where the procedure is being done. So the cost of the exact same service could vary widely based simply on which building it’s performed in: A routine injection for knee pain or inflammation could cost $65 in a doctor’s office — but more than $300 if it’s done at a hospital’s outpatient clinic. 

The reason for that huge discrepancy is that Medicare allows hospitals to charge a separate “facility fee” on top of the charge for the service itself. While the exact solution would need to be worked out by lawmakers, both sides have endorsed the idea of ensuring procedures cost the same no matter where they are performed. 

That would be a win for patients, because their out-of-pocket costs are based on the total bill. And while the effect may not be enormous, lower hospital spending could also help soften premium hikes in the years to come for all Medicare enrollees.

It’s a policy change that hospitals have long opposed, because they don’t want their payments cut. But DC insiders believe the appetite could be growing to do something about that and other narrow billing issues. Former Democratic healthcare adviser Ezekiel Emanuel and Trump healthcare ally Brian Blase co-authored a Washington Post op-ed endorsing a fix during the week leading up to the midterms.

“Hospitals will always have their friends and allies,” Kim Monk, who tracks healthcare policy for the investment research firm Capital Alpha, said. “They’re the largest employers in a lot of districts. Nobody wants their hospital to close. But I think there’s also a healthy amount of skepticism around, well, wait a minute…what are these billing practices? I think it’s at least something that Congress is willing to take a look at.”

And given how roundly voters rejected AI in the midterms, Democrats could also feel empowered to push for more transparency or even restrictions on how Medicare Advantage plans use AI in ways that lead to patients being denied coverage for medical services.

2) Fixing the No Surprises Act

Of course, fixing healthcare is easier said than done — and sometimes well-intentioned policies don’t work. That’s why the next Congress could also look at remedying an earlier bill that aimed to address hospital billing but has gone awry in practice. The No Surprises Act passed in late 2020 (and was signed by Trump) to try to make sure that Americans didn’t get a massive bill if they were treated by an out-of-network provider when taken to a hospital for an emergency.

But the arbitration process that the legislation had set up to figure out how much the hospital should be paid by the person’s insurer in that scenario has been a mess, with a huge backlog waiting to be cleared. “The No Surprises Act obviously is not working as intended. Maybe they can fix it,” Monk told me. “That’s another one we’re watching.”

Insurers have blamed the law and its alleged favoritism toward providers in the arbitration process for contributing to recent premium hikes, and Democrats argue that creating a simpler system would help rein in rate increases for everyone.

3) Making medications cheaper

Drug costs are a particular point of frustration for most Americans — and it’s another area where both Democrats and Republicans have been circling some of the same policy solutions.

For instance, many Americans with diabetes still struggle to afford insulin, and there is one proposed solution in Congress that already has bipartisan support: a $35 cap for private health insurance plans, matching the cap that already exists in Medicare. Members from both parties have also co-sponsored bills making technical changes to prevent drug companies from using patent law to extend their monopolies and stave off generic competition, which could help bring cheaper versions of breakthrough drugs to the market sooner. One such bill passed the Senate unanimously over the summer, but was never taken up by the GOP-led House.

Democrats could test Trump’s willingness to cut a healthcare deal by pushing legislation based on an idea he himself has endorsed: tying US drug prices to international averages. Democrats could also look to expand Medicare drug negotiations and make more medications eligible for cheaper prices. It’s in theory an issue where they could pick off some Republicans and even win over Trump, who has endorsed negotiations in the past.

4) Reversing the GOP’s Medicaid cuts

One other unlikely change is still worth mentioning: Democrats are going to try to reverse the One Big Beautiful Bill Act’s Medicaid cuts and restore lapsed funding for the ACA marketplaces. They have said that’s their top priority. 

Trump probably isn’t going to sign a law repealing a big part of his own signature bill. But the new Democratic majorities are certainly going to press: DC insiders told me they expect Democrats to put together a healthcare-focused budget reconciliation package that can pass the Senate with only 50 votes and make overturning the Medicaid cuts its centerpiece. 

This approach will allow them to make the case that they are trying to undo the damage that they accused Trump and the Republicans of inflicting throughout the 2026 campaign. It will force Republicans to take tough votes on an issue that has already cost them dearly at the ballot box. And it sets the stage to make a more serious run at overturning the OBBBA if Democrats win full control of the government in 2029.

“That’s an opportunity for them to drive a wedge right into the Republicans,” Monk said. “Make Trump veto it. It becomes a 2028 issue.”

What states could do on healthcare after the 2026 elections

States have less sway than the federal government in shaping healthcare policy: They can’t touch Medicare, for example, nor the large employer plans that cover tens of millions of people. But they can still take some steps to make healthcare more affordable. In states where Democrats will assume full control of the government, they will have more leeway to pursue whatever agenda they wish and get creative with how they leverage state budgets and expand coverage or control medical costs. The question is whether the new administrations decide to make a major healthcare push a priority.

5) Medicaid expansion

Democratic victories in Georgia and Texas could finally open the door to expanding Medicaid through the ACA in those states. Under the law, states can receive generous federal funding in exchange for expanding Medicaid eligibility to all people making 133 percent of the federal poverty level or less (that’s about $21,000 for an individual or $44,000 for a family of three). But after the Supreme Court decided in 2012 that the expansion had to be optional for states, 10 states have resolutely refused to accept it — with Texas in particular being the biggest holdout.

Democrat Keisha Lance Bottoms, elected Georgia’s next governor, said she would make expanding Medicaid a priority, and Democrats look likely to win control of the state House there. In Texas, Democrat Gov.-elect Gina Hinojosa also ran on covering more people through the state’s program; Democrats are likewise leading the race for the state House majority. It looks like a real possibility for the first time since the law passed in 2010. However, their success is not assured: It appears both newly elected Democrats will have to negotiate with a Republican state Senate if they are going to make expansion happen.

If those states did expand Medicaid, it could be one of the biggest impacts of the 2026 election: An estimated 1.1 million people would be covered in Texas, and another 144,000 people would get coverage in Georgia.

6) Public health insurance options

The most sweeping policy change proposed across multiple states is the creation of a new public insurance option. Public options were put forward by Democratic gubernatorial candidates in Wisconsin, Maine and New Mexico, and all three candidates prevailed on Tuesday night. In Wisconsin, Democrats actually secured full control of the state legislature for the first time in over a decade.

Colorado and Washington have had public options up and running for a few years now, setting a template that these other states could draw from. That could allow their public options plans to quickly take shape and deliver more coverage options for people in those states in the next few years.

7) Prescription drug prices

Prescription drug prices are another area where states have some limited authority to make changes in the short term. Democrats ran on prescription drug initiatives in the governors’ races in Michigan, Nevada, Maine, and Georgia, and all of those candidates won their races, including Bottoms’s historic triumph in Georgia. Some of their specific proposals included capping Medicaid prices for drugs at Medicare-negotiated rates and establishing state boards to review drug costs.

8) Canceling medical debt

Canceling medical debt was put forward by Democrats in Ohio, Nevada, and Michigan, paired with technical provisions around how healthcare debt is reported for credit scores. Once again, on a very good night for Democrats nationwide, all three candidates — Amy Acton, Aaron Ford, and Jocelyn Benson, respectively — won their elections and will have a chance to try to enact the policy in office.

9) Protecting abortion rights

One healthcare issue where states hold more power than the federal government is abortion access. In Missouri, Nevada, and Virginia, voters backed direct ballot initiatives to protect the right to have an abortion. And the Democratic victories in Wisconsin, North Carolina, Iowa, and Georgia could allow politicians in those states to either restore abortion access (by, for example, reversing an existing six-week ban in Georgia) or at least preserve it (by blocking any new restrictions, as in North Carolina after Dems seized control of the state House there).

10) Serve as an incubator for other unique healthcare policies

States are laboratories for policy innovation. The Massachusetts health reform experiment of the early 2000s turned into the Affordable Care Act for the entire country. The public options currently being test-driven at the state level could be the template for a national program. For any Democratic governors who have national ambitions, making a push in the next two years could pay off in two ways: delivering results for constituents and elevating their political profile.

Several Democrats proposed bespoke healthcare policies that they can now try to pass. In New Mexico, Democratic Gov.-elect Deb Haaland has pledged to place a limit on private equity’s ownership of healthcare providers and prohibit interference with clinical decision-making. Minnesota Democrats could aim to approve new state assistance for people who purchase insurance on the ACA marketplaces, in order to try to soften their premium increases.

It will be worth watching whether these efforts and others can gain traction and ultimately achieve results. Private equity’s encroachment into healthcare has raised serious concerns about the quest for profits negatively affecting patient care — can states identify effective strategies for pushing back and preventing those adverse outcomes? Can they use state funding to lower healthcare costs for the people they represent? We shall see.

Democrats need to figure out their long-term healthcare agenda

Even with some short-term relief, America’s healthcare crisis isn’t going away. People are fed up: Millions of people are losing their insurance, and millions more are seeing their premiums spike while struggling to afford medical bills. There is going to be pressure for Democrats to think big in the next two years, especially as the presidential race heats up and lawmakers look ahead to 2029.

“That aspirational agenda has no chance of passing the next two years, but it will lay down important markers if Democrats win the presidency and congressional majorities in 2028,” Jonathan Oberlander, professor of social medicine at the University of North Carolina and the former editor of the Journal of Health Politics, Policy, and Law, told me.

The pressure could increase if, as expected, Democrats cannot restore funding for Medicaid or the ACA while Trump is president. According to the Commonwealth Fund, the US uninsured rate spiked from 9 percent in 2024 to 11 percent in 2026. Those losses could grow in the next year as costs continue to rise for millions of people. That’s the kind of crisis that demands a policy response.

Congress and the presidential primary will be the forums for figuring out the party’s long-term plans. Candidates will put forward proposals. House and Senate committees will surely hold hearings to explore a variety of ideas; as Monk described it to me, Democrats are currently in an “all ideas are welcome” phase. 

A lot of attention will focus on Medicare-for-all or public option proposals. But Democrats have other big ideas they can start working on now, too. They could develop plans to improve Medicare benefits for current enrollees: Sen. Bernie Sanders (I-VT) has signaled he wants to make this a priority by adding vision, dental, and hearing benefits, for example. They could also work on a long-term care plan; Sen. Ron Wyden (D-OR) has been soliciting ideas. This is leftover business from the ACA — a long-term care insurance plan that passed as part of the original bill was dropped before ever taking effect — and the issue is becoming more urgent as the baby boomer generation gets older.

The real push for those policies might have to wait for 2029. But Democrats can start trying to build a consensus now.

And as they begin to identify policies to move on in 2029, they could even start figuring out what is passable via budget reconciliation ahead of the 2028 election. The Senate’s procedural rules create important guardrails for what can pass with less than 60 votes and navigating that byzantine process can be a headache; getting a head start over the next two years would help grease the wheels for quick action if Democrats control the entire government in 2029.

So even though the short-term prospects for change may be limited, this week’s elections and the policy work to come could still prove pivotal in the effort to fix American healthcare.

Forget tainted candy: The scariest thing on Halloween is parked in your driveway

30 October 2026 at 15:00
a split-view including an illustration of a car approaching head-on and a neighborhood on Halloween night

As is the custom, millions of children in the United States will be out in the streets this Halloween to trick-or-treat, decked out in costumes. Also as is custom, adults will fret about the mostly mythical dangers children may face. Once upon a time it was razor blades in apples; this year, it’s rainbow fentanyl in candy. But while fears of children receiving narcotic-spiked treats are unfounded, there is a very real danger that America’s children face on this most hallowed of evenings: cars. 

That’s because pedestrians under the age of 18 are three times more likely to be struck and killed by a car on Halloween than any other day of the year. A 2026 analysis of federal crash records found that 45 children were killed while walking on Halloween between 2010 and 2024, more than any other day. That risk grows to 10 times more likely for children aged 4 to 8 years old, according to a study from 2019 in JAMA Pediatrics. 

“You’re going to have increased numbers of children, including younger children who are out on the streets,” said Lois Lee, a professor of pediatrics and emergency medicine at Harvard Medical School. “At the same time, you have adults who are driving, and especially this year on a Monday, people will be driving home from work. If children are in costume, they may be wearing darker clothing … which makes them harder to detect.”

The JAMA Pediatrics study from 2019 corroborates this, noting that Halloween “may heighten pedestrian traffic risk, because celebrations occur at dusk, masks restrict peripheral vision, costumes limit visibility, street-crossing safety is neglected, and some partygoers are impaired by alcohol.” It’s the kind of lethal combination that can turn a fun occasion into a deadly nightmare. Adult victims included, the risk of death to all pedestrians was 43 percent higher on Halloween compared to a regular evening.

But what happens on Halloween isn’t an isolated incident. After gun injuries, motor vehicle injuries are the second leading cause of death among children in the US overall. And with pedestrian fatalities (both adult and child) at a 40-year high in the US, it’s worth asking why children roaming the streets is so inherently deadly, and what can be done about it.

“Sometimes when you talk about this issue, you get pushback from people and people say, ‘Well, of course, you have more children on the streets, of course, more children are going to die,’” Doug Gordon, a writer and podcast host who advocates for safer streets and cities, told me. “But that accepts a baseline level of danger that I think we as a society have in fact accepted on the other 364 days of the year.”

There are broader reasons for why streets have gotten even more dangerous for pedestrians recently. One is that drivers are distracted — not just by their phones, but increasingly by the infotainment systems that come as a part of newer cars. A more pressing issue is the increasing size of cars in the US; SUVs make up half of all car sales in the US, and are much more likely to kill pedestrians in crashes than smaller vehicles. “Mass times [acceleration] is force,” Gordon summed up. “When you increase the mass of something, you’re going to increase the force at which it interacts with a small vulnerable child.” 

But the biggest reason may be that American streets and cities are designed for cars, and not people. As Charles Marohn — founder and president of Strong Towns and an expert on urban planning and civil engineering — has argued, engineers who design streets prioritize getting cars as quickly from point A to point B over everything else. One recent example: A traffic safety committee in Utah could not find any way to make the five-lane road crossing to a school safer for students aside from just removing the crosswalk altogether.

But there is a lot that can be done to make streets safer, for future Halloweens and every other day of the year. In the short term, cities and towns can build on open streets programs implemented after the Covid-19 pandemic began, which involve closing certain streets to car traffic to allow for more public space. Notably, New York City announced a “Trick or Streets” plan that would see 100 car-free zones in effect from 4 to 8 pm on Halloween this year. And the Big Apple isn’t alone, as Henry Grabar reported for Slate: less dense and more car-dependent cities like St. Petersburg, Florida and Seattle will also either close off the city center for Halloween or actually allow residents to apply for permits that can close off their neighborhoods to car traffic.

In the long run, Gordon believes that places around the US should be able to pass what is known as the popsicle test, where a kid should be able to safely walk to a store, buy a popsicle, and return home before it melts. In essence, every city should be designed to be friendly and traversable to the most vulnerable in our communities. “If you start thinking along those lines, then I think you start thinking along the lines of what infrastructure is needed to make that possible, where I would feel comfortable letting my kid do that,” Gordon said. “Halloween is like a giant version of the popsicle test because it’s not just your kid, it’s every kid in the neighborhood.”

Designing safer streets for children goes beyond safety — it would make for a better Halloween. “Having sidewalks and good lighting is a good preventive measure, not just for injury prevention, but also just general health,” Lee told me, “because that encourages everybody in the neighborhood to walk, exercise, and get outside, which is better for everybody’s health as well.”

And if their safety isn’t enough motivation, designing dense, walkable cities could even lead to bigger candy hauls for kids. 

“When you build a city that’s safer, so that kids can walk around by themselves and not be worried about getting hit by a car, or the parents being worried about them being hit by a car, it’s just better,” Gordon said. “It’s awesome. They’re independent. It’s fun. And on Halloween, they get a lot of candy.”

Correction, October 31, 4 pm ET: A previous version of this story had an inaccurate definition of the equation for force.

Update, October 30, 2026, 10 am ET: This story has been updated to include new federal crash data.

Why healthcare has become such a big problem for Republicans

30 October 2026 at 11:45
People standing outside holding a sign that reads where is the Republican healthcare plan?
A Get Out the Vote rally hosted by the Republican Party of Kentucky took place on October 24, 2026. | Tom Williams/CQ-Roll Call, Inc via Getty Images

Less than a week out from the 2026 midterms, Republicans across the country are feeling the heat from their party’s vote last year to shrink Medicaid by roughly $1 trillion over the next decade. The cuts, driven largely by new work requirements and eligibility checks, are expected to leave more than 7 million Americans without insurance by 2034. They’ll also hit hospitals, clinics, and nursing homes that everyone uses, whether or not they’re on Medicaid.

These cuts weren’t supposed to be noticeable to voters just yet. Republicans designed them to take effect in 2027, after the midterms.

But some of the damage is already showing up. Paired with a reduction in tax credits to help buy insurance through the Affordable Care Act, and rising employee premiums, the cuts are colliding with a broader voter revolt against the high cost of living — and have turned healthcare into a top midterm issue.

A slew of recent polling shows healthcare costs sitting at the top of voters’ economic worries as the campaign season winds down. A KFF poll from earlier this month found healthcare outranked food, housing, and utilities as a top concern, with nearly half of voters saying it was “extremely important” for candidates to be talking about. And in late September, an Associated Press and KFF survey of rural voters found that twice as many said the Trump administration’s healthcare policies had hurt the health of people in their community as said they’d helped. 

Key takeaways

  • Healthcare costs top the list of voters’ economic concerns
  • The GOP’s new $50 billion rural fund doesn’t offset $137 billion in rural Medicaid cuts, and the savings come mostly from people losing coverage.
  • Work requirements hit nationwide in 2027, so the first wave of coverage losses lands as the 2028 campaign begins.

Republicans have tried to rebrand the One Big Beautiful Bill Act as the “Working Families Tax Cuts,” but Politico found voters largely unmoved by the new name, and Fox News recently gave Democrats a 22-point lead on who voters trust to handle healthcare.

Democrats, for their part, have put healthcare costs at the center of their closing argument. It’s the issue they’ve spent more on than any other, according to the Cook Political Report’s Battleground Issue Tracker, with more than $215 million across the  most competitive House and Senate races this year. Democrats trying to flip red seats are running ads on reversing the Medicaid cuts and on having relied on Medicaid once themselves, while outside liberal groups are spending millions of dollars in ads tying Republicans to the cuts, and leading an 8,000-mile bus tour through 36 cities. 

They’ll have even more to work with next year. The new Medicaid work requirements and the six-month eligibility checks that Republicans delayed past the midterms will all take effect in 2027, which means the first wave of people losing health insurance coverage will hit right as the 2028 campaign begins.

Republicans’ defenses aren’t holding up

Reducing Medicaid spending became a critical part of the One Big Beautiful Bill Act in order to help offset the multitrillion-dollar cost of extending President Donald Trump’s first-term tax cuts, adding some new ones, and funding ICE.

Mindful of the potential for political backlash, Republicans took steps to ward off attacks.

The main defense Republicans have relied on is to point to a $50 billion rural health fund that was also included in the bill. The GOP is touting it as “the single largest investment” in rural healthcare in over 20 years.

But fact-checkers and health analysts have been clear that this temporary infusion of funds, spread out over five years, doesn’t offset the $137 billion in permanent cuts projected to hit rural areas over the same decade. 

Maine Republican Sen. Susan Collins, who voted to let the One Big Beautiful Bill Act reach the Senate floor but against final passage, leaned on this rural healthcare fund in a debate earlier this month. “If I had not allowed the bill to go to the floor, I would never have been able to author the $50 billion fund to help rural healthcare,” she said. Troy Jackson, her Democratic challenger, emphasized that the fund comes nowhere close to covering what Mainers stand to lose. “Senator Collins is like an arsonist who helped set the fire, and then she wants credit for bringing a cup of water to put it out,” he said.

Voters don’t need a fact-check to notice when a hospital shuts down or reduces service. In some cases, medical institutions aren’t waiting for the cuts to arrive, and are making decisions based on the federal funding they expect to lose. In Iowa, for example, MercyOne Clinton Medical Center ended labor and delivery services earlier this year, citing decreased Medicaid funding as part of the reason.

“The public’s not stupid, and we’re all already absorbing a lot of additional costs that we shouldn’t have to because of Republican decision-making in Washington, DC,” Michigan Gov. Gretchen Whitmer told Politico recently.

The second is to deny there is reduced spending at all. “It’s not an actual cut,” as GOP Rep. David Valadao of California said in a debate several weeks ago — the savings, Republicans argue, come from cracking down on waste, fraud, and abuse. 

This distinction is an important one in certain campaigns. Medicaid covers over 60 percent of Valadao’s California district, and he voted for the bill. Valadao also led a letter, signed by 12 other Republicans from battleground districts, declaring that “we cannot and will not support a final reconciliation bill that includes any reduction in Medicaid coverage for vulnerable populations.” Every one of them ultimately voted for it. 

Loss of coverage is already happening in Nebraska, the only state to start enforcing its new Medicaid work requirements ahead of the deadline.

The “no actual cuts” claim rests on a technicality that the law doesn’t reduce benefits for anyone who stays enrolled. But the roughly $1 trillion in savings the Congressional Budget Office scored comes almost entirely from people losing coverage. When Arkansas tried the same 80-hour-a-month work requirement in 2018, more than 18,000 people lost their health insurance within months. This happened mostly because people didn’t know about the changes or couldn’t handle the new paperwork.

Loss of coverage is already happening in Nebraska, the only state to start enforcing its new Medicaid work requirements ahead of the deadline. Millions more across the country are getting notices in the mail that they could lose their insurance next year.

The problems driving voter anger are about to get worse

Nebraska offers the clearest preview of what’s coming. The state began enforcing its Medicaid work requirements in July, well ahead of the federal deadline, and more than 1,000 residents have already lost coverage, according to the Washington Sun. Republican Sen. Pete Ricketts, who voted for the bill, is tied with Dan Osborn, an independent, in a state that Trump carried easily.

“One out of two Republicans either are, have been or have a family member that is or has been on Medicaid,” Bob Ward, a pollster with the GOP firm Fabrizio Ward, told the Washington Sun. “It’s not like a theoretical thing.”

The rest of the country will experience these new administrative burdens beginning in January. Adults covered under the Medicaid expansion will have to prove every six months that they’re working, volunteering, or attending classes at least 80 hours per month, or demonstrate that they qualify for an exception.

There were Republicans, including some who ultimately voted for the One Big Beautiful Bill Act, who warned in 2025 that voters would not respond well to billions of dollars in Medicaid cuts. Polling at the time found that 71 percent of voters who backed Trump also said they’d oppose cutting the federal health insurance program.

Several months before voting for the bill Missouri Sen. Josh Hawley warned that cutting Medicaid would be “both morally wrong and politically suicidal.” Trump himself told his fellow “cost-cutting Republicans” to avoid going “too crazy” and “REMEMBER, you still have to get reelected.”

Leaders working in healthcare say these changes will drive up costs for all patients, irrespective of whether they use other forms of insurance. For example, if there are fewer people able to access primary care through Medicaid, then more patients will need to utilize hospital emergency rooms for care, and hospitals are required to provide treatment there regardless of whether they’ll be reimbursed. To cover that lost Medicaid revenue, experts expect that some hospitals will need to cut staff, services, or close clinics. They’ll also likely shift costs onto everyone else, through longer ER wait times and higher premiums for patients still on insurance.

Workers who get insurance through their employers are bracing for hikes, too. KFF’s annual employer survey found the average worker is paying more than $600 more toward a family plan this year than in 2025, and the cost-shifting that follows Medicaid cuts is expected to push premiums higher still. One August survey of employers found average plans are projected to rise next year by more than 8 percent. Roughly 160 million Americans get coverage this way.

Republicans have made a bet that higher costs won’t hurt them next week or in two years. Sen. Thom Tillis (R-NC), who announced his retirement days before voting against final passage of the One Big Beautiful Bill Act, warned that voters would come to understand who took away their health insurance coverage.

“If you’re a competent Democrat, you’re going to figure out how to communicate to them how it affects their lives,” he said that summer. “And it almost certainly will.”

Democrats have big healthcare plans. The industry is preparing for a fight.

29 October 2026 at 21:00
A protester holds up a “healthcare for all” sign.
Protesters in Minnesota advocate for universal healthcare. | David Berding/Getty Images for People's Action Institute

Americans want changes to their healthcare, and the candidates in this year’s midterms are making bold promises about how they are going to improve it: Medicare-for-all, or a public health insurance option, or free primary care for everyone. If Democrats win big this year, they could build up momentum to control Congress and the White House in 2029, which could leave them well-positioned to take on the thorny problem of how to fix the US health system.

History suggests that this won’t be easy. For every Affordable Care Act, you have the failed attempt to repeal it or the calamity of the Clinton-era healthcare initiative. Americans want change — but they fear it, too. I’ve spent years reading healthcare polls, talking to voters, attending focus groups. The public’s opinion of the healthcare industry has grown more and more sour, and distrust of the medical establishment is at an all-time high. People are sick of having a broken health system, but they worry that big changes could end up being bad for them. 

Even though a meaningful attempt at reform is still years away and universal health care in any form might seem like a progressive pipe dream, the industry is not sitting idly by. 

As Democrats have started to roll out policy proposals in anticipation of winning back Congress, the industry has been there to start making its case. In some campaigns, that means backing Republicans, but it also means lobbying Democratic Party leaders to hold the line against their more progressive members who want to push for far-reaching changes. 

The question now is: Will their old playbook work? Can the industry convince Democrats to scale back their policy ambitions, or is their grip on Congress loosening?

“The next two years are actually quite pivotal, for doing the groundwork and all the necessary socializing, consensus-building,” said Kim Monk, a former congressional healthcare staffer who co-founded the private-sector research firm Capital Alpha Partners. “That’s the work that gets you to a point where either party decides, okay, this will be on our platform — or not.”

That will be the tug-of-war of the next two years: a PR battle waged between health companies with hundreds of millions of dollars at their disposal on one side and progressive lawmakers, activists, and patient advocates on the other that will ultimately determine what’s possible in the next phase of American healthcare.

The healthcare industry doesn’t want Democrats to win too big

In the short term, the industry is hedging its bets in the face of a Democratic wave. 

Private enterprise has historically backed the Republican Party, but that’s starting to shift. What the healthcare industry values above all else is balance. Democrats operating without any constraints are more likely to impose government regulations on medical companies. But full GOP control comes with its own risks, like the $1 trillion in Medicaid cuts passed as part of the One Big Beautiful Bill Act, which has already led to clinics and hospitals laying off staff or even closing facilities altogether.

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

“At least for the short term, I imagine the healthcare industry would welcome control of Congress by Democrats, creating more predictability, forestalling more cuts in Medicaid and the Affordable Care Act, and potentially reversing or delaying some of the cuts that have already been made,” said Larry Levitt, executive vice president for health policy at KFF. “The longer-term political calculus for the healthcare industry is more complicated. Many Democrats are pushing for a bigger role for government in health care.”

In other words, while healthcare companies might welcome a Democratic House as a check on President Donald Trump’s unpredictability, they aren’t necessarily hoping for a massive blue wave that could make significant reforms a serious possibility if Democrats were to win the White House in 2028. 

The industry’s MO when it looks like a wave election is brewing is to balance the scales: I reported in 2016 how, in what was looking like a good year for Democrats, the drug industry poured money into the campaigns of Republican candidates by a 6-to-1 margin in competitive races, hoping to stifle the agenda of presumed President Hillary Clinton. (Of course they, like the rest of us, are still susceptible to being wrong.)

And that’s how the industry has been approaching the 2026 election: In many of the pivotal House and Senate races, they are backing the GOP. 

As healthcare journalist Merrill Goozner reported last week, the American Hospital Association PAC and PhRMA, a drug industry trade group, have given a combined $14,500 to Republican incumbent Jon Husted and none to his Democratic challenger Sherrod Brown in the historically expensive Ohio Senate race. In Maine, Republican Sen. Susan Collins has received donations from all of the major healthcare trade groups — hospitals, pharma, insurers, and doctors — while her opponent, Democrat Troy Jackson, got none. (He also has sworn off corporate PAC money.) Even in an open race without an incumbent, like the Iowa Senate campaign, the Republican candidate has scored donations from hospitals and pharma, but the Democrat has not, Goozner reported.

If Democrats take the House but not the Senate, that would immediately put a damper on their healthcare reform plans — whereas winning a Senate majority would allow them to start drafting and debating bills in both chambers with an eye toward what could actually pass if they win in 2028 too.

“If there is actually a blue tsunami next week and Democrats get 51-plus [members] in the Senate, that’s a really big deal,” Monk said. “You can’t just say this doesn’t matter because Trump’s going to veto it, because I think it very much becomes a 2028 issue.”

And even as they work to push the next Congress more to their ideological liking, the healthcare industry is preparing for the fight that comes after.

The industry is prepping its counterattacks on ambitious healthcare proposals

After the midterms wrap up, the next two years in Congress and on the presidential campaign trail will be crucial. The industry is already working to set the terms of the debate and push back against big changes.

Each subset of the industry has its own versions of this argument: Pharma warns that price controls could stifle innovation, insurers warn that coverage mandates will increase premiums, hospitals warn that constraints on their funding could lead to closures and job losses. (There’s a well-known saying among DC insiders that every congressional district has a hospital, making every member potentially susceptible to the industry’s message that new healthcare legislation could result in their own constituents losing their jobs.)

They’ve started by trying to discredit the more sweeping health policy proposals before new members ever arrive in Washington, DC. In Texas, for instance, Republican groups have leaned on an industry-commissioned study to attack Democratic Senate candidate James Talarico for supporting Medicare-for-all, warning that it would lead to cuts for rural hospitals — at least according to an analysis produced by the Partnership for America’s Future, a coalition of industry groups that exists explicitly to oppose Medicare-for-all or a public option. They ran a similar ad against Democrat Janelle Stelson, who’s trying to topple incumbent Rep. Scott Perry in Pennsylvania. 

The industry is trying to plant the idea in voters’ minds that these big, bold proposals may sound superficially appealing, but carry significant risks: You could lose your plan, you could lose your doctor, you could pay higher taxes. (And they often have their own studies to back those arguments, like the one cited in this year’s campaign, to counter the evidence offered by advocates in support of reform.) And it might work exactly like it has in the past. As John McDonough, a former congressional healthcare staffer and author of America’s Wrong Turn: US Health Care in the Neoliberal Era, put it to me, the history is clear: “Every comprehensive effort, defeat, and every incremental effort succeeds.” That is in part because of the healthcare industry’s influence and its success in framing the debate.

On top of trying to sway the competitive races, the industry is also trying to keep its most important allies within both parties happy ahead of the midterms. As the Center for Health and Democracy’s data shows, the health insurance industry PACs alone have given tens of thousands of dollars to Democratic and Republican leaders, as well as senior members of the healthcare-focused House and Senate committees.

It’s another hedge, an attempt to keep the members who will decide what’s on the agenda next year on their side. The industry supports reversing the GOP’s massive Medicaid cuts and increasing funding for the ACA marketplaces, two top-priority items for Democrats if they win Congress in the midterms. But they are hoping the party’s leaders will steer their members away from some of their more radical ideas for overhauling healthcare. Because while individual sectors within healthcare may squabble over smaller-scale reforms, the entire industry is united against plans to fundamentally change the US health system. (They are also increasingly owned by the same parent company, as consolidation in the medical sector becomes more and more common.)

“The healthcare industry is all for more people having coverage and stable government financing,” Levitt said, “but will circle the wagons to fight Medicare-for-all.”

Already, whenever Democrats start talking about their health policy ideas, the industry is ready with a response. Last month, as some Democrats announced support for a public insurance option, the Partnership for America’s Health Care Future argued it would reduce access. “A public option is not the answer to the affordability and access challenges patients and families are facing,” said the group’s executive director, Lauren Crawford Shaver.

Meanwhile, the health insurance lobbying group, AHIP, released a 40-page document in October on how to improve affordability and access, using it in part to argue against a public option because it would “stifle competition and threaten the coverage most Americans want to keep.” Centrist Democratic groups who receive industry support have said they are “preparing for war” against Medicare-for-all, according to the news outlet Sludge.

The industry is not omnipotent, however, and the debate could still change if Americans’ healthcare gets worse over the next few years. The US uninsured rate has been on the rise as pandemic protections expire and the costs of healthcare rise for millions. Unless Democrats succeed in stopping the Republican Medicaid and ACA cuts in the OBBBA, that problem is going to get worse — and that could also force Democrats to think bigger about how to fix it.

“I am not sure anyone has fully absorbed how damaging and disruptive that is going to be — including to hospitals and health systems,” Jonathan Oberlander, professor of social medicine at the University of North Carolina and the former editor of the Journal of Health Politics, Policy and Law, told me over email. “Large coverage losses will trigger great instability in health politics and perhaps open more of a window to bolder proposals.”

So, will the industry’s arguments still have juice? After the medical industry enjoyed a brief rebound in popularity during the pandemic, 50 percent of Americans say they have a negative view of it, while 37 percent have a positive view, per Gallup. And the appetite for reform is growing: 64 percent of Americans say it is the government’s responsibility to make sure that everyone has healthcare coverage — the highest share at any time, except for the late 2000s, shortly before the ACA became law.

Even the hospital industry, which has long enjoyed more public support than pharma or insurance companies, is seeing its popularity waver: A Families USA poll from August found that an overwhelming 81 percent of Americans thought hospital prices were unreasonable.

“Hospitals have done a great job of pleading poverty on Capitol Hill. ‘We’re probably the only provider who basically has to provide care to whoever shows up. We have no reason to be efficient. Just give us more money,’” Monk said. “I think that argument is wearing a little bit thin.”

The 2026 election could reshape healthcare

22 October 2026 at 22:00
Protestors supporting universal healthcare
New Yorkers march in support of universal healthcare this summer. | LightRocket via Getty Images

Americans are furious about the state of our healthcare system. 

A recent KFF poll found 60 percent of US adults worry about the cost of medical care — more than gasoline, food and groceries, or their rent or mortgage. One in three Americans say they worry every day or almost every day about their ability to afford healthcare, per a new survey from the Pew Research Center. There seems to be a growing appetite for reform, too: More than 65 percent of Americans say they support the government spending more tax dollars to lower healthcare costs. 

Democrats are trying to weaponize those frustrations against the Republicans who currently hold Congress and the White House. By a 2-to-1 margin, voters say they trust Democrats over Republicans on healthcare. That could mean single-payer Medicare-for-all or a new public insurance option or maybe something else. What all this energy leads to will depend on what happens in November. The candidates themselves are framing the stakes in those existential terms. 

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

“Medicare for all is where we need to go,” Abdul El-Sayed, the Democratic candidate in the Michigan Senate race whose support for the policy has been widely covered, said during an August interview with CNN. “And my hope is, both coming out of the 2026 midterms and then out of 2028, that we’re going to be on our way to a Senate majority to be able to get this done.”

Real change will have to wait for the 2028 presidential election and a new occupant in the White House. But this year’s midterms are still a make-or-break moment: The candidates who get elected this year, and how they shape the upcoming presidential primary debate and actions in Congress, will determine whether healthcare reform happens at all. 

If you’re fed up with the state of American healthcare, and you want to see a change, you should show up for the midterms on Tuesday, November 3.

Big midterm wins can beget big healthcare wins 

The classic pattern in American elections is that more voters go to the polls during presidential campaigns than during the midterm elections when only House and Senate seats are on the ballot. Turnout has started to tick up for the midterms in recent years, but it still trails behind presidential years. Midterms suffer from the perception that there’s not as much at stake if the White House is not on the line.

But that’s never been strictly true. 

Midterm elections are extraordinarily important in shaping the future of policymaking, even if the payoff is delayed. They help determine both the character of the Congress that could eventually pass a major bill after the next presidential election, and the kind of ideas and policies that are going to be prioritized.

“Voters should see 2026 and 2028 as the elections that will guide the next big change in our healthcare system,” said Natalie Davis, CEO and co-founder of the advocacy group United States of Care, in a statement to Vox. “These elections will be how voters’ demands are heard — and will tell us whether the next real window for change will come with serious reforms or missed opportunity.”

A walk through the recent history of healthcare reform should help make the stakes of the 2026 elections clear.

In 2006, the national mood looked similar to what we’re seeing today. A very unpopular Republican president was in office, and the country had soured on his agenda. George W. Bush’s foreign wars and his misguided attempt to overhaul Social Security gave Democrats an opportunity to win big in the 2006 midterms — and they did. Dems won more than 30 seats and secured a comfortable majority in the House. In the Senate, they won six seats and narrowly took control of that chamber too.

It was a resounding rejection of the Bush administration, and it set up the next decade of Democratic policymaking. At the highest level, the midterms gave energy to the progressive wing of the Democratic Party, united as they were around their opposition to the Iraq War, and that energy carried over to the presidential primary. Barack Obama defeated Hillary Clinton and won the presidency, springboarding off of the excitement that started with the 2006 elections.

Dems’ success in the midterms also helped put lowering healthcare costs at the forefront of the Democratic agenda. That encouraged both Obama and Clinton to develop detailed healthcare policy proposals during their primary campaigns and ultimately set the stage for the Democrats to pursue the Affordable Care Act once they had full control of the government in 2009.

And then there is the literal size of the congressional majorities that parties need to pass their agenda. Voters may not spend much time thinking about whip counts, but one or two elections in a midterm year can ultimately decide the fate of the next president’s agenda. 

Part of the reason Democrats were able to pass the ACA was that they built on their huge wins in 2006 with more wins in 2008 and held massive congressional majorities once Obama was sworn in. And once the debate over healthcare reform really got started, they needed every single vote. It was especially important in the Senate: Democrats had exactly 60 votes in 2009. That meant if all of them united together, they could pass filibuster-proof legislation — so long as nobody defected. That was only possible because in 2006 Mark Pryor won a Senate seat in Arkansas, Sherrod Brown triumphed in a Senate race in Ohio, and Jon Tester beat an incumbent Republican in Montana. 

Without those wins in 2006, the Democratic legislative agenda in 2009 would probably have looked different. They might’ve had to pursue a more limited healthcare reform plan; maybe the ACA wouldn’t have passed at all.

What kind of Democrats will be on the rise in 2028?

The 2006 midterms both created the opportunity for the ACA — and set the limits on what the legislation could actually achieve. Democrats had that 60-seat Senate majority, but within it were many more moderate members. Policies like the public option (which would have authorized the government to create its own health insurance plan to sell alongside private insurance) couldn’t get sufficient support. That is the dilemma of policymaking: You need those swing-seat members to win, which often means tacking to the center, but you also can’t pass anything they won’t get on board with. 

Nevertheless, that is a good kind of political problem to have, one which Democrats would be thrilled to face in January 2029. All of which brings us to 2026. What are we going to do now?

It all starts with the vote count. Most projections expect the Democrats to win between 10 and 20 House seats. But the difference between 10 and 20 could be substantial. The cushier the majority, the further you can push the policy agenda. More than 30 House Democrats actually voted against the ACA, but they could still narrowly pass the bill because of the huge majority that they had started building in 2006. 

If you live in one of the districts — like Arizona’s Sixth or Colorado’s Eighth or Florida’s 22nd, to name just a couple of the 21 toss-up races identified by the Cook Political Report this year — that forecasters say is competitive this year, you could have an outsized say in what the future of policymaking looks like. But even in safe districts, you should vote: Elections are the most reliable way we have to gauge public opinion, and strong victories for the candidates who prioritize healthcare send a message.

The same goes for the Senate. If Democrats sweep all of the competitive races, they could have up to 55 seats in the Senate in 2027 — with a chance to build on it in 2028. If you are a voter in Kansas, Michigan, Ohio, Texas, Alaska, Maine, New Hampshire, or Iowa, your ballot carries extra weight for the next steps in US healthcare reform. If the Democrats can reach 60 votes again in 2029, they would have much more flexibility about what to pass. Even if they fall short of that magic number, the more of a cushion they have above 50, the more likely that their Senate leaders can find support for altering Senate rules for the filibuster and get an ambitious bill approved.

How you can get involved this election

If there is ever going to be a path to a true healthcare overhaul, it starts with this year’s elections. If you want to see a change, you can vote — and you can do more than that. 

The results of this year’s midterms will also set the terms of the debate among Democrats. We are likely to see “show” bills advanced by Dems next year that may have no chance of being signed by President Donald Trump, but that will give us a sense of what kind of policies the party wants to pursue and how much support there is for them. Believe it or not, the first Medicare prescription drug negotiations bill passed the House in 2007 after Democrats’ big wins in 2006 — even though the policy didn’t become law for another 15 years. The broader public may not pay much attention to this kind of doomed-to-fail legislation, but it is often a window into the future.

“One challenge for Democrats is finding the next big health care idea beyond the Affordable Care Act that will resonate with voters and respond to their affordability concerns,” said Larry Levitt, executive vice president for health policy at KFF. “One big difference between now and 2006 is that back then there was already a lot of coalescing around ideas that ultimately led to the ACA. All the major Democratic candidates for president in 2008 supported something like that. I’m not sure that’s true now, at least not yet.”

Democrats are already aligning on a wide range of healthcare ideas, from reviving the public option to free primary care to the full-blown Medicare-for-all supported by progressive candidates, some of whom are in competitive elections. If El-Sayed wins the Senate race in Michigan, for example, that could supercharge a debate around Medicare-for-all. It could also provide momentum to any progressives who run for president — Alexandria Ocasio-Cortez, to name one obvious example — and decide to make Medicare-for-all a pillar of their platform.

But if El-Sayed and other progressives were to fall short, that could make Democrats more timid about being ambitious in the 2028 campaign and afterward. Still, he’s far from the only candidate in a crucial race to put their support behind Medicare-for-all. There is Randy Villegas in an important California House race. Troy Jackson has bet on it as part of his bid to topple Sen. Susan Collins in Maine. All of these races will send a signal to the party about what the public wants and is willing to turn out for.

In some ways, winning elections is the easy part. Legislating is hard, and any eventual healthcare law will surely involve compromises and unexpected surprises. Who knows what will be happening in the world in 2029? 

“The bottom line is: 2026 is a healthcare election,” the leaders of the advocacy group Protect Our Care wrote in a campaign memo this month. “After November, it’s up to Democrats to keep up the fight to deliver relief to families and make healthcare affordable and accessible for every American.”

What Christina Applegate’s misdiagnosis reveals about MS

21 October 2026 at 21:30
Christina Applegate on the red carpet
Christina Applegate at the 2023 Screen Actors Guild awards. | Valerie Macon/AFP via Getty Images

Christina Applegate, the actor who has been one of the most visible faces of multiple sclerosis since her 2021 diagnosis, made a stunning revelation this week: She does not have MS after all. And her doctors still don’t know what is causing her debilitating symptoms.

“I’m back at square one,” Applegate told fellow actor Jamie Lynn Sigler, who does have MS, on Sigler’s podcast MeSsy. “I was not happy at all. Everybody else was so happy.”

It is a harrowing predicament for Applegate, and hopefully her medical team is able to get her the diagnosis and treatment she needs. But the fact is, her experience is not unique. Even as more and more Americans get diagnosed with multiple sclerosis, misdiagnosis remains all too common. According to one meta-analysis, roughly 15 percent of MS diagnoses may actually be false positives.

How could such a common medical condition — roughly 1 million Americans are living with the disease, about one in every 350 people — remain such a mystery? After Applegate’s announcement, I called some leading experts on MS to ask why diagnosing the disease is such a challenge, and what they want people to know. Here’s what I learned.

Why MS can be challenging to diagnose

Multiple sclerosis is an autoimmune condition: The body mistakenly attacks cells meant to protect your brain and spinal cord, and the resulting damage interrupts nerve signals and causes the disease’s telltale symptoms of motor impairment, tingling sensations, and vision problems. Some people experience a rollercoaster of relapses and remissions; others see the disease steadily progress, eventually leading to serious disability.

The reality is, scientists still don’t really know what causes MS to develop, said Dr. Andrew Solomon, a neurologist at the University of Vermont who specializes in MS. Smoking is a known risk factor. Obesity and metabolic problems play a role, but we need more research. Even the precise role of genetics remains something of a mystery. “We don’t really know what causes or triggers the autoimmune response in any given individual,” Solomon said. 

And that’s where the challenge in diagnosing it begins.

First, the testing can be imprecise; there is not a single test that reliably diagnoses MS. If a doctor suspects their patient may have MS, they usually undergo an MRI, which their physicians then scour for lesions that are typically associated with the disease. But those scans are still subject to interpretation: Other rare conditions sometimes resemble MS in imaging, as can diseases of blood vessels in the brain. You can also receive a spinal fluid analysis to check for abnormalities in your immune system, which the vast majority of MS patients have.

The nature of MS symptoms adds to the difficulty. They can often be vague early on: brain fog or fatigue or a general malaise. The tingling or vision problems can be similar to symptoms for other conditions that are not MS, and they are easily dismissed if they go into temporary remission, as often happens during the initial phases of the disease.

“Neurological symptoms sometimes can be vague — numbness, pins and needles — and it’s usually short-lived,” Dr. Saud Sadiq, chief research scientist and director of the Tisch Multiple Sclerosis Research Center of New York, told me. “Unless they’re taken seriously initially, they may be ignored because by the time the patient goes through the healthcare system and is actually referred to a neurologist, the symptoms have abated.”

If your doctor is diagnosing you with MS, ask directly: What’s the evidence?

One 2025 study by Solomon and his colleagues found that 40 percent of people who had later been diagnosed with multiple sclerosis were initially misdiagnosed with a different disease.

“Because it’s so heterogeneous, it doesn’t present in the same way in everybody and can have varying severity, it can be hard to diagnose sometimes,” Solomon said.

Lastly, when people are experiencing debilitating symptoms, there is pressure to deliver some diagnosis — and that may push some doctors to leap to MS even if they are not sure, Solomon said. The recent advent of effective treatments that help manage the disease’s symptoms, especially when it is caught early, may add to that pressure, even if the better course would be to continue monitoring the person before they start a medication.

“There may be a lot of clinicians who, if they can’t find a better explanation than MS, may be inclined to diagnose MS, even if they don’t really meet our diagnostic criteria, because they’re worried about missing a window of opportunity to treat somebody,” Solomon said.

There is reason to hope the MS misdiagnosis problem could get better. The National Multiple Sclerosis Society released new diagnostic criteria in 2024 that Solomon said more physicians should become familiar with to better distinguish MS from problems like migraines or vascular disease. And because imaging is involved in diagnosis, there is optimism that AI could be a powerful new tool in delivering more accurate results.

What everyone should know about MS symptoms and diagnosis

The good news is that MS, when diagnosed properly, is a treatable condition these days. “The prognosis with new drugs is extremely good for long-term care,” Sadiq told me. “If patients stick to treatment at a good MS center, you can look forward to a life without disability in 2026.”

So it is worth being vigilant and talking to your doctor if you experience any concerning symptoms. You should seek care if you have numbness or pins and needles that persists for more than 24 to 48 hours, Sadiq said, or have motor problems, like one hand won’t work as you try to play piano. Dr. Annette Langer-Gould, who develops and evaluates programs for MS care at Kaiser Permanente, said numbness in your abdomen, chest or back, as opposed to your extremities, is a particular cause for concern. If one eye has normal vision and the other is blurred, that’s another good reason to get checked out. 

If you do get tested, make sure the actual images of your MRIs end up being reviewed by an expert in MS. “The most common reasons the disease is still misdiagnosed are related to the providers’ lack of expertise usually in reading MRI scans,” Langer-Gould said. The spinal tap may sound scary, and doctors sometimes don’t recommend them because their insurance reimbursement is low — but they add to the confidence of a diagnosis. They are worth it, she said.

“American patients are very afraid of the spinal tap,” Langer-Gould said. “My message to patients is: Listen, just get the spinal. This way we’ll be sure.”

And do not be afraid to seek a second opinion for such a serious diagnosis, Sadiq added. Every state has a recognized MS center. If your doctor is diagnosing you with MS, ask directly: What’s the evidence? If your doctor is recommending that you start treatment, it could also be worth checking whether they have a relationship with a pharmaceutical company that affects how you perceive their judgment, Langer-Gould said.

People who have already been diagnosed may also be shaken by the Applegate news and question whether their own diagnosis might be wrong. Solomon said that folks should have a frank conversation with their physician about how exactly their case met the diagnostic criteria. With proper imaging and the spinal fluid tests, you can get to a confident diagnosis for the vast majority of people. But be your own advocate to make sure you’re satisfied.

“For many people, the diagnosis actually can be very straightforward,” Solomon said. “We really have no question about what it is.”

America’s next big healthcare reform might already be underway

19 October 2026 at 12:00
an illustration of a doctor treating a young girl in a hospital bed hooked up to an IV

If you live in Colorado and buy your own health insurance, there’s a good chance you’re one of the 139,000 people enrolled in a public plan crafted by your state leaders. You’re paying $0 for primary care visits and certain mental health visits, $0 for prenatal and postnatal care, and you don’t have to meet your deductible first.

On average, enrollees in these plans pay an estimated $14 to $33 less a month in premiums than people in comparable plans, and their annual out-of-pocket spending has fallen about 15 percent while holding steady for everyone else on the marketplace. 

Colorado didn’t build a government insurance company, rather, it designed the plan itself, down to the copays, and then required private insurers to sell it alongside their own.

A public health insurance option was supposed to be part of the Affordable Care Act. President Barack Obama supported the idea throughout his time in office, endorsing a government plan that could, in his words, “keep insurance companies honest” by giving them a government-backed competitor. But the idea was stripped from the bill before passage, after it became clear Senate leaders couldn’t get garner enough votes. Joe Biden campaigned for president on reviving a public option in 2020, but he never prioritized it once in office, and the progressive activists who championed it under Obama largely turned their sights to single-payer health care, which would cover all Americans.

Key takeaways

  • Three states built a public option while Congress stalled. In Colorado it’s now half the individual market.
  • It worked by forcing hospitals to charge less, not by the government selling insurance.
  • Whether it spreads depends on Medicaid cuts — states won’t pick two fights at once.

The problems a public option was intended to address — access, costs, reliability — have still not gone away and a growing number of policy wonks and elected officials have started to ask if the idea deserves a spot again on the national agenda. 

Healthcare costs are soaring, and voters tell pollsters it’s among their top economic concerns. Medicaid work requirements are set to take effect in January, which could leave millions of low-income Americans uncovered, and private insurers have asked to raise ACA marketplace premiums by a median of 15 percent next year, after a roughly 20 percent hike in 2026. Two-thirds of adults say they favor a national government health plan, and polls suggest most voters imagine proposals like Medicare-for-all as a competitor to private insurance, rather than a systemwide replacement.

While the debate around public options stalled in Congress, three states have gone ahead and built their own. Washington state launched a public option in 2021, Colorado in 2023, and Nevada earlier this year. They all built on a provision of the Affordable Care Act that lets states apply to run their own version of the law — one Sen. Bernie Sanders fought for in the hopes that Vermont would use it to build a single-payer system.

Their experience also shows the challenges involved: Not only in overcoming political objections from competing insurers, but medical providers as well, who may have to accept lower payments in order to keep the public option’s premiums affordable.

Colorado leaders say this push to control costs was critical to their success.

“The driving point behind what we were doing was to set hospital prices,” said Michael Conway, Colorado’s insurance commissioner and an architect behind the program. “That was what we were driving towards and that’s what we did.”

It’s not clear if other states, or the federal government, will be willing to pick those kinds of fights with the broader medical industry. But if ever there was a time for it to happen it would be now, with affordability a massive political issue, and the public seemingly eager for serious action on health care. Just as the ACA began with a state-level experiment in Massachusetts, the success or failure of these early public-option states could presage much bigger changes nationally.

What Colorado did

The motivation behind the public option in Colorado was simple enough: Healthcare was simply becoming too expensive.

Dylan Roberts, the Colorado state senator who sponsored the bill, represents mountain counties that had some of the highest individual-market premiums in the United States.

“Back then, the top issue on the minds of my constituents was the cost of healthcare and the cost of health insurance,” Roberts told the Century Foundation, which interviewed the officials and advocates behind the Washington and Colorado programs for a report last year.

Colorado Gov. Jared Polis made the issue a priority as well. One of his first acts in office was creating an Office of Saving People Money on Healthcare, run out of his lieutenant governor’s office.

When the state finally moved, it moved against unified opposition. Hospitals and insurers were lined up against essentially everything public officials proposed. Roberts described the opponents as “basically anybody in the status quo health care industry” — meaning insurers, doctors, hospitals, and pharmaceutical companies.

Colorado first introduced a bill for a state-run insurance plan, where the state itself would sell coverage. This is the kind of arrangement closest to Obama’s ACA vision, and what most people think of when they hear “public option.” 

“It was really in large part to scare the bejesus out of the insurance companies that we were going to really come in and truly be a state-run competitor against them,” Conway, the state’s insurance commissioner, said last month at a panel in Washington, DC.

But then in 2021, when Colorado officials mapped out what building a state-operated insurance company would involve, they concluded that a state-run plan would not have been able to sell a single policy until 2025 or 2026.

Officials decided that was too long given the urgent need, so they rewrote the bill before it passed, requiring the insurers already operating in Colorado to sell a marketplace plan the state would design. This coverage launched in 2023.

“We would just be starting today if we actually truly stood up a public option,” Conway said on the late September panel. He thinks this is what the federal debate around a public option keeps getting wrong. “People want action now. They’re pissed off, they’re hurting. … They don’t have four years to wait.”

Importantly, while hospitals in Colorado were not mandated to participate, the state gave itself the power to force them. Colorado gave private insurers a target: By 2025, the state-designed plans had to cost 15 percent less than that insurer’s plans had cost in 2021, adjusted for inflation. How they got there was up to them, but an insurer can only squeeze its own profits and overhead so far. So the rest effectively had to come out of the costs insurers paid to hospitals. And if an insurer missed the target, the commissioner could haul both the insurer and the hospitals responsible into a public hearing to defend their prices — and then order the hospitals to take less.

People sitting on a panel

That threat of a hearing was a powerful enforcement mechanism. “No one wants to be called in front of a public hearing where press are going to be there,” Kyla Hoskins, Colorado’s deputy insurance commissioner, told the Century Foundation. The hospitals cared about that more than the insurers did, according to Conway. The state launched complaints against nearly every carrier in the individual market and then pulled hospitals in with them. After that, according to Adam Fox of the Colorado Consumer Health Initiative, the price negotiations started happening, meaning no enforcement hearing actually took place.

Doctors complained early, but Conway said hospitals were the harder fight. The state worried that a single large hospital system refusing to participate could sink the entire plan, but in the end, no hospital refused. 

The result is the Colorado Option, a standardized plan that every insurance company in the state’s individual and small-group markets has to sell. There are 36 of these plans on the individual market for 2026. 

And people are choosing it. Enrollment went from about 14 percent of the state marketplace’s customers in 2023, the first year, to a third in 2024, to roughly half today.

Researchers at Brown University found the savings weren’t limited to the public option. Across Colorado’s individual market, the cheapest silver plans — a benchmark middle-tier ACA plan — now cost more than $100 a month less than equivalent plans in similar states.

Not everyone is celebrating Colorado’s policy development. Two industry-funded groups, the Partnership for America’s Health Care Future and its state affiliate Colorado’s Health Care Future, have campaigned against the program for years, citing a 10 percent rise in individual market premiums in its first year, and a 2024 report they commissioned from Hoover Institution researchers, which estimated Coloradans in public option plans collectively paid $13.3 million more in 2023 than if they had chosen the cheapest nonpublic options plans. 

Andrew Shermeyer, a doctoral candidate in health policy at the University of Minnesota, found the program made coverage cheaper for people receiving federal subsidies but more expensive for those who don’t. Hoskins, who oversees the program, disputed that, pointing to the Brown analysis finding premiums fell across the state, including on private plans.

Cara Welch, a spokesperson for the Colorado Hospital Association, pointed to the looming Medicaid cuts with HR 1. “Public option plans that would further weaken the healthcare system and shut doors to care are the wrong solution,” she told me.

How the public option died in 2009, and where it went

While states are working to implement their own public options, a national version would still have to overcome the same barriers it faced the last time it was tried.

The original idea for a national public option was a government-run insurance plan that would be sold on the new Obamacare exchanges, next to the private plans. 

Jeanne Lambrew, who worked on the Affordable Care Act in the Obama administration and now directs health care reform at the Century Foundation, said on the DC panel that there were several reasons that made that particularly hard at the time, and that she doesn’t think those reasons have been resolved. 

The first challenge was determining who would end up in the plan, because if sick and expensive patients concentrated in the public option, then it would cost too much to run. But if sick people were concentrated in private plans instead, that could also make it too expensive for those insurers and they could pull out of the market. Something like that second scenario, what economists call “adverse selection,” played out in the early years of Obamacare, when insurers raised prices and pulled out of unprofitable areas, leaving some counties on the brink of having no insurer at all.

The second challenge Lambrew outlined is whether doctors and hospitals would take the public plan, and what they would get paid. In 2009 Democrats pitched participation in a public option as voluntary, which was a problem because it meant that in order to induce the most desirable doctors or the hospital everyone wants, the government would have to pay them high enough rates — which would make the savings effectively disappear. 

The third challenge was whether a government agency would sell insurance directly, or whether private companies would sell a plan the government designed, as Colorado later decided to do. 

While the public option was ultimately cut from the Affordable Care Act, what survived was a provision letting states apply for federal waivers to try their own designs, so long as coverage stayed as broad and affordable and didn’t cost the federal government more. 

That provision’s biggest champion was Sanders, who wanted Vermont to use it to build the first single-payer system in the country. Though Vermont tried and gave up in 2014, the clause instead became a legal opening for Washington, Colorado, and Nevada to later use. So although the ACA didn’t include a public option, Lambrew emphasized, it still built the path to the ones that exist now.

Washington state went first, passing its law in 2019, and made the opposite choice from Colorado on hospital mandates. Instead Washington asked hospitals to participate voluntarily, and many unsurprisingly didn’t. In the first year the plan was sold in 19 of the state’s 39 counties, cost about 11 percent more than the cheapest comparable plan, and drew roughly 1 percent of enrollees.

So the legislature went back and passed a second law in 2021, this time requiring hospitals to contract with at least one public option plan if one made them an offer. The requirement took effect for 2023, and enrollment has climbed every year since. By 2025 the plan was available in every county in the state. About 115,000 people signed up for a public option plan for 2026, or roughly 40 percent of Washington’s marketplace.

Nevada’s plans went on sale this year, and the state gave itself the least leverage of the three. It sets premium targets but cannot set hospital rates, and it suspended its provider participation requirement for the program’s first year. Enrollment has come in below projections. “The story is unfinished here,” Lambrew said of Nevada.

Taking the public option national

The hospital industry uses the plight of rural hospitals, which are often struggling financially, to argue against public options or the government getting involved more generally to lower costs. 

Healthcare reformers tend to respond by exempting rural hospitals from price caps, though Conway, Colorado’s insurance commissioner, says that is a mistake. Rural hospitals are generally paid far less by private insurers than large systems are, and at the price levels under discussion, he said, a cap would actually represent a raise for most of them. Tell a rural hospital it will get three times what Medicare pays and “they would think you were the savior,” he stressed.

Conway has been getting a lot of calls from other states interested in adopting what they’ve done. But in every conversation he’s blunt with the person on the phone, saying they’d have to be prepared to take on hospital prices. “When I bring that up with other states, the appetite isn’t there right now,” he said on the September panel.

Conway blames Medicaid cuts for the reticence. The Congressional Budget Office estimates 7.5 million Americans will lose their health insurance by 2034, and states bracing for that are not eager to pick fights with hospitals at the same time. Undoing those Medicaid cuts, Conway said, is “an incredibly important floor” and “the foundation to actually doing anything else past that.”

The federal government does have one tool that Colorado and other states lack: a public insurance program that already exists. Hannah Garden-Monheit, a former Federal Trade Commission official on the healthcare panel, pointed out that Medicare, unlike a private insurer, is “a price setter, not a price taker.” Meaning it can announce what it will pay rather than negotiate for it. Some public option proposals in Congress would let people buy into Medicaid through the marketplace, or create a new plan that pays what Medicare pays, instead of building something from scratch. 

Roberts, who sponsored the Colorado bill, told the Century Foundation that the goal should be saving customers money, getting more people insured, and getting them the care they need. He said what the public program “actually looks like at the end of the day doesn’t matter as much as the outcomes of the product that people have.”

Laura Kate Zaichkin, who runs competition and affordability at Washington’s exchange, says the path to a workable public option might not be easy, but the rewards are worth it.  

“It takes a lot of political will, collaboration with partners, thoughtful design and implementation,’ she told the Nation’s Health. “It is a long-term investment that states can make to lower healthcare premium costs.”

With Democrats potentially set to expand their statehouse presence after the midterms, there may be more room to act on healthcare in other states next year. Even if Democrats don’t end up enacting a public option at the federal level, they could boost states in their efforts by restoring Medicaid funding, which could give lawmakers more room to stand up to health providers on costs. If these public options continue to grow, they might end up an unexpected ACA legacy.

A door to single-payer healthcare could open after November 3

19 October 2026 at 20:30
Sign that says healthcare is a human right
Protest signs seen at protect Medicaid lights up Capitol amid budget showdown, on May 7, 2025, in Washington, DC. | Leigh Vogel/Getty Images for Caring Across Generations

Twelve years ago, Vermont Democrats tried to make their state the first in the nation to have a single-payer government-financed healthcare system — a bold experiment to push the limits of American health coverage when Obamacare was just being launched.

Their plan failed, and rebooting it became politically impossible, even in Vermont: The Democrats lost the governorship to Republican Phil Scott for what turned out to be a decade.

This year, that could finally change. A progressive political newcomer named Amanda Janoo is taking on Scott in what polls show is a tight governor’s race.

And if she wins, the state could be poised to try a whole new national experiment: One of Janoo’s central campaign promises is to create a pioneering health system where the state pays the full tab for primary and preventive care, while leaving the rest to the existing system.

Key takeaways

  • Amanda Janoo, the Democratic nominee for governor of Vermont, wants to move primary and preventive healthcare to a single-payer system — where the state would pay providers for such care, make it free for patients, and cut insurers out.
  • Previous attempts to pass or enact full single-payer systems have failed at the state level, including in Vermont in 2014.
  • Janoo is trying to focus first on this one relatively smaller slice of the health system, but hopes it could be a starting point to full single-payer reform eventually.
  • Yet even this more limited reform faces difficult political and practical challenges.

Janoo’s candidacy is an example of the policy experiments that are becoming possible nationwide in a projected “blue wave” year, when Democrats could sweep into power in a number of states. But in the healthcare universe, her plan is also an example of how even progressive policy idealists are trying to learn from past failures and focus on what they think can actually be achieved.

Compared to the sweeping ambition of Vermont’s 2014 effort, or Bernie Sanders’s signature “Medicare-for-all” idea, Janoo’s proposal for single-payer has very specific limits. Under Janoo’s proposal for “universal primary and preventive care” (she typically avoids the term “single-payer”), the state government would pay for Vermonters seeing primary care providers such as doctors and nurse practitioners. This government coverage would be universal and free for patients, and insurance companies would be cut out.

However, other parts of the health system — such as hospitals, specialists, and prescription drug companies — would remain under the existing insurance system, for now.

Every effort so far to enact full single-payer at the state level has failed — even in blue states, bills and ballot initiatives have regularly gone down to defeat. Vermont’s previous single-payer experiment made it the furthest — it was signed into law but abandoned before being implemented, when the governor concluded it was unworkable. Wherever it’s gained steam, politicians and voters have blanched at the high costs of moving their health systems onto state budgets, and the high taxes that would be necessary to fund them.

Now, Janoo is making an attempt to refurbish single-payer as something more achievable, by cutting off a smaller slice of it.

“I think it’s clear at this point that a profit-oriented healthcare system is a terrible idea,” Janoo told me in an interview on Monday. But after assessing that the state budget made it “unrealistic” to do single-payer immediately, she concluded, “we could do universal primary and preventive care,” financed by a tax on the wealthiest.

Indeed, single-payer for primary care seems more achievable precisely because primary care is a relatively less expensive part of the healthcare system. But Janoo hopes it will pay major dividends — that better preventive care will improve Vermonters’ health, reducing costs elsewhere in the system by, for instance, making some hospital visits unnecessary.

In speaking to health policy experts about this idea, I heard much sympathy for the goal of universal primary care, but many questions about the details. Would Janoo’s plan be sufficient to bring more primary care doctors to Vermont — and, not unrelatedly, would it pay them more? Would her hoped-for cost savings from preventive care actually materialize? Is picking up the tab for a relatively less expensive part of the healthcare system the best use of sparse state funding?

These questions are becoming national ones, as healthcare gains traction as a political issue again. It isn’t just Vermont where primary care reform ideas are gaining steam: Democrats in Minnesota, Washington state, and elsewhere have discussed them. “There is growing interest in a number of states across the country in doing a universal primary care for all program,” Kevin Grumbach, a family physician and a professor of family and community medicine at the University of California San Francisco, told me. Even Scott, Janoo’s opponent, signed a law calling for a study of universal primary care.

One dividing line emerging, though, is whether to keep insurers involved, or to clear them out with a single-payer system, as Janoo wants. Insurers are unpopular with the public, but they can be a formidable political opponent when they argue that the benefits voters currently enjoy might be lost. Scott has said that the idea of universal primary care is appealing — but that if universal is “just code for single payer, I’m not interested. We’ve already been through that.”

Yet Janoo is hoping that single-payer for primary care will be a stepping stone — a trial run for eventually making the rest of the state’s health system single-payer down the road.

“I think about this often,” Janoo told me. “How do you build the new system as you transition the old — or hospice the old?”

Amanda Janoo is tired of “corporate neoliberal bullshit”

Janoo has long been an unorthodox economic policy thinker. Her rise is part of a broader trend in which progressives and leftists are winning primaries and gaining influence in the Democratic Party — but she doesn’t fit the prototype of the democratic socialist candidates in New York City, Colorado, and elsewhere who’ve gotten much attention this year. Instead, she comes from a different strand of the left, a movement based on a dissident strain of economics and openly skeptical of the benefits of economic growth.

Dating back to when she graduated from college in 2010, in the aftermath of the financial crisis, she was part of a younger cohort rebelling against what seemed the glaring failures of the economic establishment. “The one thing coming out of university I was clear on was that neoliberalism was the worst,” Janoo said on a podcast last year. “This whole idea that governments should just take a hands-off approach to the economy and trust in sort of the disciplinary powers of the global free market to lead them to infinite growth seemed highly problematic and very anti-democratic.”

So for graduate school, Janoo attended Cambridge to study development economics under the “heterodox” economist Ha-Joon Chang. She then spent several years working abroad in international development for the United Nations and other organizations, before moving back to Vermont and working as an economic policy consultant.

In recent years, Janoo became deeply involved with the “well-being economy” movement: an international group of advocates, academics, and experts who criticize what they deem modern capitalism’s obsession with economic growth, and say the “well-being” of humans and the environment should be prioritized instead. They overlap with the “degrowth” movement, which outright argues economic growth should be reduced; last year, Janoo led a workshop at a DeGrowth Institute event on “Degrowth Policy Design.”

Trump’s return to power horrified Janoo. “I’m feeling angry about the rise of fascism and the growing threat of world war, because I feel like we don’t have time for this shit,” she said in a speech at an environmental event last year. ”The planet is on fire and ecosystems are collapsing, and that should really be the focus of all of our attention.” But, she said, “I believe I was born in this moment of history for a reason” and vowed “to fight for democracy — for life.”

So Janoo decided to jump in the race for governor of Vermont. While she is not running on a degrowth platform, her campaign is deeply informed by aspects of the movement’s thought: skepticism about growth’s benefits, a sense that untrammeled capitalism is leading the world to disaster, and that localism provides a better way. For instance, candidates for governor typically pledge that they’d help bring business investment in, but Janoo said in a July debate: “A lot of the problems we’re facing is because we focus so much on attracting external business.” 

“Our economy is not super-diversified, and it is not really centered in the most essential kinds of goods and services you want to make sure people have access to no matter what happens — because honestly, things are bad now and they’re going to get worse,” Janoo told me. “I feel a little bit like a collective prepper right now. My motto is, protect what we love, produce what we need.”

In the Democratic primary, Janoo’s opponent, Aly Richards, had closer ties to the party establishment and led in fundraising. But Janoo ran as a progressive outsider; she promised to advance a “more economically populist vision” instead of “corporate neoliberal bullshit.” Her health plan became a point of contrast with Richards, who said she wouldn’t run on “magical thinking,” and that she wanted a version of universal primary care that would keep insurance companies involved. Janoo won the primary by 2.5 percentage points.

Now, she’s facing Governor Scott, who’s long been viewed as politically untouchable in the state — in 2024, he won his fifth two-year term by a margin of 52 points. But polls show a much closer race this time around, and Janoo could have a national blue wave at her back. If that wave helps carry her into the governor’s mansion. And if she makes it there, Vermont will have its first Democratic trifecta in a decade — and with it, the opportunity for major progressive policy change.

Amanda Janoo’s plan: Single-payer for primary care

Advocates for primary care reform argue that it should be at the top of Democrats’ agenda, in Vermont and elsewhere, because the system is in crisis.

Primary care providers are overwhelmed and underfunded, they say — and, as a result, there aren’t enough. Grumbach, the family physician and UCSF professor, said “the workload, the lack of resources, and the gap in compensation” — as compared to more highly paid specialists — “has made it very hard to recruit people coming out of medical school to want to be family doctors like me.” 

Patients, then, are having trouble finding doctors they like, and aren’t getting sufficient access to preventive care that could help them be healthier. “The emergency rooms are functioning and doing a lot of the work that normally primary care would do,” Janoo told me. “People are waiting a really long time to see anyone, and so often health issues that could have been caught sooner become more serious and dangerous.” 

Finally, both providers and patients complain that insurance companies make the preceding problems worse, by adding administrative burdens and bureaucratic hassle. 

So what would Janoo’s plan do?

First, her plan would guarantee free, government-paid primary and preventive healthcare for all in the state, by cutting insurers out of that part of the system.

Second, she wants to phase out the “fee-for-service” model of care, where primary care providers are paid based on specific services. She’s suggested, instead, either government-paid annual salaries, or per-patient per-month payments.

Third, she wants to try and try and make sure there are more primary care providers in the state, via more spending. “We would need some relocation incentives, so maybe $100 grand if you want to move here, or a student loan repayment program,” she told me. “My hope would also be that we could be a place for foreign-trained medical professionals to come here and be safe and accepted and to bring some cultural diversity,” she added.

As for how it would be paid for, Janoo proposes an income tax increase on the wealthiest Vermonters that, she said, would be comparable to the tax break they got in President Trump’s One Big Beautiful Bill Act last year. Though she hasn’t settled on a final amount, she hopes these new taxes would raise hundreds of millions of dollars.

Would Janoo’s plan work in practice?

In speaking with health policy experts both inside and outside Vermont, though, I heard various questions and doubts about Janoo’s plan.

Some of the problems mix the practical and political. For instance, under this plan, primary care visits would be free, but tests such as MRIs would likely still require the existing insurance system, as would most prescription drugs. Janoo acknowledged to me that deciding how many things the government should pay for would “always be a challenge,” but said her first priority was access to getting people at least some healthcare.

There are also questions about whether this primary spending is really targeted at patients’ most urgent problems. Erasing the copay for your doctor visit might be nice, but those copays weren’t driving people into medical bankruptcy. Janoo’s reform plan leaves the bulk of hefty health spending from hospitals and treatments for very sick people untouched.

The core challenge to Janoo’s reform will be the one that has dogged single-payer reform attempts everywhere: money.

Other questions are about whether Janoo’s hoped-for benefits from better preventive care — she’s said the state could save as much as $300 million a year — will materialize.

“There’s no question that better access to primary and preventive care makes people healthier in the end,” Larry Levitt, executive vice president of the health policy nonprofit KFF, told me. “But advocates have long tried to sell prevention as saving money. I think it’s more likely that it costs money, but keeps people healthier.” One reason for this, he said, is that better preventive care could help identify more underlying illnesses and conditions in patients, and spur more spending to try and address them.

The shift to a salaried model for providers could bring other practical challenges. Though Janoo hopes that ditching fee-for-service will free up providers to see more patients, others suspect a guaranteed salary might incentivize them to see fewer, and wonder what role the government would play in trying to hold such providers accountable.

Finally, I also heard some disconnect between what providers said they wanted, and what Janoo thought they wanted. When we talked, she told me her impression was that primary care providers were most eager for changes in their work environment. “I’ve asked them, ‘If you could get paid a good annual salary — like, average for the nation — and you didn’t have to deal with insurance and the fee-for-service structure, would you do that?’ They say, ‘Absolutely.’”

Yet Grumbach told me that, for the primary care system, “Problem number one is not enough money, problem two is not enough money, and problem three is not enough money.” In his telling, it’s more money that’s the real key to incentivize more new doctors to practice primary care, and help pay other staff and health workers who could actually deliver good preventive care.

If so, the core challenge to Janoo’s reform will be the one that has dogged single-payer reform attempts everywhere: money.

If the government takes on the responsibility of paying primary care providers and setting salaries for them, providers will want those salaries to be high. If they aren’t high enough, the shortfall in primary care providers will worsen. But the higher such salaries are, the higher the taxes the state would need to raise to pay them. Essentially, taxpayers would be asked to shore up doctors’ salaries to keep them in the state — turning the healthcare argument from one kind of difficult political issue to another.

Getting the balance right would be a challenge for the government, with much at stake. But Janoo says her background in industrial policy has convinced her that it’s possible. Furthermore, she hopes, it will be just a starting point for the full single-payer system she still thinks is urgently needed.

“​​My hope is, when I’m governor, that I can start to work with some of our neighboring states,” Janoo said. “Because if we could create a New England-wide system, we could move to universal healthcare really quickly. “I think it’s a moment where people recognize we need a universal healthcare system.”

And, she added, “If we had done it previously, it would be much cheaper than it is now.”

Why your health insurance is dropping GLP-1 coverage

15 October 2026 at 22:00
GLP-1 pens

The promise of GLP-1 drugs has always depended on people being able to afford them. These drugs still cost hundreds of dollars per month if you’re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them — unless their health insurance covers it.

For a while, the trend lines for GLP-1 insurance coverage were positive. As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. Over the summer, Medicare launched a new $50-per-month prescription program. The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system.

At least that’s how things appeared earlier this year. But now, private plans are pulling back from GLP-1 coverage. People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health.

The dilemma reveals one of the structural flaws in American healthcare. For working-age adults, your insurance depends on your job. Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term — but there is a strong incentive to minimize short-term costs as much as possible. It’s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person’s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems, improving their health and saving all of us money as they get older.

“An employer or an insurer making coverage decisions doesn’t necessarily care if they’re saving Medicare money,” said Dan Sacks, a healthcare economist at the University of Wisconsin-Madison. “That’s a classic problem with the American health insurance system, and it’s certainly salient here.”

This mismatch between what’s good for people’s health and what’s good for the corporate bottom line has long been one of the underlying flaws in the US health system. Now access to GLP-1 drugs is shrinking just as these drugs were starting to make a real dent in the US obesity crisis. The stakes couldn’t be higher.

Why employer-sponsored health plans are suddenly dropping GLP-1 coverage

From the beginning, insurance coverage was the big question hanging over GLP-1s and their potential to revolutionize US healthcare. But recently, it looked like we’d turned a corner.

When I attended the Aspen Ideas: Health festival over the summer, pharmaceutical reps seemed visibly relieved that GLP-1 coverage had been picking up among private insurers. In 2026, about two out of every three employer-sponsored plans were covering some of these drugs for weight management, up from about 20 percent just the year before.

“They’re recognizing that this is an investment in their workforce,” said Laura Steele, who leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo. “Yes, there is a budget, and there is a benefit design that every employer has. That’s real. That’s not going away. But they’re also recognizing the overall cost that they’re experiencing by not dealing with this too.”

But as employers and private insurers make coverage decisions for next year, they are suddenly pulling back. At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to one survey by the Business Group on Health — and that number may still increase. A Mercer survey of large employers found that 6 percent had dropped coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it. A separate report from the Health Policy Commission in Massachusetts found that the number of commercially insured people in the state taking a GLP-1 drug had fallen by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off. 

Some of the biggest brands in the US are reportedly eliminating or reducing their coverage: PepsiCo, Starbucks, and Lowe’s among them. And their reasons are simple: It’s too expensive. The drugs still carry a high net price tag — $600 or more for a 30-day supply — and potential demand is high (two in every five American adults have obesity). 

When a lot of people start taking an expensive medication all at once, it’s going to raise costs for employer insurance plans — and they have to figure out how to adapt. Insurers set premiums at the start of each year, based on how many people are on the plan and how much healthcare they are expected to need. But if those estimates are off — say, if more people take an expensive GLP-1 drug than the insurer expected — they have to offset those costs somehow, and raising premiums the following year is a common solution. According to one estimate, premiums are projected to grow by 5 to 13 percent due to GLP-1 costs — and the burden of paying those higher premiums is likely to fall on the workers. The employer can also try to limit GLP-1 use by, for example, asking workers to pay more out of pocket for these drugs; according to Mercer, 27 percent of large US employers instituted some kind of utilization controls for GLP-1 drugs over the past year or plan to next year.

They also have the option to simply stop covering these drugs for weight loss altogether — and that’s the route more and more of them are deciding to take. The abrupt reversal has even caught economists like Sacks off guard.

3 big reasons employer health plans are dropping GLP-1 coverage

  • Employers aren’t invested in people’s long-term health: As Americans switch jobs more often, companies want to cut short-term costs.
  • GLP-1 prices are still high, upward of $600 per month per person for insurers.
  • A lot of people are eligible to take them for weight loss; two in five US adults have obesity.

“I was surprised that anyone would do an about-face because I thought they understood the trade-offs well,” Sacks said. “My guess is that it turned out to be more expensive than they anticipated: Take-up is higher, and possibly more people are sticking with it. That’s one reason that you might not want to continue to offer it.”

For employers, the short-term costs of covering a drug often outweigh the long-term benefits that medication may confer, at least from the employer’s POV. One analysis — notably produced by Blue Cross Blue Shield Kansas — concluded that covering GLP-1s for weight loss increased average employee health costs by $7,000 in the first year and another $4,200 in the second, largely due to the cost of the drugs themselves. And yet at the same time, there were no decreases in obesity-related medical events in that time period. Another study from Sacks and his colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not lead to any cost savings over five years.

So in the short term, these employers are arguably making an economically rational decision — but one that may still come at their employees’ expense. “I’m completely screwed,” said one person on Reddit about Cigna’s plans to drop GLP-1 coverage for their own employees. They’re looking at at least $300 for one month’s supply at cash prices. 

They weren’t alone either: “I’m devastated,” said another person, commenting on Starbucks’s decision to stop covering GLP-1 drugs. They said they had an autoimmune condition that had made it difficult to lose weight — until this new class of medicines came along.

Where GLP-1 coverage goes from here

How could we end up here, where it makes good business sense for companies to make a decision that could potentially harm their workers’ health in the long term? It is at least in part a result of the haphazard way the US has ended up insuring people.

When employer-sponsored insurance started to arise in the mid-20th century, eventually becoming the primary way to cover the working-age population, people tended to stay at the same job for a long period of time. In theory, there was a synergy: Companies wanted their workers to stay productive, and so it was worth it for the company to invest in their long-term health via their insurance benefits. And research has found that people who stay with the same company — and the same insurance plan — tend to have better health than those who switch a lot.

But these days, people change jobs all the time or work various gigs to piece together an income. You probably don’t expect to stay at your job for 10 years — and your employer doesn’t expect you to either. Instead, they want to keep their own costs as low as possible in the short term. This leads them to cut GLP-1 coverage, even though doctors do believe that people could benefit tremendously long term from the weight loss these drugs help them achieve and all of its potential health benefits. 

“There are very real health benefits of these drugs,” Sacks told me. “The fact that we don’t find offsets or they’re even more expensive than we thought doesn’t necessarily mean that we shouldn’t cover them.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here.

In theory, the market is supposed to fix the price problem: Drug companies get a period of exclusivity for the drugs they develop, and then, once that time elapses, cheaper generic versions can come onto the market. But generic semaglutide won’t be available in the US until at least 2031 — and for some versions, the generic competitors aren’t going to debut until the 2040s. Offering GLP-1 coverage could become a competitive advantage for employers, a perk they can offer to entice potential workers as part of their benefits package.

Beyond that, though, the path to more affordable GLP-1s is not immediately obvious right now. A lot of people are already willing to pay cash for these drugs — and that may continue as long as people can afford to do it. But with inflation still steadily rising, these drugs could slip out of reach for more and more Americans.

The government could get involved, but, for now, the federal government’s negotiating authority only covers Medicare, not the private plans that are dropping coverage. Serious healthcare reform is probably off the table until at least 2028, and then only if Democrats win both Congress and the White House and decide to make a healthcare package their legislative priority.

But the lesson of these recent developments is that, at some point, the US may have to look seriously at the underlying problem creating this mess in the first place. A patchwork method of insuring people that privileges short-term cost-cutting over people’s long-term health isn’t a real healthcare system.

The liver transplant system tried to fix its sex bias. Did it work?

12 October 2026 at 12:00
Batches of test tubes.

In theory, getting a donor liver in the United States when you need one should be an extremely equitable process: The sickest patients with the greatest chance to benefit from a donated organ should jump to the front of the line regardless of their gender, race, or other factors. 

But in practice, things look quite different. 

One study from 2020 showed that women were 8.6 percent more likely than men to die waiting for a liver transplant and 14.4 percent less likely to receive a deceased donor liver transplant compared to men. That gap may not seem enormous, but it still represents a significant disparity. As it turns out, it’s rooted in the very system that’s supposed to make the process fairer, a process that unintentionally ranks women lower on the waitlist for livers.

The system in question is known as the Model for End-Stage Liver Disease (MELD). The scoring model has been used since 2002 to rank candidates on the waiting list based on how likely they are to survive without a liver transplant in the short term. The higher your score, the reasoning goes, the sicker you are and the more urgently you need a liver transplant.

One of the values used to calculate the score is creatinine — a waste product made by muscles as they break down proteins or other compounds to release energy. In medicine, the creatinine levels in your blood are used to determine how well your kidneys are functioning because they process and remove creatinine. 

And this is where the system designed for equity gets a little less than equitable for some patients. 

Creatinine levels are affected by muscle mass, and women typically have lower muscle mass than men. A man and woman experiencing the same level of kidney dysfunction will therefore have different levels of creatinine in the body. The MELD model doesn’t take this difference into account — and so lower levels of creatinine in a woman’s blood can make her seem healthier than she is, bumping her farther down the liver waiting list. 

(function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})();

In 2023, Dr. Ray Kim, a transplant hepatologist at Mayo Clinic in Arizona who developed the original system, debuted a new model called MELD 3.0. The model not only seeks to address the sex disparity in liver access but also improve the accuracy of scores for all patients. Among other changes, it takes into account the sex of the transplant candidate and uses it to adjust the MELD score by 1.33 points for women. This is meant to address the difference in creatinine levels between men and women and provide a more accurate understanding of how sick a female patient really is.

Simple fix, right? Even though MELD 3.0 took the sex disparity in liver access seriously and developed changes to combat it, early research on its efficacy found that even this new and improved system hasn’t yet brought men and women to parity on the liver waitlist. 

And the problem may lie less with what MELD 3.0 did than with what it did not do, prompting the question: Are we focusing on the wrong problem? 

Sex matters…but so does size

Before the MELD score, liver transplants were largely conducted on a first-come, first-served basis. Those who were added to the waiting list first, received livers first. If a really sick candidate was added to the waiting list late, say because of delayed diagnosis, they would almost certainly die while waiting for a liver to become available.

The original MELD fixed that problem by creating a measure of urgency that was easy to calculate. The initial model used three main blood test values — bilirubin, creatinine, and a measure of blood clotting time — and later improvements also took into account the sodium level. 

Key takeaways

  • Women are more likely than men to die waiting for a liver transplant in part because the system used to rank candidates on the liver waiting list underestimates how sick women are.
  • In 2023, the liver transplant system adopted a new version of that scoring model, which adds 1.33 points to women’s scores to correct for differences in muscle mass between the sexes. Early research shows that the new model increased transplant rates for women, but the gains were transient.
  • Experts say that the score is only part of the problem. A donated liver has to physically fit inside the body receiving it, so smaller candidates end up waiting longer for a liver they can accept. 
  • The organ allocation system currently has no way to prioritize smaller livers toward smaller patients, who are more often women. Fixing this is likely the key to ensuring equitable liver access for men and women.

Traditionally, the MELD model assigns a score between 6 and 40 to liver transplant candidates. MELD 3.0 adds 1.33 points to women’s scores to account for the differences in creatinine levels between the sexes. The new model also measures albumin, an additional biomarker, and adjusts for interactions between the different variables.

Sommer Gentry, a professor at NYU Grossman School of Medicine and contributor to the paper on MELD 3.0, said that using sophisticated algorithms with more biomarkers not only helps to better predict risk for women, but using a more accurate model also benefits the whole population. The researchers estimate that this fine-tuned MELD 3.0 model will reduce at least 20 waiting list deaths per year. Last year, around 800 liver transplant candidates died while waiting for a liver. 

But creatinine is only one of the two main problems that create a disparity in liver access for women. The second, Gentry says, is body size, an issue that’s not addressed by MELD 3.0. A transplanted liver has to physically fit inside the body of a recipient, and women are typically smaller than men, so a very large liver cannot be offered to a small woman. But the reverse is not necessarily true because receiving a liver that is small for the potential recipient doesn’t typically harm the candidate.    

“The smaller you are, the less likely you are to be offered something that’s actually going to work for you,” Gentry said, adding that women end up waiting longer to receive a liver that will actually fit their body. 

Part of the conversation on sex disparity in liver access is based around which of the two problems — creatinine or body-size interventions — to fix first, and whether it is possible to create equity by addressing just one of the two, Gentry said. MELD 3.0 was an attempt to remove the former barrier. 

“I think that some other papers are coming out that suggest that perhaps the other aspect of size matching is still a concern and still possibly not addressed by the resulting liver transplant system,” Gentry said. 

Why is the new model still falling short?

Gentry believes that MELD 3.0 has increased liver transplant rates for female candidates since its adoption in 2023. But early research, however, suggests that the new model falls short of fixing the problem. 

Studies done on MELD 3.0’s impact on liver transplant rates for women indicate that the model increased the number of liver transplants for female candidates — but the gains were short-lived. 

An analysis published in July of nearly 10 million daily records from over 60,000 candidates on the US liver transplant registry found that rates of completed liver transplants for women increased in the period immediately after MELD 3.0 was implemented, but the increase was temporary. Women’s estimated odds of receiving a transplant drifted back to pre-MELD 3.0 levels by the end of the study period, 15 months after the new model was implemented. Women on the waiting list and women who had received a transplant also had higher scores in the three months right after MELD 3.0 took effect, but their scores later fell back to levels comparable to those of men.

Both the successes and shortfalls of MELD 3.0 demonstrate how rethinking existing policies and standards can help reduce inequities in organ access and healthcare.

The authors think that the early surge in liver transplant rates for women was a onetime catchup. MELD 3.0 pushed a group of women who had been stuck on the list — sicker than their old scores suggested — over the priority threshold all at once, leading them to receive liver transplants. 

Notably, the one effect that did persist was that under MELD 3.0, women received more “organ offers” than before. Every time a deceased donor liver becomes available, the system generates a ranked list of the patients suitable to receive that organ. Under MELD 3.0, the number of times an available liver was offered to a female candidate increased, probably because their (more accurate) MELD 3.0 scores better reflected how sick they were. But they’re not necessarily receiving those livers, presumably because of organ size issues. 

These findings suggest that revising the MELD criteria alone may not be enough to eliminate the sex disparity, especially if the body-size disadvantage is part of the problem. 

The authors say that a patient’s sex is merely a poor proxy for the real issue — we don’t have allocation systems in place to ensure that candidates with smaller body sizes also have the same robust access to livers.

Toward liver donation equity for all

If we could figure out how to better address questions of body size in organ donation, the benefits could be enormous. According to Gentry, body-size disparity affects the organ allocation system in general. Similar issues arise with heart and lung transplants too, where the size of the organ relative to body size has to be taken into consideration during organ allocation.

She says that a size-aware organ allocation system would therefore benefit patients on the waiting list across the board. Whether an available organ is the right fit for the potential recipient should be weighed heavily in allocation algorithms, rather than just a list of ranked waitlisted candidates. 

“That should be a larger consideration in sorting the patients who will be offered a certain organ — to ask if this organ is especially suited to one kind of patient over another,” Gentry said.

Under such a system, she said, smaller livers could be offered first to the smallest candidates on a ranked list of those who are also sickest. The assumption is that a smaller candidate will have to wait longer for a viable liver that fits them, even if they have a very high MELD score. 

For such a policy to be instituted, the Organ Procurement and Transplantation Network – a nonprofit that oversees the distribution of donor organs — would have to approve it. And before such a system could be presented to the regulatory organization, more research is required.  

It is often the case in medicine that our definition of what counts as a healthy body is measured against the average white male. This too often lowers access and quality of care for both women and people of other races. For example, the standards for creatinine levels in blood reduced access to kidney transplants for Black transplant candidates for years until recent efforts were made to start correcting it. 

In that sense, both the successes and shortfalls of MELD 3.0 demonstrate how rethinking existing policies and standards can help reduce inequities in organ access and healthcare. The conversations and critiques that followed its rollout have exposed a clear gap in organ allocation strategies, one that disadvantages a large group of patients. Closing that gap, not just in liver transplantation but across the board, could bring us a step closer to equity while also making more efficient use of the organs available to save lives.

“There’s no mechanism right now, if a small liver is available, for offering it preferentially to the small women who might not be able to accept lots of other organs that are becoming available,” Gentry said. While fixing the model to rank women more accurately on the liver waiting list is a start, including body-size considerations in the organ allocation system might be the real bottleneck to address.

Is this the cure for Alzheimer’s?

8 October 2026 at 22:00
A healthy brain
Scientists in the US and Europe are exploring whether an experimental surgery can treat Alzheimer’s disease. | Fiordaliso/Getty Images

The videos are astonishing. In one scene, a senior Chinese woman appears lost in the wilderness of dementia, unable to answer basic questions; in the next, she seems to be lucidly chatting and shucking beans for dinner. By all appearances, years of cognitive decline had been rapidly reversed after the patient underwent an experimental new surgery.

The only problem is: No one is sure if it’s real. 

It’s difficult to take any video at face value in the age of AI, and this experimental procedure happened in China, a country with a recent history of controversial science touting extraordinary but questionable claims. In the past few years, researchers there have published several papers reporting promising results from a procedure that purports to attack Alzheimer’s disease in a peculiar way: by connecting vessels from the lymph nodes in the neck to nearby veins in an attempt to drain the brain of harmful waste. But these have been small studies that did not include a control group. The doctor who first pioneered the surgery there has reportedly been placed under arrest, and the Chinese government has sought to stop most physicians from performing any more of these operations. 

Is that because it’s a scam? Or because it’s dangerous? Or could it be because there have not yet been proper randomized trials, tested against a placebo, to assess the procedure’s safety and efficacy? There are new studies being planned in China to more rigorously evaluate the surgery.

But scientists elsewhere in the world have a lot of questions. And now, a small group of researchers in the US and Europe are endeavoring to find the answers. Within the next few years, we should know whether this surgery really could be the miracle that the viral videos make it appear to be — or another much-hyped treatment that ultimately fizzles out.

Dr. Adnan Siddiqui, a neurosurgeon at the University at Buffalo who is leading an initial US-based study of this procedure, previously helped develop a new treatment for severe stroke patients. This gave doctors a valuable new technique for treating patients during an emergency, and he told me he saw it rapidly change the standard of care around the world. In an interview, he cautioned that a lot more work needs to be done to assess this proposed new Alzheimer’s treatment — but at the same time, he’s optimistic.

“The whole world’s paradigm changed in literally a blink of an eye. It can happen. And I’m hoping this might be that second home run,” he said. In “2027, we’ll start getting clear signals in one direction or the other. By 2028, 2029, we would know whether this is real or not.”

Why this Alzheimer’s surgery really might work

The promise of this controversial new procedure lies in the lymphatic system, which is essentially the body’s drainage system. According to scientists’ best current theories about Alzheimer’s, the brain’s filtration system gets worse as we age, and as a result, plaque made up of amyloid proteins as well as tangles of tau proteins can accumulate in people’s brains and eventually lead to neurological damage, leading to the severe memory loss of Alzheimer’s disease. Researchers have found evidence that those amyloid and tau proteins also accumulate, not just in the brains, but also in the lymph nodes in older people. 

So could a minimally invasive surgery to improve the brain’s drainage have such a dramatic impact on Alzheimer’s disease? 

Siddiqui, who also runs the Jacobs Institute at the University of Buffalo, which is focused on new technology for vascular and neurological disease, had been interested in the lymphatic system’s role in Alzheimer’s before he ever heard about this experimental work out of China from a colleague years ago. The colleague had gone to see Dr. Qingping Xie, the surgeon who started performing lymphatic surgery on Alzheimer’s patients about six years ago. To investigate further for himself, Siddiqui went to South Korea to meet a plastic surgeon, Dr. Joon Pio Hong, who was performing a new “more refined” version of the same basic procedure, as Siddiqui put it. But as in China, these were not proper randomized experiments. There was no placebo.

So Siddiqui wanted to see if he could test it himself. After performing proof of concept operations in 2025 with a new microrobotic tool (for a rare disorder involving constricted blood vessels in the brain), he and his colleagues decided to take an even bigger swing: testing this new technology to perform the lymphatic surgery for Alzheimer’s.

The researchers applied to the US Food and Drug Administration and received approval late last year for five initial procedures; over the summer, they got the green light to perform the procedure on 15 patients. Several operations have already been performed, and Siddiqui told me he had four more lined up next week.

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

The mechanism makes superficial sense: If Alzheimer’s is the byproduct of amyloid and tau building up in the brain because the body gets worse at filtering them out, bypassing a clogged “drain” in the lymphatic system could help to clear the proteins and relieve symptoms. It is, by a different method, the same therapeutic target as recent breakthrough drugs that slow down the cognitive decline of an Alzheimer’s patient.

But instead of an injection, the procedure involves a small incision in the neck, allowing surgeons to connect lymph nodes to a vein. The hope is that creating this new drainage route will help the brain clear amyloid and tau more effectively and “hopefully bypass whatever plugs that might be there in the system,” Siddiqui said.

This first round of US surgeries are part of what’s called an early feasibility study. “You’re just trying to prove that it’s definitely safe and definitely doable and maybe effective,” Siddiqui said. They’re measuring not only the patients’ cognitive performance but other data points — such as changes to their gait — for any sign of benefit or harm.

If results are promising, a second feasibility study will involve a larger number of patients — 50 or so. After that, if the evidence suggests they should move forward, the scientists would start to introduce placebos. In the case of surgery, that means some patients would receive “sham” surgeries that wouldn’t actually do anything. Then investigators would compare the experiences of the two groups: the people who received the fake surgery and the people who got the real thing.

If the latter group improves significantly more than the former, that would allow scientists to say definitively: Yes, this surgery actually works to treat Alzheimer’s.

“Obviously, this is exactly the kind of disease where there’s so much hype and so much hope,” Siddiqui told me. So it is essential to build out the careful research to substantiate it.

But let’s not get ahead of the science

Siddiqui has been in this position before — and he’s seen it go both ways. There was the new stroke treatment that proved successful and has since become the standard around the world. But he was also an early investigator of a multiple sclerosis treatment, somewhat similar to the Alzheimer’s surgery. After initial promise, it failed when the randomized trials began.

“I wouldn’t be a neurosurgeon if I was not an eternal optimist,” he said. “However, I’m a clinical trialist, and I always respect placebo.”

Placebos are essential, but they are also tricky. If somebody thinks they have received an active treatment in a study, they tend to think they’re going to benefit. This goes for surgical treatments as well. So following patients’ and their symptoms after the intervention is essential to seeing just how much of the effects can be attributed to the treatment and how much could be placebo effect. The latter of which could also be reinforced by loved ones who are desperate to see their parent or spouse get better. 

Alzheimer’s is also a complicated disease that we still don’t totally understand. While scientists think there is a relationship between amyloid and tau proteins and Alzheimer’s disease, other factors, such as inflammation and vascular health, could also have a role. Some prior drug candidates have successfully cleared amyloid plaque, but patients didn’t get better. Some people have amyloid build-up in their brains but never develop Alzheimer’s disease.

Dr. Bohdan Pomahac, division chief of plastic and reconstructive surgery at Yale School of Medicine, is overseeing studies designed to establish more of the basics of how these proteins pass through the lymphatic system. This research includes investigating whether obstruction actually occurs in Alzheimer’s patients, and if so, where exactly those blockages usually are. Only after they do this work, he said, would his team be comfortable proposing surgeries to relieve the blockage and see if that helps improve Alzheimer’s patients’ symptoms.

He told me about having seen Xie, the procedure-pioneering Chinese surgeon, speak during a plastic surgery conference a few years ago. (Plastic surgeons are experts in the kind of microsurgery necessary for the procedure, and several are involved in the ongoing Alzheimer’s trials.) 

“I think most people, including myself at the time, dismissed it as, ‘This is some sort of a charlatan.’” Pomahac said. “But he kept coming back to conferences every year and started to show more and more videos. We were not sure. Is it actors? You couldn’t tell what’s going on.”

Which is why he is dedicated to doing more of the foundational research to understand Alzheimer’s first. “Rushing to the operating room makes no sense in my mind at this point,” Pomahac said. “I think there’s a lot of work that needs to be done to really identify the site of surgery and what type of intervention would be most effective.”

Even if you set this surgery aside, this is an exciting moment for Alzheimer’s science. And although waiting any longer is excruciating for those watching loved ones with the disease progress, progress’ velocity by all accounts is increasing.

“We are finally doing the kinds of rigorous studies that will give us some degree of confidence that there’s something real here or not,” Siddiqui told me. “We’re not quite there yet.” But in just a year or two, we should know much more.

The real reason the Russia plague case should scare you

6 October 2026 at 22:55
A researcher at a BSL-4 in Hungary during the Covid-19 pandemic.
A researcher at a BSL-4 in Hungary during the Covid-19 pandemic. | Akos Stiller/Bloomberg via Getty Images

A woman’s death last week near a Russian facility studying the plague immediately put the world on alert. This is the plague, after all, responsible for the deaths of some half of the humans in Europe during the worst outbreak in the 1300s. And it happened in Russia, a country with a long history of bioweapon experimentation.

After the Covid-19 pandemic — which many people, including many scientists, genuinely believe started with the virus escaping from a Chinese laboratory — the worst-case scenario was obvious: What if this is another lab leak that seeds a global outbreak?

That’s not likely, for a number of reasons (the facility is very isolated, plague is not nearly as infectious as Covid, it’s easily treated if caught early). But that doesn’t mean our work with such dangerous pathogens has gotten any safer; in fact, it may be betting less so. The anxiety about the Russian outbreak is a window into two trend lines that do worry global health experts: In the six years since the Covid-19 outbreak, the world has been building even more bioresearch facilities, some in places where that kind of work has never been done before; meanwhile oversight of the science and the security measures at those facilities is struggling to keep up.

Every day, humanity is playing with fire, studying and tinkering with deadly viruses, bacteria, and parasites in laboratories all over the world. And despite the recent debates over rogue AIs or AI-assisted humans intentionally developing bioweapons to wipe out humanity, the Russian incident is a reminder that a simple accident — human error — could pose as much of a threat as malice. While it is hard to confirm the details, local reporting suggests the worker may have been infected after breaking a test tube. And if that’s true, this would, of course, not be the first time that a mistake at a highly secure lab has put people’s lives at risk.

“We are rolling back any progress we made post-Covid, in ways that are going to have long-term effects on our ability to respond to any kind of outbreak.”

Gregory Koblentz, co-founded the Global BioLabs project

Since the pandemic, there has been a dramatic uptick in facilities being built to handle some of the most dangerous pathogens in existence. At the same time, there is still no global authority in charge of oversight for these sites. The US, once the world’s public health leader, has pulled out of the World Health Organization, which issues security guidance for labs around the world and helps coordinate a response when there is a possible emergency, and cut funding for the federal agencies responsible for overseeing US biosecurity facilities. And even after something as global as Covid, the world is still struggling to cooperate and rapidly share information during a health crisis; even now, it can be hard to be sure what is happening in Siberia. Our only sources of information are a Russian government prone to withholding and distorting information, and local news reports that are difficult to verify.

Even if this Russian plague threat fizzles out as expected, one day, we may not be so lucky. 

“We are rolling back any progress we made post-Covid, in ways that are going to have long-term effects on our ability to respond to any kind of outbreak, whether it’s natural or deliberate or an accident,” Gregory Koblentz, who studies global biosecurity at George Mason University and co-founded the Global BioLabs project, told me. 

But there are clear things that can be done, before our luck runs out. 

Countries are building more high-level biolabs, but oversight is falling behind

One of the side effects of the pandemic was a biological laboratory building boom that followed in its wake. Global BioLabs, the research initiative Koblentz helps run, has sought to create a comprehensive survey of high-level labs around the world. Take Biosafety Lab, Level 4 facilities, for example; these are built to handle the most dangerous pathogens in existence, like ebola and smallpox. Global BioLabs noted in its 2023 report that “the number of BSL4 labs is rapidly increasing.” 

This is not the first time that a public health emergency has led to a biolab buildout: The post-9/11 anthrax scares and the first SARS outbreak in the early 2000s both led to countries constructing new facilities. In the late 1990s, there were fewer than 10 BSL4 labs in the world; by the late 2010s, there were almost 40. 

But the pandemic accelerated construction once again. In 2021, there were 59 BSL4 labs either in operation, under construction or actively being planned worldwide; by 2023, 10 more facilities had been completed or were in the works, according to Global BioLabs.

Part of the reason for the buildout is a harsh lesson of the pandemic: Developing countries realized they could not depend on wealthier countries to also prioritize their needs during a serious crisis. So they wanted the capacity to handle deadly biological material themselves in case, for instance, they have a local outbreak and want to be able to safely identify the cause. India alone is planning four new BSL4 facilities; at least five countries — including Brazil, Kazakhstan, Saudi Arabia, Singapore, and Spain— have started building or recently opened their first BSL4 lab. As a result, this construction is happening in places with less institutional experience doing this kind of work, where government oversight and stability have been weaker. 

“The more facilities that are working on this raises concerns about whether all this work is necessary,” Koblentz said. “And do they have the appropriate biosafety and biosecurity management systems in place?” 

That could raise the risks of unsound safety protocols — and ultimately of more high-stakes accidents. On top of that, according to the 2023 Global BioLabs report, about 75 percent of the existing operational BSL4 labs in the world are located in city centers, having at least 50,000 people living within 2.5 miles of the lab, “where dense populations could exacerbate the impact of an accidental release.”

And yet, even as lab construction takes off, national and international standards for governing these facilities and the research conducted there remain lax. There is no global organization that inspects or regulates these sites. One key voluntary group — the International Experts Group of Biosafety and Biosecurity Regulators — has actually gone defunct in recent years, Koblentz said. And national laws are patchy: Only one of the 27 countries with a BSL4 lab has comprehensive national legislation regulating “dual-use” gain-of-function research, in which scientists can tinker with pathogens to make them more transmissible or more virulent — and better understand how they work.

The WHO’s pandemic treaty initially included stronger biosecurity protections, but those were watered down during the debate over the document  — and either way, the treaty has still not been finalized. The US has of course also withdrawn from that and other international efforts to improve pandemic preparedness, further examples of the failure to forge more global cooperation in the wake of Covid. 

We need a more transparent approach to dangerous — but potentially life-saving — science

It could be easy to say we should simply stop studying dangerous viruses or enhancing them, even in highly controlled laboratory settings — but the situation is not that simple. Scientists do this kind of work to prepare for the next pandemic, to better understand how the viruses and bacteria that pose the biggest threat to humanity actually function, so that we can beat them back as quickly as possible. 

If you told somebody on the street that scientists are tinkering with a virus to see how it could become more dangerous, they would probably want the scientists to stop. But if you told them those scientists are doing work that could lead to faster therapeutics or vaccines during the next pandemic and avoid the need for lockdown and save millions of lives, they might be more open to this kind of research.

“The real question is: ‘What are the risks and what are the benefits?’” Beth Cameron, senior adviser to the Brown Pandemic Center at Brown University, told me. “We need to have a more rational conversation about what we’re actually talking about,” she said about these sorts of threats that are poised to have, as she puts it, “large-scale societal consequences.” 

And some of those are still circulating today. The reason Russia has this Siberian lab dedicated to plague research is because plague is still endemic in Russia.

“The dangerous pathogens are there already,” Koblentz said. The question is, he said: “How do you do it safely and securely?”

A starting point would be individual labs adopting new safety protocols, such as those from the International Organization for Standardization that were introduced shortly before the pandemic, Koblentz said. Additionally, as countries are building out their lab facilities, they need to develop strong oversight standards at the same time; the buildings may be flashy and have state-of-the-art equipment, but governments also need to address the mundane work of how to inspect and maintain safety once work begins as an equally important part of the process.

“If this is their first lab, in some cases, they don’t have very strong national legal and regulatory mechanisms for biosafety and biosecurity. They might not have the human capital,” Koblentz said. The regulatory side of the project unfortunately gets “short shrift,” he said.

Ideally, the world would have an international mechanism for auditing these sites, Koblentz said, something like an International Atomic Energy Agency but for biosecurity. There would be more transparent debates about what kind of research is done at high-security labs and whether it is truly important.

Better worldwide biosecurity will also likely require the US once again becoming a global health leader. The withdrawal from multinational groups like the WHO and cuts to government science funding have left everyone more vulnerable. Politics has consequences — including for our risks of a biosecurity catastrophe.

“Our level of preparedness for an outbreak, whether it is a lab accident or a natural outbreak of plague or anything else has been dramatically reduced in the last two years,” Koblentz said. “We’ve got a whole lot of problems that are self-inflicted at this point because of what the Trump administration is doing.”

The pandemic should have been a lesson in how important biosecurity really is. Instead, we’re unlearning its lessons in less than a decade. The Russian plague incident could be an essential wake-up call.

Why are doctors paid less for procedures on women?

23 October 2026 at 12:22
an illustration of two doctors in white coats with stethoscopes around their necks. The doctor on the left side is a woman and holding a patient’s chart. The doctor on the right is a man holding a stack of oversized cash in the same position.

This story was originally published in The Highlight. To get access to member-exclusive stories like this every month, become a Vox Member today.

In the moody alcoves of a lobby bar in Chicago in 2021 over French 75s, Dr. Louise King, a gynecologic surgeon, and Katie L. Watson, a bioethics professor, found themselves in conversation about a topic that had long frustrated them both: Female surgeons are consistently underpaid compared to male surgeons, even after accounting for specialty, rank, age, and other factors. 

What troubled them even more was how the pay gap compounded in King’s own field. Surgeons who perform procedures that are specifically for women, like gynecological surgeries, are paid less for their services than surgeons who perform comparable surgeries for the male anatomy. Gynecologic surgeons are also predominantly women. Over the course of the conversation, Watson termed this situation “double discrimination,” a phrase that captures the overlapping dilemma of lower pay for surgeries in a specialty that is overwhelmingly female and also serves a primarily female patient population.

Key takeaways

  • Doctors are paid less for gynecologic surgeries than for similar surgeries on men. That pay gap has barely improved in the last 20 years.
  • The value of each procedure is largely set by a committee of doctors that relies on self-reported, and sometimes inaccurate, surveys in which doctors report the skill and time their own procedures require.
  • When doctors are paid less to treat women’s health concerns, hospitals allocate fewer resources to those services, leading to worse outcomes for women 
  • Experts say the gap can be closed by reconsidering how gynecologic surgeries are valued and removing sex-specific billing codes.

That term, which has since entered the medical literature, stuck because the problem it describes has been well documented for decades. In 1997, a group of gynecologic surgeons published a paper in the journal Gynecologic Oncology with a title that gets straight to it — “Is Adam worth more than Eve?” Dr. Barbara A. Goff, now chair of Obstetrics and Gynecology at University of Washington Medicine, and colleagues found that doctors are paid around 44 percent more for performing male-specific procedures than analogous female-specific ones. 

In the three decades since, the problem hasn’t been fixed. To the contrary, it has been effectively institutionalized, built into the systems and codes that determine how surgeons bill for procedures of all kinds. Today, gynecologic or female-specific procedures are in large part still reimbursed at lower rates than male-specific procedures even when they take similar time and skill.

Those disparities have consequences that extend beyond the compensation of individual doctors. When gynecological procedures don’t bring in as much money to hospitals, those same hospitals are disincentivised to offer women’s health services. That can lead to worse care for women and, crucially, fewer training opportunities for the surgeons who do that work. 

But this historically persistent inequality is not a foregone conclusion.

How healthcare services are billed changes all the time as procedures get reevaluated, new ones get added, and medical societies and experts push for revisions. In fact, one of the biggest changes in how maternity care is billed and reimbursed is set to take effect early next year, splitting up services for prenatal care, delivery, postpartum care, and more. While this is a long-overdue fix for obstetrics, gynecologic surgery — which covers most of a woman’s life outside of childbearing years — continues to be left out of the conversation. 

And although real change will require concerted efforts, King and Watson — and other advocates who have spent years documenting this disparity — have a fairly clear sense of how to start fixing it.  

How surgical procedures are valued

The work of deciding how much a medical procedure is worth starts well above the head of any given doctor, medical practice, or hospital. In the United States, the Centers for Medicare and Medicaid Services, a federal agency that administers healthcare and health insurance policies, sets rates for different procedures based on a metric called relative value units (RVUs). An RVU is supposed to take into account how long a procedure takes, the skill it requires, and the intensity of work it demands. Both Medicare and private insurers consider these figures when they’re settling on reimbursement levels. If a procedure has a higher RVU, it is valued more highly, and makes more money.

In a recent study, cheekily titled “Price and Prejudice,” researchers from the Mount Sinai Health System found that out of 55 pairs of sex-specific procedures that they evaluated in 2023, 75 percent had lower RVUs for procedures on female patients. On average, RVUs for male-specific procedures were 30 percent higher, and when those procedures were performed in a hospital or surgical center, surgeons were paid around 26 percent more.

For example, doctors will often perform biopsies — taking a small sample of tissues, cells, or fluids — on both male and female genitalia to diagnose problems. In 2023, researchers found that Medicare’s standard national rate for reimbursing surgeons was $121.32 for a penile biopsy but only $65.74 for a vaginal biopsy. 

Loading interactive graphic…

.ag-root{--ag-m: #3b3fb6;--ag-f: #e2552c;--ag-m-ink: #3b3fb6;--ag-f-ink: #c74d2a;--ag-bg: transparent;--ag-knock: #ffffff;--ag-card: #f5f4f1;--ag-ink: #16161d;--ag-ink-2: #4a4a55;--ag-ink-3: #686872;--ag-rule: #16161d;--ag-grid: #e4e3df;--ag-track: #ebeae6;--ag-focus: #1a73e8;--ag-head: var(--ag-host,Georgia,"Times New Roman",serif);--ag-ui: -apple-system,BlinkMacSystemFont,"Segoe UI","Helvetica Neue",Helvetica,Arial,sans-serif;--ag-head-weight: 700;--ag-head-track: -0.01em;--ag-ease: cubic-bezier(.2,.8,.2,1);container-type: inline-size;container-name: ag;display: block;position: relative;width: 100%;max-width: 760px;margin: 2.25em auto;padding: 14px 0 10px;border-top: 3px solid var(--ag-rule);background: var(--ag-bg);color: var(--ag-ink);font-family: var(--ag-ui);font-size: 16px;line-height: 1.4;text-align: left;-webkit-font-smoothing: antialiased;-webkit-text-size-adjust: 100%;box-sizing: border-box}.ag-root.ag-root{font-family: var(--ag-ui);font-size: 16px;line-height: 1.4;font-style: normal;font-weight: 400;letter-spacing: normal;word-spacing: normal;text-transform: none;text-indent: 0;text-align: left;color: var(--ag-ink)}.ag-root.ag-root i,.ag-root.ag-root em{font-style: normal}.ag-root.ag-root .ag-ft em{font-style: italic}.ag-root.ag-root *,.ag-root.ag-root *::before,.ag-root.ag-root *::after{box-sizing: border-box;letter-spacing: inherit;font-family: inherit;text-transform: inherit}.ag-root[data-ag-palette="teal"]{--ag-m: #00829b;--ag-f: #d4661a;--ag-m-ink: #007a91;--ag-f-ink: #b85a1a}.ag-root[data-ag-palette="violet"]{--ag-m: #5b3fb0;--ag-f: #c4661c;--ag-m-ink: #5b3fb0;--ag-f-ink: #b35e1c}.ag-root[data-ag-style="feature"]{--ag-head: "Bricolage Grotesque","Helvetica Neue",Arial,sans-serif;--ag-ui: "Instrument Sans","Helvetica Neue",Arial,sans-serif;--ag-head-weight: 800;--ag-head-track: -0.025em}.ag-root[data-ag-style="minimal"]{--ag-head: var(--ag-ui);--ag-head-weight: 650;--ag-head-track: -0.015em}.ag-root[data-ag-mode="dark"]{--ag-bg: #141417;--ag-knock: #141417;--ag-card: #1f1f24;--ag-ink: #ededf2;--ag-ink-2: #b9b9c4;--ag-ink-3: #8b8b97;--ag-rule: #ededf2;--ag-grid: #2c2c33;--ag-track: #26262c;--ag-focus: #8ab4f8;--ag-m: #6f73e8;--ag-f: #e5603a;--ag-m-ink: var(--ag-m);--ag-f-ink: var(--ag-f);color-scheme: dark}.ag-root[data-ag-mode="dark"][data-ag-palette="teal"]{--ag-m: #1e9db3;--ag-f: #dd7430;--ag-m-ink: #1e9db3;--ag-f-ink: #dd7430}.ag-root[data-ag-mode="dark"][data-ag-palette="violet"]{--ag-m: #8a6ee6;--ag-f: #cf7f22;--ag-m-ink: #8a6ee6;--ag-f-ink: #cf7f22}@media (prefers-color-scheme: dark){.ag-root[data-ag-mode="auto"]{--ag-bg: #141417;--ag-knock: #141417;--ag-card: #1f1f24;--ag-ink: #ededf2;--ag-ink-2: #b9b9c4;--ag-ink-3: #8b8b97;--ag-rule: #ededf2;--ag-grid: #2c2c33;--ag-track: #26262c;--ag-focus: #8ab4f8;--ag-m: #6f73e8;--ag-f: #e5603a;--ag-m-ink: var(--ag-m);--ag-f-ink: var(--ag-f);color-scheme: dark}.ag-root[data-ag-mode="auto"][data-ag-palette="teal"]{--ag-m: #1e9db3;--ag-f: #dd7430;--ag-m-ink: #1e9db3;--ag-f-ink: #dd7430}.ag-root[data-ag-mode="auto"][data-ag-palette="violet"]{--ag-m: #8a6ee6;--ag-f: #cf7f22;--ag-m-ink: #8a6ee6;--ag-f-ink: #cf7f22}}.ag-root[data-ag-mode="dark"]{padding-left: 16px;padding-right: 16px}@media (prefers-color-scheme: dark){.ag-root[data-ag-mode="auto"]{padding-left: 16px;padding-right: 16px}}.ag-root.ag-root .ag-x,.ag-root.ag-root p,.ag-root.ag-root h2,.ag-root.ag-root h3,.ag-root.ag-root button,.ag-root.ag-root select,.ag-root.ag-root input,.ag-root.ag-root ul,.ag-root.ag-root li,.ag-root.ag-root label,.ag-root.ag-root table{margin: 0;padding: 0;border: 0;background: none;box-shadow: none;font: inherit;color: inherit;letter-spacing: normal;text-transform: none;text-decoration: none;line-height: inherit;min-height: 0;width: auto;max-width: none;float: none}.ag-root.ag-root svg,.ag-root.ag-root .ag-pt-svgwrap svg{display: block;max-width: none;height: auto;overflow: visible}.ag-root.ag-root button{cursor: pointer;-webkit-appearance: none;appearance: none;border-radius: 0}.ag-root.ag-root :focus{outline: none}.ag-root.ag-root :focus-visible{outline: 2px solid var(--ag-focus);outline-offset: 2px;border-radius: 4px}.ag-root.ag-root .ag-sr{position: absolute !important;width: 1px !important;height: 1px !important;padding: 0 !important;margin: -1px !important;overflow: hidden !important;clip: rect(0 0 0 0) !important;white-space: nowrap !important;border: 0 !important}.ag-root.ag-root [hidden]{display: none !important}.ag-root.ag-root .ag-hed{font-family: var(--ag-head);font-size: 23px;line-height: 1.12;font-weight: var(--ag-head-weight);letter-spacing: var(--ag-head-track);color: var(--ag-ink);text-wrap: balance}.ag-root.ag-root .ag-dek{font-size: 15px;line-height: 1.4;color: var(--ag-ink-2);margin-top: 6px;text-wrap: pretty}@container ag (max-width: 480px){.ag-root.ag-root .ag-hed{font-size: 22px}.ag-root.ag-root .ag-dek{font-size: 14px}}.ag-root.ag-root .ag-ft{margin-top: 14px;padding-top: 12px;border-top: 1px solid var(--ag-grid);font-size: 12px;line-height: 1.45;color: var(--ag-ink-3)}.ag-root.ag-root .ag-method{margin-bottom: 8px;font-size: 12.5px;line-height: 1.5;color: var(--ag-ink-2);text-wrap: pretty}.ag-root.ag-root .ag-method b{font-weight: 600;color: var(--ag-ink)}.ag-root.ag-root .ag-ft-row{display: flex;flex-wrap: wrap;align-items: baseline;gap: 2px 14px}.ag-root.ag-root .ag-ft em{font-style: italic}.ag-root.ag-root .ag-credit{color: var(--ag-ink-3);white-space: nowrap}.ag-root.ag-root .ag-about-btn{margin-left: auto;padding: 4px 0;font-size: 12px;font-weight: 500;color: var(--ag-ink-2);display: inline-flex;align-items: center;gap: 6px;white-space: nowrap}.ag-root.ag-root .ag-about-btn::after{content: "";width: 5px;height: 5px;margin-top: -3px;border-right: 1.5px solid currentColor;border-bottom: 1.5px solid currentColor;transform: rotate(45deg)}.ag-root.ag-root .ag-about-btn:hover{color: var(--ag-ink)}.ag-root.ag-root .ag-ft-end{margin-left: auto;display: flex;align-items: center;gap: 14px}.ag-root.ag-root .ag-logo{flex: none;align-self: center;width: 31px;height: 15px;background-color: var(--ag-ink);-webkit-mask: url("data:image/png;base64,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") center / contain no-repeat;mask: url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAIQAAABACAQAAABxNBeOAAANcUlEQVR42tXbedRcZX0H8M+9d94kJITERBIoYASBtiyCpQcKLYgoHkpVVJCKylZ7WpYCttjWhUJdEE9BkKIeWpFTgZMeKBL2IOeAbMq+SAQEArIECCQEQhID78y9T/+Y5x1muffOwKE13Plv5j6/53m+v32ZxCW2kJhnhkJitKeQ4QXLrTVmgX+VKQSbWGAMmbnmIJcOrM018IJnZC51kkxunXjGZCZ7l+8KcmGETyG40ofMNVkm66KVashkxsx1oIdKKLYE9/q0ucY0rKPPFfGg9Z+W4OKR6M10bx8UTcFZxqzDz5jUh0cCopB7r8QkSaUqJRKTsKNmFxBNwdeRaIyshP/vT4KNrI6CX68Wy2wQV9Q/Ga7vgNsUnM26CkK3MVtuKcLQNbliRHATN0WKuYbbHC2Tj7DD7xCIINGybCQgpttgROrBkg71NQ6OamLdlogUz4+kQuuZMZJq6MBaSJ1gscaIsvQ7BSLBsyNIRCExa2QgNkYuc5+z1p2IYZiNaAMxCo/fObI0bB/3OF4+ktq9DYFIhipRbrJdMOYa16/b8tANRIhAjCLyc0akvJN5CsFJ1vmnF4jnB2TkzQOR4ACkrnHHui4P/ZC8y6tDQ6qm4AKGZAqJxFRPC4LdY3D1NnkSrG/pUCBagmuGXq2BTwkKN40oZesYGA8MzUFbgjuH2pIUNyoEf/H2koeJw/9saOKVCxbLaqHIJHZRKNwjXUflIelNGtM+IIZnGwlmWH+ok/17icSpiiFAJP1HeiuuNYThDWlka2km3MB3ojmszz9ftVmN5qcS77FW4eHKZD2RafSpTLusk7xBALIus52NoIQTb0wyw7TXmdtv+58dyahONtPTNYi3HG0KzjCuodW3Po1VjfYzxXSp1dYoYibSGDlDzeSRznSpV+TxfKHm7LlNHWRvW1pf02MucbZXe5nawEFDJaJtJfasNIGJxGzLFZ42rU8ekg7wG/mYky3wmCUWud8ST7rSyfY2tYdvwyKghn39h3st9YIHnW+fkni5e0XiK17qu8/dNhsUmg+MULlsCfavjCQaOF4Q/HPfO+3LzXCwK70caV1uV7PM9D6Xx28e902bREDr3XPiML8cON0Cc0qhSLGBq2Is1JIrFFpeE9xpvf5XtxkSRUyEVEdUAJFITLFYYZlZXZdJJdjQiZ6KVMYV/rNn7d2aURqXOa6Wswl2cUuUz2a8VK6lJXjIpgNrE6lpbon7Dt7nC/0aNNeqkWLLEyuAmFCv4Ftdb7Sd7TGejRLV0lJ40lSpRqfC+U+CpjyCcZkZpVC05eoETUGrRHrHBXeZ0mN22yp5Wfx1UNVz9wyawaeGKkdT8L0KIFKJ2xVe8XuSjh6zvZvj2qJD49geqBIf78QwRbzO7AEoGtjIQkFRGe+MC77TY2ca+FoFDO3PK4NW9Z6RgLiw1KBl2FMQfL8jBxkOt7oLhLbEvWR2l+pk2KcnmBsX/NzkHs42sLPHBWtrwr5CS8u2HUZk2F2ra//Bz5rBiywcGlu2BNdViu3lCmttKZHGo3y7s6obyv/ugTLDx/reGo9176wLhv290uO9qlk1v4sVUzxW4w0LoT8YaODcoQ40F9xboRbbGo/ZaRal4ZweWXgdyk91OdP2zp8d2Lkp+FAXraPj94td7Y4aW1YovGoeUhnOsMr8SuhaCpcOAvHNkYB4wqSBbCPD2YKmHToR3zklmlkIVpnTs76B4wZ2bincoxGvc5IguMIHTQZH1shuM7rvyRLbCA6SWqoohaIl+MQgEEeNFGSvGCjgphIbe1lwGRGGb5UaqJbg+j7VauCUkp3HBfuB0wXPOrAnmD6lEoqW4I5I9za30bFBeckON/fbuwZdtrsOiHGbl1zlREHhTzEpivp4Bbf+pc/rNHBBqWrcbmOpHwluMi9CkETdn2xxBZfbZ9waBwq2wxj+diCcGhes8Ptlxm7XoXFE+/c/6msGJNb3lML1sa23ldXyUkq5YI8+r9OuXwya1PvMwoWCi0wpAe+va2XiYCxzftwrw36e6Hvvwb6bdI6zpdZQKPKOEes/VPDnmCRxU8UR293T3hZRgjGP95izpuBes012teACyYDDTiSmeabCCDYFpzhSMLdTE8kw0zF+6jeWW+IGx5pWFggkmGXFSLHlp3v4k8jcp3CHtANKs5JTN5VUQjbx2659xwW32sB0Nwpu77jiQVU+rWKnQrDYuJMH3LSYP08tbWl0gMgsHimkOqYvhN5XEPwlMjM8J690VsGNfdfKsFsHhkJTsNCYOe4W5G6oyDsy7KSoYFvbu02NuUl3uJ12VUCS6oz91qHmsin4RhcQKa5VeCDOwXypxvPkgvtKOHt4XNMG8Ed4j0cErwkerJnESP2qgnEthf0rUvqBilZakqwuHakoMqeLL8FO9pL4rqZgmr8Tagt0G1pvIArZDrSkUl/yebu4xVZx4mpKTLvLZKJwJRXN5USrAsIwrC/fwPeHRhItwSUdrDOcp/AbU2Ux+2zV+pymrQc68dfKvSZ4yodxgDWRSi54siR8e1059qgxl2cM7cDUAPHVkYC4MV4glXi31YIvxvjh6prMMBfcIDikK8B+3WcE882I8cjE5XLBY5USkWCaZ0vNe0twy8h9+xptrXefi7pWfFuw1DukQysaLcFfWeK6PgvzXsE99sUmrhK6IpBccP+QYuzFpScuBCvNfnNQDKbDVUA8bUqUh3dYGsfEJuOTtasLwcbOEmwf441EQ2ZH+4PjvNi3viwg72fd0RWsG4x33lCT530jjZSttGEMXI8RvGTjWGc6fYjHeAZba7nHzL69D7VoIGFv0zq3RtNT7FjhQifm+BpvDojNhraCC0HLlkhN8pDgTKJ/vq5GIlqChUQHe79P2MRsW9nPDyzpuLzByxxfc5l2Xe3JUoNZFry9xa3gQrAzOECwxhaxYjDmsZpwrBlrmZNi5hg0re46dl4hRR+oFe8Ml5TCXwhW22gUK5GWzMOs8eLQxl9BNEPH4SKPSxWYUWuc2qXA9nDZl+1tgee1LPGIlkJWwrkg9bL7KiOFCaq/KD1xIjfN7pFJ/yet4KbgMIk9FcZtL4nX2Nx4rTTl/rDjdtt9rtkm19RAWgoLhwj3sFjix6OYy/JGyGiDp3MEX5C4wiJpbL1NqjFMBZ7zRKTdloBXveg1e9Y0kxOXDgGiwANWSUvOnGFv0+TDlKN8g2dHkp31zLWv4LSeQ4XaMbRHre0cOFfEnsYfV5wkaFjtMuSx/tgoUaAgscIvS9UnUdjY+4crRzkQz4wExDRHGHOdWzvywBqv1gLxQN+eiWBL8ypykxyXWyqTSGMvK1cMzFxkghdr5OWzwyd+G29SIlLsZS5O7RjHgBVWdPL8sudXA3QKu0i1KtpFnInMOLa2nRmWW+SJ2AmfgKHlUPsJpVzP8FFzvRDN+RuKLfcc+U8sd/ZUFlIqK1PljrCB/6owlS3B1TFo29nCTv3ztxbYrkMnldjCa+7s6ngMGsx/rOzV1vK63QouRmgGH9CzQQOnxsLKaCVfGh4uhb3QkttRgsMjCC3NCPIq+0ZKGW72vDmVBaVc4Unr9RVoDAu0Rm0F5woPGeshnuGDlccJlvTVIdqg55Xh8VngI52qVeiqYK3xBzGoP0ywDy6uYEFbtr7YJxNt8zl12ETMUyNN131+gHhissdLS+wtwe19wtiQOLJUMdrJ93SJWZaWpPXNqDYNM61xPhKHVCplIbfSuzunnZicOtijJSWiN9QKnhC3/nGO6kJdU/CTPguRYUHJ8dtt3N06WUmzopm/A86z2sxYAHilUo5zwW3W60xXMOZEwel1c1ejtIKbgn8oMUCJxMzS0m1T8O99lW9mWD5w+PZQwBFRYu6uKPM0BYfaQfC5TufrokrlaN/mZtuD2Q5yh+C8+smc4a3gQuEFM0uJZPhMSY+rKfhqn2lN7DcAePsqX4veYraXK7icC67yhJ91tW/qvV0uaLrD7ZYJgp9I66f4hreC6/P8LLrE8YE1R/WsyTC/b5+24fx6J6nfzNpKcW8POs7rOPBU4ue1ktwN0oVxVmdIkHVk7TxBYaWNSlsuE/Z4kuv7oGgKDu8p0CXmWNl1zSKOAx3VmWxgA8sqgRgXHNpldTK8f0iZsTCuGQdZho6oZkNawc1YiMlqPc80VwvyDpWm4G+6gGjgy51jT+j2r+3RV828sYtGPww/LJnbO7dmRKi9y7hju4zmECD+RMt4HPvq/TQ1rbV5pTy8foXUqZ3hsSI2hSb+ODuGd1oml2tFENY61QYDAdrnYpNn0JxePTCpm0itb1EpFBNDavfaNY6ejJRHbFkbQ5w3QobfFry9/KIjEa3e2TWXddn4V5xjm5JR01Tq2jhtV3SGCIPgYlNKhDvFPI9G9/r6irZyrXDCQE+9JtZOBNN9zzSh5PeAEzwiGSGFaSdGH3GYPc0G/+M0zxmzva/EUt9Kd7vcJZ6OfaswcL7pfuzjfUnhvzkznlRJGjfXD3yy7/vF5vuhJfGNN5J0vCXPRI64qT+zm21tq2GV1Ppetsiv3ekuT3ZS6aKCLXzGIbYz1SoPW2i+52tmrtsX/ajD7GSGtZ52l5+63uq6Oe//BeYA3+6agCy9AAAAAElFTkSuQmCC") center / contain no-repeat}.ag-root.ag-root .ag-about{margin-top: 8px;padding-left: 10px;border-left: 2px solid var(--ag-grid);display: grid;gap: 6px;font-size: 12.5px;line-height: 1.5;color: var(--ag-ink-2)}.ag-root.ag-root .ag-about a{color: inherit;text-decoration: underline;text-decoration-color: var(--ag-ink-3);text-underline-offset: 2px}.ag-root.ag-root .ag-about a:hover{text-decoration-color: currentColor}.ag-root.ag-root .ag-sw{display: inline-block;width: 10px;height: 10px;border-radius: 50%;flex: none;vertical-align: baseline}.ag-root.ag-root .ag-sw-m{background: var(--ag-m)}.ag-root.ag-root .ag-sw-f{background: var(--ag-f)}.ag-root.ag-root .ag-num{font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-btn{display: inline-flex;align-items: center;justify-content: center;gap: 8px;min-height: 44px;padding: 10px 18px;border-radius: 999px;background: var(--ag-ink);color: var(--ag-knock);font-size: 15px;font-weight: 650;line-height: 1;transition: transform .15s var(--ag-ease),opacity .15s}.ag-root.ag-root .ag-btn:hover{opacity: .88}.ag-root.ag-root .ag-btn:active{transform: scale(.97)}.ag-root.ag-root .ag-btn[disabled]{opacity: .35;cursor: default}.ag-root.ag-root .ag-btn-ghost{background: transparent;color: var(--ag-ink);box-shadow: inset 0 0 0 1.5px var(--ag-grid)}.ag-root.ag-root .ag-btn-ghost:hover{box-shadow: inset 0 0 0 1.5px var(--ag-ink-3);opacity: 1}.ag-root.ag-root .ag-icon-btn{display: inline-flex;align-items: center;justify-content: center;width: 44px;height: 44px;flex: none;border-radius: 50%;color: var(--ag-ink);box-shadow: inset 0 0 0 1.5px var(--ag-grid);transition: box-shadow .15s}.ag-root.ag-root .ag-icon-btn:hover{box-shadow: inset 0 0 0 1.5px var(--ag-ink-3)}.ag-root.ag-root .ag-icon-btn svg{width: 18px;height: 18px}.ag-root.ag-root .ag-axis-cap{display: flex;justify-content: space-between;gap: 12px;font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-bar-track{position: relative;height: 16px}.ag-root.ag-root .ag-bar{position: absolute;left: 0;top: 0;bottom: 0;width: 0;border-radius: 0 4px 4px 0;transition: width .9s var(--ag-ease)}.ag-root.ag-root .ag-bar-m{background: var(--ag-m)}.ag-root.ag-root .ag-bar-f{background: var(--ag-f)}.ag-root.ag-root .ag-bar-guess{background: repeating-linear-gradient(135deg,color-mix(in srgb,var(--ag-f) 55%,transparent) 0 2px,transparent 2px 7px);box-shadow: inset 0 0 0 1.5px var(--ag-f);transition: none}.ag-root.ag-root .ag-q-stage{margin-top: 12px}.ag-root.ag-root .ag-q-prog{display: flex;align-items: center;gap: 6px;margin-bottom: 8px;font-size: 12px;color: var(--ag-ink-3);font-weight: 600}.ag-root.ag-root .ag-q-prog span{margin-left: 6px}.ag-root.ag-root .ag-ink-m{color: var(--ag-m-ink)}.ag-root.ag-root .ag-ink-f{color: var(--ag-f-ink)}.ag-root.ag-root .ag-q-chart{margin-top: 10px;display: grid;gap: 8px}.ag-root.ag-root .ag-q-row{display: grid;grid-template-columns: 1fr;gap: 5px}.ag-root.ag-root .ag-q-row-hd{display: flex;justify-content: space-between;align-items: baseline;gap: 10px;font-size: 13px;color: var(--ag-ink-2)}.ag-root.ag-root .ag-q-row-hd b{font-weight: 650;color: var(--ag-ink);font-size: 15px;font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-q-lab{display: inline-flex;align-items: center;gap: 6px;font-weight: 600}.ag-root.ag-root .ag-q-guess-tick{position: absolute;top: -5px;bottom: -5px;width: 2px;margin-left: -1px;background: var(--ag-ink);opacity: 0;transition: opacity .3s .6s}.ag-root.ag-root .ag-q-guess-tick.is-on{opacity: 1}.ag-root.ag-root .ag-q-guess-lab{position: absolute;top: 100%;margin-top: 7px;transform: translateX(-50%);white-space: nowrap;font-size: 12px;font-weight: 600;color: var(--ag-ink-2);opacity: 0;transition: opacity .3s .7s}.ag-root.ag-root .ag-q-guess-lab.is-on{opacity: 1}.ag-root.ag-root .ag-q-guess-lab.is-end{transform: translateX(-100%)}.ag-root.ag-root .ag-q-guess-lab.is-start{transform: none}.ag-root.ag-root .ag-range{display: block;width: 100%;height: 40px;margin-top: 2px;background: transparent;-webkit-appearance: none;appearance: none;cursor: grab;touch-action: pan-y}.ag-root.ag-root .ag-range:active{cursor: grabbing}.ag-root.ag-root .ag-range::-webkit-slider-runnable-track{height: 4px;border-radius: 2px;background: var(--ag-grid)}.ag-root.ag-root .ag-range::-moz-range-track{height: 4px;border-radius: 2px;background: var(--ag-grid)}.ag-root.ag-root .ag-range::-webkit-slider-thumb{-webkit-appearance: none;width: 28px;height: 28px;margin-top: -12px;border-radius: 50%;background: var(--ag-knock);border: 2px solid var(--ag-f);box-shadow: 0 1px 4px rgba(0,0,0,.18)}.ag-root.ag-root .ag-range::-moz-range-thumb{width: 24px;height: 24px;border-radius: 50%;background: var(--ag-knock);border: 2px solid var(--ag-f);box-shadow: 0 1px 4px rgba(0,0,0,.18)}.ag-root.ag-root .ag-range:focus-visible{outline: none}.ag-root.ag-root .ag-range:focus-visible::-webkit-slider-thumb{outline: 2px solid var(--ag-focus);outline-offset: 2px}.ag-root.ag-root .ag-q-hint{font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-fade-in{animation: ag-in .5s var(--ag-ease) both}@keyframes ag-in{from{opacity: 0;transform: translateY(8px)}to{opacity: 1;transform: none}}.ag-root.ag-root .ag-q-end{text-align: left}.ag-root.ag-root .ag-q-recap{margin: 12px 0 4px;display: grid;gap: 6px}.ag-root.ag-root .ag-q-recap-row{display: grid;grid-template-columns: minmax(0,1fr) auto;gap: 2px 12px;font-size: 13px;color: var(--ag-ink-2);align-items: center}.ag-root.ag-root .ag-q-recap-row .ag-num{color: var(--ag-ink);font-weight: 600}.ag-root.ag-root .ag-q-mini{grid-column: 1 / -1;position: relative;height: 8px;border-radius: 4px;background: var(--ag-track)}.ag-root.ag-root .ag-q-mini i{position: absolute;top: -2px;width: 12px;height: 12px;margin-left: -6px;border-radius: 50%;border: 2px solid var(--ag-knock)}.ag-root.ag-root .ag-q-mini i.ag-g{background: var(--ag-knock);border: 2px solid var(--ag-ink-2);width: 12px;height: 12px}.ag-root.ag-root .ag-q-cta{display: flex;flex-wrap: wrap;gap: 10px;margin-top: 12px}.ag-root.ag-root a.ag-btn{text-decoration: none;color: var(--ag-knock)}.ag-root.ag-root .ag-pt-svgwrap{position: relative;margin-top: 8px;touch-action: manipulation}.ag-root.ag-root .ag-pt-svgwrap svg:focus-visible{outline: 2px solid var(--ag-focus);outline-offset: 4px}.ag-root.ag-root .ag-pt-dot{transition: transform .9s var(--ag-ease),opacity .5s,r .15s;cursor: pointer}.ag-root.ag-root .ag-pt-dot.is-m{fill: var(--ag-m)}.ag-root.ag-root .ag-pt-dot.is-f{fill: var(--ag-f)}.ag-root.ag-root .ag-pt-dot{stroke: var(--ag-knock);stroke-width: 2px}.ag-root.ag-root .ag-pt-dot.is-on{stroke: var(--ag-ink);stroke-width: 2.5px}.ag-root.ag-root .ag-pt-dim .ag-pt-dot:not(.is-on):not(.is-hit){opacity: .45}.ag-root.ag-root .ag-pt-grid{stroke: var(--ag-grid);stroke-width: 1px}.ag-root.ag-root .ag-pt-zero{stroke: var(--ag-ink);stroke-width: 1.5px}.ag-root.ag-root .ag-pt-tick{fill: var(--ag-ink-3);font-size: 11px;font-family: var(--ag-ui);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-pt-card{margin-top: 14px;min-height: 88px;padding-top: 14px;border-top: 1px solid var(--ag-grid);display: grid;gap: 8px}.ag-root.ag-root .ag-pt-empty{font-size: 14px;color: var(--ag-ink-3);align-self: center;justify-self: center;text-align: center}.ag-root.ag-root .ag-ex-ctl{display: grid;gap: 10px;margin-top: 16px}.ag-root.ag-root .ag-ex-head{display: grid;grid-template-columns: minmax(0,40%) minmax(0,1fr) 66px;gap: 14px;align-items: end;margin-top: 18px;padding-bottom: 6px;border-bottom: 1px solid var(--ag-grid)}.ag-root.ag-root .ag-ex-legend{display: flex;flex-wrap: wrap;gap: 4px 12px;font-size: 12px;color: var(--ag-ink-2)}.ag-root.ag-root .ag-ex-legend span{display: inline-flex;align-items: center;gap: 5px}.ag-root.ag-root .ag-ex-axis{position: relative;height: 16px;font-size: 11px;color: var(--ag-ink-3);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-ex-axis span{position: absolute;bottom: 0;transform: translateX(-50%);white-space: nowrap}.ag-root.ag-root .ag-ex-axis span:first-child{transform: none}.ag-root.ag-root .ag-ex-axis span:last-child{transform: translateX(-100%)}.ag-root.ag-root .ag-ex-pcth{font-size: 11px;color: var(--ag-ink-3);text-align: right;line-height: 1.2}.ag-root.ag-root .ag-ex-list{list-style: none}.ag-root.ag-root .ag-ex-row{border-bottom: 1px solid var(--ag-grid)}.ag-root.ag-root .ag-ex-btn{display: grid;grid-template-columns: minmax(0,40%) minmax(0,1fr) 66px;gap: 14px;align-items: center;width: 100%;padding: 7px 0;text-align: left;transition: background .15s}.ag-root.ag-root .ag-ex-btn:hover{background: color-mix(in srgb,var(--ag-card) 70%,transparent)}.ag-root.ag-root .ag-ex-names{display: grid;gap: 1px;font-size: 13px;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-ex-names span{display: flex;gap: 6px;align-items: baseline;min-width: 0}.ag-root.ag-root .ag-ex-names span>i{overflow: hidden;text-overflow: ellipsis;white-space: nowrap;font-style: normal}.ag-root.ag-root .ag-ex-names .ag-sw{width: 8px;height: 8px;transform: translateY(-1px)}.ag-root.ag-root .ag-ex-names .is-f{color: var(--ag-ink-2)}.ag-root.ag-root .ag-ex-track{position: relative;height: 22px}.ag-root.ag-root .ag-ex-track::before{content: "";position: absolute;left: 0;right: 0;top: 50%;height: 1px;background: var(--ag-track)}.ag-root.ag-root .ag-ex-gl{position: absolute;top: 0;bottom: 0;width: 1px;background: var(--ag-track)}.ag-root.ag-root .ag-ex-bar{position: absolute;top: 50%;height: 3px;margin-top: -1.5px;border-radius: 2px;opacity: .45;transition: left .7s var(--ag-ease),width .7s var(--ag-ease)}.ag-root.ag-root .ag-ex-bar.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-ex-bar.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-ex-dot{position: absolute;top: 50%;width: 13px;height: 13px;margin: -6.5px 0 0 -6.5px;border-radius: 50%;box-shadow: 0 0 0 2px var(--ag-knock);transition: left .7s var(--ag-ease)}.ag-root.ag-root .ag-ex-dot.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-ex-dot.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-ex-pct{text-align: right;font-size: 14px;font-weight: 650;font-variant-numeric: tabular-nums;display: flex;justify-content: flex-end;align-items: center;gap: 5px}.ag-root.ag-root .ag-ex-pct .ag-sw{width: 7px;height: 7px}.ag-root.ag-root .ag-ex-detail{padding: 4px 0 14px;display: grid;gap: 8px;animation: ag-in .35s var(--ag-ease) both}.ag-root.ag-root .ag-cpt{color: var(--ag-ink-3);font-size: 12px;font-weight: 400;margin-left: 6px;white-space: nowrap;font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-flag{font-size: 12px;color: var(--ag-ink-2);border-left: 2px solid var(--ag-grid);padding: 2px 0 2px 10px}.ag-root.ag-root .ag-ex-none{padding: 24px 0;text-align: center;color: var(--ag-ink-3);font-size: 14px}.ag-root.ag-root .ag-ex-row.is-enter{animation: ag-in .45s var(--ag-ease) both}@container ag (max-width: 540px){.ag-root.ag-root .ag-ex-head{grid-template-columns: minmax(0,1fr) 60px}.ag-root.ag-root .ag-ex-head .ag-ex-legend{grid-column: 1 / -1}.ag-root.ag-root .ag-ex-btn{grid-template-columns: minmax(0,1fr) 60px;gap: 4px 12px;padding: 10px 0}.ag-root.ag-root .ag-ex-names{grid-column: 1 / -1}}.ag-root.ag-root .ag-cpt{color: var(--ag-ink-3);font-size: 12px;font-weight: 400;font-style: normal;margin-left: 6px;white-space: nowrap;font-variant-numeric: tabular-nums;letter-spacing: 0}.ag-root.ag-root .ag-cpt-wrap{position: relative;display: inline-block}.ag-root.ag-root .ag-cpt-btn{padding: 2px 0;margin-left: 6px;line-height: 1.2;cursor: help;text-decoration: underline dotted;text-decoration-color: var(--ag-ink-3);text-underline-offset: 3px}.ag-root.ag-root .ag-cpt-btn:hover,.ag-root.ag-root .ag-cpt-wrap.is-open .ag-cpt-btn{color: var(--ag-ink);text-decoration-color: currentColor}.ag-root.ag-root .ag-tip{position: absolute;left: 0;bottom: calc(100% + 6px);z-index: 5;width: max-content;max-width: min(260px,72vw);padding: 8px 10px;border-radius: 6px;background: var(--ag-ink);color: var(--ag-knock);font-size: 13px;font-weight: 500;line-height: 1.35;white-space: normal;text-align: left;box-shadow: 0 4px 14px color-mix(in srgb,var(--ag-ink) 18%,transparent);display: none;pointer-events: none}.ag-root.ag-root .ag-cpt-wrap.is-open .ag-tip{display: block;animation: ag-fade .15s linear both}@keyframes ag-fade{from{opacity: 0}to{opacity: 1}}.ag-root.ag-root .ag-tip-k{display: block;margin-bottom: 2px;font-size: 11px;font-weight: 500;opacity: .7}.ag-root.ag-root .ag-pair{display: grid;gap: 4px}.ag-root.ag-root .ag-pair-row{display: flex;justify-content: space-between;align-items: baseline;gap: 12px}.ag-root.ag-root .ag-pair-name{font-size: 15px;font-weight: 500;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-pair-val{font-size: 15px;font-weight: 600;white-space: nowrap}.ag-root.ag-root .ag-find{position: relative}.ag-root.ag-root .ag-find svg{position: absolute;left: 0;top: 50%;width: 15px;height: 15px;margin-top: -7.5px;color: var(--ag-ink-3);pointer-events: none}.ag-root.ag-root .ag-find input{display: block;width: 100%;min-height: 40px;padding: 8px 0 8px 24px;border-radius: 0;background: transparent;border-bottom: 1px solid var(--ag-grid);font-size: 16px;color: var(--ag-ink);-webkit-appearance: none;appearance: none;transition: border-color .2s}.ag-root.ag-root .ag-find input:hover{border-bottom-color: var(--ag-ink-3)}.ag-root.ag-root .ag-find input:focus-visible{outline: none;border-bottom-color: var(--ag-ink)}.ag-root.ag-root .ag-find input::placeholder{color: var(--ag-ink-3);opacity: 1}.ag-root.ag-root .ag-find input::-webkit-search-cancel-button{-webkit-appearance: none}.ag-root.ag-root.ag-root .ag-q-btn{min-height: 42px;padding: 10px 20px;border-radius: var(--ag-r);background: transparent;color: var(--ag-ink);box-shadow: inset 0 0 0 1px var(--ag-ink);font-size: 15px;font-weight: 500;transition: background-color .2s,color .2s,transform .15s}.ag-root.ag-root.ag-root .ag-q-btn:hover{background: var(--ag-ink);color: var(--ag-knock)}.ag-root.ag-root .ag-pt-find{margin-top: 10px;max-width: 340px}.ag-root.ag-root .ag-pt-hits{list-style: none;margin-top: 6px;display: grid;gap: 0}.ag-root.ag-root .ag-pt-hits:empty{display: none}.ag-root.ag-root .ag-pt-hit{display: block;width: 100%;padding: 6px 0;text-align: left;font-size: 14px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-pt-hit:hover{text-decoration: underline;text-underline-offset: 3px;text-decoration-color: var(--ag-grid)}.ag-root.ag-root .ag-pt-none{padding: 6px 0;font-size: 13px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-pt-finding .ag-pt-dot:not(.is-hit):not(.is-on){opacity: .15}.ag-root.ag-root .ag-pt-dot.is-hit{stroke: var(--ag-ink);stroke-width: 2px}.ag-root.ag-root .ag-pt-cap{margin-top: 6px}.ag-root.ag-root .ag-pt-cap>span{display: inline-flex;align-items: baseline;gap: 5px;font-weight: 500;white-space: nowrap}@container ag (max-width: 340px){.ag-root.ag-root .ag-pt-cap{font-size: 11px;gap: 6px}.ag-root.ag-root .ag-pt-cap>span{gap: 3px}}.ag-root.ag-root .ag-arrow{font-weight: 400;color: var(--ag-ink-3)}.ag-root.ag-root .ag-pt-card{margin-top: 12px;min-height: 0;padding-top: 12px;border-top: 1px solid var(--ag-grid);display: grid;gap: 8px}.ag-root.ag-root .ag-pt-empty{font-size: 14px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-ex-ctl{display: flex;flex-wrap: wrap;gap: 12px 32px;align-items: end;margin-top: 16px}.ag-root.ag-root .ag-ex-ctl .ag-find{flex: 1 1 220px}.ag-root.ag-root .ag-ex-sels{display: flex;gap: 20px;flex-wrap: wrap}.ag-root.ag-root .ag-mini{display: grid;gap: 2px}.ag-root.ag-root .ag-mini-k{font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-mini-v{position: relative;display: block}.ag-root.ag-root .ag-mini-v::after{content: "";position: absolute;right: 2px;top: 50%;width: 6px;height: 6px;margin-top: -5px;border-right: 1.5px solid var(--ag-ink-2);border-bottom: 1.5px solid var(--ag-ink-2);transform: rotate(45deg);pointer-events: none}.ag-root.ag-root .ag-mini-sel{display: block;min-height: 40px;padding: 8px 20px 8px 0;background: transparent;border-bottom: 1px solid var(--ag-grid);font-size: 15px;font-weight: 500;color: var(--ag-ink);-webkit-appearance: none;appearance: none;cursor: pointer;border-radius: 0}.ag-root.ag-root .ag-mini-sel:hover{border-bottom-color: var(--ag-ink-3)}.ag-root.ag-root .ag-mini-sel:focus-visible{outline: none;border-bottom-color: var(--ag-ink)}.ag-root.ag-root .ag-ex-head{margin-top: 24px}.ag-root.ag-root .ag-ex-names .ag-ex-n{overflow: hidden;text-overflow: ellipsis;white-space: nowrap;font-style: normal;min-width: 0}.ag-root.ag-root .ag-ex-names .ag-cpt{margin-left: 0;flex: none;font-size: 11px}.ag-root.ag-root .ag-ex-names .is-f{color: inherit}.ag-root.ag-root .ag-ex-pct{font-weight: 600}.ag-root.ag-root .ag-ex-detail{padding: 4px 0 12px;gap: 8px}.ag-root.ag-root .ag-ex-detail .ag-pair-name,.ag-root.ag-root .ag-ex-detail .ag-pair-val{font-size: 15px}.ag-root.ag-root .ag-ex-pager{display: flex;justify-content: space-between;align-items: center;gap: 12px;margin-top: 8px}.ag-root.ag-root .ag-ex-count{font-size: 13px;color: var(--ag-ink-3);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-ex-pbtns{display: flex;gap: 8px}.ag-root.ag-root .ag-icon-btn[disabled]{opacity: .3;cursor: default}@container ag (max-width: 480px){.ag-root.ag-root .ag-ex-sels{width: 100%}.ag-root.ag-root .ag-ex-sels .ag-mini{flex: 1 1 0;min-width: 0}.ag-root.ag-root .ag-mini-sel{width: 100%}}.ag-root.ag-root .ag-stat{display: block;text-wrap: pretty}.ag-root.ag-root .ag-stat-num{font-family: var(--ag-head);font-weight: 600;font-size: 30px;line-height: 1.05;letter-spacing: -0.025em;font-variant-numeric: tabular-nums;color: var(--ag-ink);margin-right: 8px}.ag-root.ag-root .ag-stat-cap{font-size: 15px;font-weight: 500;line-height: 1.35;color: var(--ag-ink-2)}.ag-root.ag-root .ag-stat-cap span{white-space: nowrap}.ag-root.ag-root .ag-stat-num.ag-ink-m{color: var(--ag-m-ink)}.ag-root.ag-root .ag-stat-num.ag-ink-f{color: var(--ag-f-ink)}.ag-root.ag-root .ag-stat.is-small .ag-stat-num{font-size: 24px}.ag-root.ag-root .ag-stat.is-small .ag-stat-cap{font-size: 14px}.ag-root.ag-root .ag-mu-ctl{display: flex;gap: 6px;align-items: stretch;margin-top: 14px}.ag-root.ag-root .ag-select-wrap{position: relative;flex: 1 1 auto;min-width: 0}.ag-root.ag-root .ag-select{display: block;-webkit-appearance: none;appearance: none;cursor: pointer;font-size: 16px}.ag-root.ag-root .ag-select-wrap .ag-select{position: absolute;inset: 0;width: 100%;height: 100%;opacity: 0;min-height: 0}.ag-root.ag-root .ag-select-face{display: flex;align-items: center;min-height: 40px;height: 100%;padding: 6px 34px 6px 12px;border-radius: var(--ag-r);background: transparent;box-shadow: inset 0 0 0 1px var(--ag-grid);transition: box-shadow .2s;font-size: 15px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-select-wrap:hover .ag-select-face{box-shadow: inset 0 0 0 1px var(--ag-ink-3)}.ag-root.ag-root .ag-select-wrap:has(.ag-select:focus-visible) .ag-select-face{outline: 2px solid var(--ag-focus);outline-offset: 2px}.ag-root.ag-root .ag-select-wrap::after{content: "";position: absolute;right: 14px;top: 50%;width: 6px;height: 6px;margin-top: -5px;border-right: 1.5px solid var(--ag-ink-2);border-bottom: 1.5px solid var(--ag-ink-2);transform: rotate(45deg);pointer-events: none}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn{width: 40px;height: auto;min-height: 40px}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn svg{width: 14px;height: 14px}.ag-root.ag-root .ag-mu-sum{margin-top: 14px}@container ag (max-width: 480px){.ag-root.ag-root .ag-mu-ctl{gap: 4px}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn{width: 32px}.ag-root.ag-root .ag-select-face{font-size: 14px;padding-left: 10px;padding-right: 28px}.ag-root.ag-root .ag-select-wrap::after{right: 11px}}.ag-root.ag-root .ag-mu-strip-wrap{margin-top: 12px}.ag-root.ag-root .ag-mu-strip-lab{font-size: 13px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-mu-strip{position: relative;height: 48px;margin-top: 2px}.ag-root.ag-root .ag-mu-strip::before{content: "";position: absolute;left: 0;right: 0;top: 31px;height: 1px;background: var(--ag-grid)}.ag-root.ag-root .ag-mu-zero{position: absolute;top: 15px;bottom: 0;width: 0;border-left: 1.5px dashed var(--ag-ink-2);margin-left: -0.75px}.ag-root.ag-root .ag-mu-zero-lab{position: absolute;top: 0;transform: translateX(-50%);font-size: 11px;font-weight: 500;line-height: 1;color: var(--ag-ink-2);white-space: nowrap}.ag-root.ag-root .ag-mu-tick{position: absolute;top: 23px;width: 2px;height: 16px;margin-left: -1px;padding: 0;border-radius: 1px;opacity: .45;transition: height .25s var(--ag-ease),top .25s var(--ag-ease),width .25s var(--ag-ease),opacity .2s}.ag-root.ag-root .ag-mu-tick.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-mu-tick.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-mu-tick::after{content: "";position: absolute;inset: -8px -3px}.ag-root.ag-root .ag-mu-tick:hover{opacity: .9}.ag-root.ag-root .ag-mu-tick.is-on{opacity: 1;top: 16px;height: 30px;width: 4px;margin-left: -2px;box-shadow: 0 0 0 2px var(--ag-knock);z-index: 2}.ag-root.ag-root .ag-mu-pair{margin-top: 14px;padding-top: 12px;border-top: 1px solid var(--ag-grid);display: grid;gap: 10px}.ag-root.ag-root .ag-mu-side{display: grid;gap: 4px}.ag-root.ag-root .ag-mu-line{display: flex;justify-content: space-between;align-items: baseline;gap: 12px}.ag-root.ag-root .ag-mu-name{font-size: 15px;font-weight: 500;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-mu-val{font-size: 15px;font-weight: 600;white-space: nowrap}.ag-root.ag-root .ag-mu-pair .ag-bar-track{height: 12px}.ag-root.ag-root .ag-q-prog{display: block;margin: 0 0 8px;font-size: 12px;font-weight: 500;color: var(--ag-ink-3)}.ag-root.ag-root .ag-q-lab{display: inline-flex;align-items: baseline;flex-wrap: wrap;font-size: 15px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-q-row-hd b{font-weight: 600}.ag-root.ag-root .ag-q-foot{display: flex;flex-wrap: wrap;align-items: center;justify-content: space-between;gap: 10px 16px;margin-top: 6px}.ag-root.ag-root .ag-q-foot.is-result{margin-top: 26px}.ag-root.ag-root .ag-q-endline{font-size: 17px;font-weight: 500;line-height: 1.35;color: var(--ag-ink);text-wrap: pretty}.ag-root.ag-root .ag-q-endnum{font-family: var(--ag-head);font-weight: 600;font-size: 30px;letter-spacing: -0.025em}.ag-root.ag-root .ag-q-hint{display: flex;flex-wrap: wrap;align-items: center;gap: 4px;font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-q-ring{display: inline-block;width: 10px;height: 10px;border-radius: 50%;box-shadow: inset 0 0 0 2px var(--ag-ink-2)}.ag-root.ag-root .ag-q-cta{display: flex;flex-wrap: wrap;align-items: center;gap: 10px 18px;margin-top: 12px}.ag-root.ag-root .ag-q-link{font-size: 15px;font-weight: 500;color: var(--ag-ink);text-decoration: underline;text-decoration-color: var(--ag-grid);text-underline-offset: 4px}.ag-root.ag-root .ag-q-link:hover{text-decoration-color: currentColor}.ag-root.ag-root{--ag-ui: "Geist","Helvetica Neue",Arial,sans-serif;--ag-head-weight: 600;--ag-head-track: -0.02em;--ag-r: 8px}.ag-root.ag-root[data-ag-mode="light"]{--ag-card: #f3f3f6;--ag-grid: #e2e2e8;--ag-track: #ececf1}@media (prefers-color-scheme: light){.ag-root.ag-root[data-ag-mode="auto"]{--ag-card: #f3f3f6;--ag-grid: #e2e2e8;--ag-track: #ececf1}}.ag-root.ag-root[data-ag-style="editorial"]{--ag-head-weight: 700}.ag-root.ag-root[data-ag-style="feature"]{--ag-head-weight: 700}.ag-root.ag-root.ag-root{font-family: var(--ag-ui)}.ag-root.ag-root.ag-root .ag-hed{letter-spacing: var(--ag-head-track)}.ag-root.ag-root.ag-root .ag-mu-name{font-weight: 500}.ag-root.ag-root.ag-root .ag-q-row-hd b,.ag-root.ag-root.ag-root .ag-mu-val,.ag-root.ag-root.ag-root .ag-pair-val,.ag-root.ag-root.ag-root .ag-ex-pct{font-weight: 600}.ag-root.ag-root.ag-root .ag-dek{text-wrap: pretty}.ag-root.ag-root.ag-root .ag-btn,.ag-root.ag-root.ag-root .ag-icon-btn,.ag-root.ag-root.ag-root .ag-select-face{border-radius: var(--ag-r)}.ag-root.ag-root.ag-root .ag-bar{border-radius: 0 2px 2px 0}.ag-root.ag-root.ag-root .ag-btn{font-weight: 600}.ag-root.ag-root.ag-root .ag-btn{transition: transform .15s var(--ag-ease),background-color .2s}.ag-root.ag-root.ag-root .ag-btn:hover{opacity: 1;background: color-mix(in srgb,var(--ag-ink) 82%,var(--ag-knock))}.ag-root.ag-root.ag-root .ag-btn:active,.ag-root.ag-root.ag-root .ag-icon-btn:active{transform: translateY(1px)}.ag-root.ag-root.ag-root .ag-icon-btn{transition: box-shadow .2s,background-color .2s,transform .15s}.ag-root.ag-root.ag-root .ag-icon-btn:hover{background: var(--ag-card)}.ag-root.ag-root.ag-root .ag-btn-ghost{background: none;box-shadow: none;padding-left: 4px;padding-right: 4px;font-weight: 500;text-decoration: underline;text-decoration-color: var(--ag-grid);text-underline-offset: 4px}.ag-root.ag-root.ag-root .ag-btn-ghost:hover{background: none;text-decoration-color: currentColor}.ag-root.ag-root.ag-root .ag-q-prog span{margin-left: 0;font-weight: 500}.ag-root.ag-root.ag-root .ag-q-mini{background: none;height: 12px}.ag-root.ag-root.ag-root .ag-q-mini::before{content: "";position: absolute;left: 0;right: 0;top: 50%;height: 1px;background: var(--ag-grid)}.ag-root.ag-root.ag-root .ag-q-mini i{top: 0}.ag-root.ag-root.ag-root .ag-range::-webkit-slider-thumb{box-shadow: 0 1px 3px color-mix(in srgb,var(--ag-ink) 22%,transparent)}.ag-root.ag-root.ag-root .ag-range::-moz-range-thumb{box-shadow: 0 1px 3px color-mix(in srgb,var(--ag-ink) 22%,transparent)}@media (prefers-reduced-motion: reduce){.ag-root.ag-root *,.ag-root.ag-root *::before,.ag-root.ag-root *::after{transition: none !important;animation: none !important}} (window.AG = window.AG || {}).data = [{"id":1,"cat":"Biopsies & lesions","mName":"Biopsy penis","mCpt":"54100","m":121.32,"fName":"Biopsy vagina","fCpt":"57100","f":65.74,"pct":59.42},{"id":2,"cat":"Biopsies & lesions","mName":"Remove penis lesion","mCpt":"54110","m":624.88,"fName":"Remove vaginal lesion","fCpt":"57135","f":191.8,"pct":106.06},{"id":3,"cat":"Biopsies & lesions","mName":"Biopsy scrotum","mCpt":"55120","m":356.83,"fName":"Biopsy vulva","fCpt":"56605","f":59.98,"pct":142.44},{"id":4,"cat":"Biopsies & lesions","mName":"Biopsy prostate","mCpt":"55705","m":265.34,"fName":"Biopsy endometrium","fCpt":"58110","f":40.33,"pct":147.22},{"id":5,"cat":"Biopsies & lesions","mName":"Removal of scrotal lesion","mCpt":"55120","m":356.83,"fName":"Removal of vulvar lesion","fCpt":"56440","f":184.01,"pct":63.91},{"id":6,"cat":"Biopsies & lesions","mName":"Excision penile lesion","mCpt":"54115","m":428.0,"fName":"Excision vaginal lesion","fCpt":"57100","f":65.74,"pct":146.74},{"id":7,"cat":"Biopsies & lesions","mName":"Laser penis","mCpt":"54057","m":98.95,"fName":"Laser vulva","fCpt":"56501","f":136.57,"pct":-31.95},{"id":8,"cat":"Genitals & other","mName":"Distal hypospadias repair","mCpt":"54328","m":934.61,"fName":"Revision of cervix","fCpt":"57700","f":365.3,"pct":87.59},{"id":9,"cat":"Biopsies & lesions","mName":"Destruction penile lesions simple","mCpt":"54050","m":108.1,"fName":"Destruction vulvar lesions simple","fCpt":"56501","f":136.57,"pct":-23.27},{"id":10,"cat":"Genitals & other","mName":"Resection of scrotum","mCpt":"55150","m":496.11,"fName":"Simple complete vulvectomy","fCpt":"56620","f":598.11,"pct":-18.64},{"id":11,"cat":"Genitals & other","mName":"Revision of scrotum","mCpt":"55180","m":690.96,"fName":"Extensive vulva surgery (partial radical)","fCpt":"56630","f":976.63,"pct":-34.26},{"id":12,"cat":"Genitals & other","mName":"Drain prostate abscess","mCpt":"52700","m":443.92,"fName":"Drain ovarian abscess open","fCpt":"58820","f":347.01,"pct":24.51},{"id":13,"cat":"Genitals & other","mName":"Excision hydrocele","mCpt":"55040","m":339.89,"fName":"Excision Bartholins gland","fCpt":"56740","f":321.25,"pct":5.64},{"id":14,"cat":"Genitals & other","mName":"Penis/scrotoplasty","mCpt":"54360","m":721.8,"fName":"Perineoplasty","fCpt":"56810","f":276.86,"pct":89.11},{"id":15,"cat":"Genitals & other","mName":"Excision of sperm cord lesion","mCpt":"55520","m":465.95,"fName":"Excision of Bartholins","fCpt":"56740","f":321.25,"pct":36.76},{"id":16,"cat":"Prostate & uterus","mName":"Interstitial prostate","mCpt":"55875","m":780.08,"fName":"Interstitial cervix","fCpt":"55920","f":463.24,"pct":50.97},{"id":17,"cat":"Urinary tract","mName":"Insert tandem male","mCpt":"53444","m":792.62,"fName":"Insert tandem female","fCpt":"57155","f":286.01,"pct":93.94},{"id":18,"cat":"Urinary tract","mName":"Reconstruction of male urethra","mCpt":"54352","m":1408.35,"fName":"Reconstruction of female urethra","fCpt":"53430","f":975.27,"pct":36.34},{"id":19,"cat":"Urinary tract","mName":"Revise remove sling male","mCpt":"53448","m":1271.79,"fName":"Revise remove sling female","fCpt":"57287","f":754.33,"pct":51.08},{"id":20,"cat":"Urinary tract","mName":"Male sling insert uro/neck sph","mCpt":"53445","m":757.72,"fName":"Female insert mesh pelvic floor add on","fCpt":"57267","f":252.12,"pct":100.13},{"id":21,"cat":"Urinary tract","mName":"Reconstruct urethra male","mCpt":"53415","m":1126.07,"fName":"Revise urethra female","fCpt":"57220","f":353.11,"pct":104.51},{"id":22,"cat":"Urinary tract","mName":"Total urethrectomy male","mCpt":"53215","m":926.14,"fName":"Total urethrectomy female","fCpt":"53210","f":776.7,"pct":17.55},{"id":23,"cat":"Genitals & other","mName":"Partial removal of penis","mCpt":"54120","m":633.01,"fName":"Partial vaginectomy","fCpt":"57106","f":546.94,"pct":14.59},{"id":24,"cat":"Genitals & other","mName":"Removal of penis","mCpt":"54125","m":825.49,"fName":"Complete vaginectomy","fCpt":"57110","f":919.02,"pct":-10.72},{"id":25,"cat":"Genitals & other","mName":"Exploratory laparotomy male","mCpt":"49000","m":778.05,"fName":"Exploratory laparotomy female","fCpt":"58960","f":1009.84,"pct":-25.93},{"id":26,"cat":"Testes & ovaries","mName":"Excise lesion testis","mCpt":"54512","m":538.47,"fName":"Ovarian cystectomy","fCpt":"58925","f":781.44,"pct":-36.82},{"id":27,"cat":"Testes & ovaries","mName":"Removal of testis","mCpt":"54530","m":511.02,"fName":"Oophorectomy","fCpt":"58940","f":567.27,"pct":-10.43},{"id":28,"cat":"Testes & ovaries","mName":"Suspension/relocation of testes","mCpt":"54680","m":787.54,"fName":"Ovarian transposition","fCpt":"58825","f":722.81,"pct":8.57},{"id":29,"cat":"Testes & ovaries","mName":"Laparoscopic orchiectomy","mCpt":"54690","m":655.38,"fName":"Laparoscopic BSO","fCpt":"58661","f":662.83,"pct":-1.13},{"id":30,"cat":"Testes & ovaries","mName":"Laparoscopic orchiopexy","mCpt":"54692","m":755.01,"fName":"Laparoscopic ovarian transposition","fCpt":"58825","f":722.81,"pct":4.36},{"id":31,"cat":"Testes & ovaries","mName":"Removal of epididymis","mCpt":"54861","m":569.64,"fName":"Removal of fallopian tubes","fCpt":"58700","f":814.31,"pct":-35.36},{"id":32,"cat":"Testes & ovaries","mName":"Vas deferens vasectomy","mCpt":"55250","m":230.43,"fName":"Essure hysteroscopy","fCpt":"58565","f":466.97,"pct":-67.83},{"id":33,"cat":"Testes & ovaries","mName":"Orchiectomy with staging","mCpt":"54530 + 38770","m":1320.25,"fName":"Oophorectomy with staging","fCpt":"58950","f":1169.79,"pct":12.08},{"id":34,"cat":"Testes & ovaries","mName":"Extensive testis surgery","mCpt":"54535","m":744.5,"fName":"Removal of ovaries extensive","fCpt":"58943","f":1188.42,"pct":-45.93},{"id":35,"cat":"Testes & ovaries","mName":"Reduce testis torsion","mCpt":"54600","m":454.43,"fName":"Reduce ovarian torsion","fCpt":"58920","f":728.24,"pct":-46.3},{"id":36,"cat":"Genitals & other","mName":"Remove penis and LN","mCpt":"54135","m":1503.24,"fName":"Vaginectomy and LN","fCpt":"57109","f":1751.97,"pct":-15.28},{"id":37,"cat":"Testes & ovaries","mName":"Revise vas deferens/spermatic ducts","mCpt":"54901","m":1056.94,"fName":"Revise fallopian tubes","fCpt":"58740","f":917.67,"pct":14.11},{"id":38,"cat":"Prostate & uterus","mName":"TURP","mCpt":"52601","m":727.22,"fName":"Hysteroscopic myomectomy","fCpt":"58561","f":360.9,"pct":67.33},{"id":39,"cat":"Prostate & uterus","mName":"Remove prostate","mCpt":"55801","m":1093.2,"fName":"Hysterectomy","fCpt":"58150","f":1028.82,"pct":6.07},{"id":40,"cat":"Prostate & uterus","mName":"Extensive prostate surgery","mCpt":"55845","m":1355.49,"fName":"Extensive TAH","fCpt":"58285","f":1440.21,"pct":-6.06},{"id":41,"cat":"Prostate & uterus","mName":"Subtotal prostatectomy","mCpt":"55821","m":837.69,"fName":"Abdominal trachelectomy","fCpt":"57530","f":381.57,"pct":74.82},{"id":42,"cat":"Prostate & uterus","mName":"Prostatectomy","mCpt":"55840","m":1165.38,"fName":"TAH","fCpt":"58150","f":1028.82,"pct":12.45},{"id":43,"cat":"Prostate & uterus","mName":"Prostatectomy LND","mCpt":"55845","m":1355.49,"fName":"TAH BSO LND","fCpt":"58200","f":1362.6,"pct":-0.52},{"id":44,"cat":"Prostate & uterus","mName":"Perineal approach prostatectomy","mCpt":"55815","m":1751.97,"fName":"Radical vaginal hysterectomy","fCpt":"58285","f":1440.21,"pct":19.53},{"id":45,"cat":"Prostate & uterus","mName":"Radical prostatectomy perineal approach","mCpt":"55810","m":1301.27,"fName":"Radical vaginal hysterectomy","fCpt":"58285","f":1440.21,"pct":-10.14},{"id":46,"cat":"Urinary tract","mName":"Removal of bladder and LN","mCpt":"51575","m":1809.92,"fName":"Anterior exenteration (no code for anterior only)","fCpt":"58240","f":2967.84,"pct":-48.47},{"id":47,"cat":"Urinary tract","mName":"Cystectomy complete with conduit","mCpt":"51596","m":2344.32,"fName":"Pelvic exenteration","fCpt":"58240","f":2967.84,"pct":-23.48},{"id":48,"cat":"Biopsies & lesions","mName":"Biopsy penis","mCpt":"54100","m":121.32,"fName":"Biopsy vulva","fCpt":"56605","f":59.98,"pct":67.67},{"id":49,"cat":"Biopsies & lesions","mName":"Biopsy prostate","mCpt":"55700","m":129.11,"fName":"Biopsy endometrium","fCpt":"58100","f":63.71,"pct":67.84},{"id":50,"cat":"Biopsies & lesions","mName":"Destruction penile lesions extensive","mCpt":"54065","m":172.83,"fName":"Destruction vulvar lesions extensive","fCpt":"56515","f":216.88,"pct":-22.61},{"id":51,"cat":"Prostate & uterus","mName":"TURP","mCpt":"52601","m":727.22,"fName":"Hysteroscopy","fCpt":"58558","f":233.48,"pct":102.79},{"id":52,"cat":"Genitals & other","mName":"Drain prostate abscess","mCpt":"55720","m":453.07,"fName":"Drain ovarian abscess","fCpt":"58820","f":347.01,"pct":26.51},{"id":53,"cat":"Genitals & other","mName":"Excision varicocele","mCpt":"55530","m":354.12,"fName":"Excision Bartholins","fCpt":"56740","f":321.25,"pct":9.73},{"id":54,"cat":"Genitals & other","mName":"Excision hydrocele","mCpt":"55500","m":395.8,"fName":"Excision Bartholins","fCpt":"56740","f":321.25,"pct":20.79},{"id":55,"cat":"Genitals & other","mName":"Scrotoplasty","mCpt":"55175","m":367.68,"fName":"Perineoplasty","fCpt":"56810","f":276.86,"pct":28.18}]; window.AG.copy = {"shared":{"method":"Percent difference is the gap between the two payments divided by their average. Because neither the male nor female procedure serves as the baseline to compare against, the average is used, yielding a single figure for each pair. Negative values mean the procedure on women pays more.","source":"Source: Penn et al., Journal of Women\u2019s Health (2025), Table 3.","credit":"Graphic: Anusha Subramanian/Vox","logoLabel":"Vox","aboutButton":"About the data","about1":"Amounts are Medicare\u2019s 2023 national reimbursement rates when the procedure is done in a hospital or surgical center.","about2":"Researchers matched each procedure on male anatomy with a comparable one on female anatomy. Some procedures appear in more than one pair. CPT codes are the billing codes listed in the study. Look any code up in Medicare\u2019s Physician Fee Schedule tool.","difference":"pay difference","srHigherMale":"higher for the male procedure","srHigherFemale":"higher for the female procedure","paysMoreFemale":"Pays more for female","paysMoreMale":"Pays more for male","noMatches":"No matching procedures","cptPrefix":"CPT"},"pattern":{"hed":"Medicare often reimburses more for procedures on men","dek":"Percent difference in 2023 Medicare reimbursement rates among pairs of comparable male and female procedures. Each dot is one pair.","findPlaceholder":"Find a procedure or code","emptyCard":"Tap or hover over a dot to see the pair","moreHits":"and {n} more, highlighted on the chart"},"quiz":{"hed":"Can you guess what Medicare pays?","dek":"Drag the slider to estimate what Medicare pays for the second procedure.","round":"Round {i} of {n}","submit":"Submit","next":"Next pair","seeResult":"See the result","yourGuess":"Your guess {amount}","endLede":"{n} of {total}","endText":"matched pairs pay the surgeon more for the procedure on male anatomy.","legendMale":"Male","legendFemale":"Female","legendGuess":"Your guess","playAgain":"Play again with new pairs","seeAll":"See all 55 pairs"},"matchup":{"hed":"Similar procedures, different pay","dek":"What Medicare paid a surgeon for matched procedures in 2023","stripLabel":"Where this pair falls among all 55","noDifference":"No difference"},"explorer":{"hed":"Every matched pair, side by side","dek":"What Medicare paid a surgeon for each procedure in 2023","searchPlaceholder":"Search a procedure or code","legendMale":"Male procedure","legendFemale":"Female procedure","pctHeader":"% diff.","count":"{from}\u2013{to} of {n} pairs","countFiltered":"{from}\u2013{to} of {n} matching pairs","sortGap":"Sorted by largest difference","sortStudy":"Sorted in the study\u2019s order","sortPay":"Sorted by highest payment","essureFlag":"Essure was taken off the U.S. market in 2018."}}; (function () { var AG = (window.AG = window.AG || {}); AG.components = AG.components || {}; if (AG.__core) return; AG.__core = true; AG.CATEGORIES = ["Biopsies & lesions", "Testes & ovaries", "Prostate & uterus", "Urinary tract", "Genitals & other"]; var P = function (d) { return ''; }; AG.icons = { prev: P("M168.49,199.51a12,12,0,0,1-17,17l-80-80a12,12,0,0,1,0-17l80-80a12,12,0,0,1,17,17L97,128Z"), next: P("M184.49,136.49l-80,80a12,12,0,0,1-17-17L159,128,87.51,56.49a12,12,0,1,1,17-17l80,80A12,12,0,0,1,184.49,136.49Z"), shuffle: P("M240.49,175.51a12,12,0,0,1,0,17l-24,24a12,12,0,0,1-17-17L203,196h-2.09a76.17,76.17,0,0,1-61.85-31.83L97.38,105.78A52.1,52.1,0,0,0,55.06,84H32a12,12,0,0,1,0-24H55.06a76.17,76.17,0,0,1,61.85,31.83l41.71,58.39A52.1,52.1,0,0,0,200.94,172H203l-3.52-3.51a12,12,0,0,1,17-17Zm-95.62-72.62a12,12,0,0,0,16.93-1.13A52,52,0,0,1,200.94,84H203l-3.52,3.51a12,12,0,0,0,17,17l24-24a12,12,0,0,0,0-17l-24-24a12,12,0,0,0-17,17L203,60h-2.09a76,76,0,0,0-57.2,26A12,12,0,0,0,144.87,102.89Zm-33.74,50.22a12,12,0,0,0-16.93,1.13A52,52,0,0,1,55.06,172H32a12,12,0,0,0,0,24H55.06a76,76,0,0,0,57.2-26A12,12,0,0,0,111.13,153.11Z"), search: P("M232.49,215.51,185,168a92.12,92.12,0,1,0-17,17l47.53,47.54a12,12,0,0,0,17-17ZM44,112a68,68,0,1,1,68,68A68.07,68.07,0,0,1,44,112Z") }; AG.pairSep = " vs. "; AG.reduced = function () { return !!(window.matchMedia && window.matchMedia("(prefers-reduced-motion: reduce)").matches); }; AG.h = function (tag, attrs, kids) { var svg = /^(svg|g|circle|line|text|path|rect|tspan)$/.test(tag); var el = svg ? document.createElementNS("http://www.w3.org/2000/svg", tag) : document.createElement(tag); attrs = attrs || {}; for (var k in attrs) { var v = attrs[k]; if (v == null || v === false) continue; if (k === "text") el.textContent = v; else if (k === "html") el.innerHTML = v; else if (k.slice(0, 2) === "on") el.addEventListener(k.slice(2), v); else if (k === "class" && svg) el.setAttribute("class", v); else if (k === "class") el.className = v; else el.setAttribute(k, v === true ? "" : v); } (kids || []).forEach(function (c) { if (c == null || c === false) return; el.appendChild(typeof c === "string" ? document.createTextNode(c) : c); }); return el; }; AG.money = function (v, opts) { var round = opts && opts.round; return v.toLocaleString("en-US", { style: "currency", currency: "USD", minimumFractionDigits: round ? 0 : 2, maximumFractionDigits: round ? 0 : 2 }); }; AG.pct = function (p) { var a = Math.abs(p); return (a >= 10 ? a.toFixed(0) : a.toFixed(1)) + "%"; }; AG.pctExact = function (p) { return (p 0 ? "m" : "f"; }; AG.byId = function (id) { for (var i = 0; i 0 ? "higher for the male procedure" : "higher for the female procedure"; }; AG.t = function (key, vars) { var parts = key.split("."), v = AG.copy || {}; for (var i = 0; i < parts.length && v != null; i++) v = v[parts[i]]; if (typeof v !== "string") v = key; return v.replace(/\{(\w+)\}/g, function (m, k) { return vars && k in vars ? vars[k] : m; }); }; AG.tx = function (tag, key, attrs, vars) { var el = AG.h(tag, attrs || {}); var s = AG.t(key, vars); if (/ rr.right) dx = rr.right - tr.right; if (tr.left + dx < rr.left) dx = rr.left - tr.left; tip.style.transform = "translateX(" + Math.round(dx) + "px)"; } var openedAt = 0; function show(on) { if (on && !wrap.classList.contains("is-open")) openedAt = Date.now(); wrap.classList.toggle("is-open", on); btn.setAttribute("aria-expanded", String(on)); if (on) place(); } btn.addEventListener("mouseenter", function () { show(true); }); wrap.addEventListener("mouseleave", function () { show(false); }); btn.addEventListener("focus", function () { show(true); }); btn.addEventListener("blur", function () { show(false); }); btn.addEventListener("click", function (e) { e.stopPropagation(); var open = wrap.classList.contains("is-open"); show(!open || Date.now() - openedAt < 400); }); btn.addEventListener("keydown", function (e) { if (e.key === "Escape") show(false); }); return wrap; }; AG.pairRows = function (d) { var h = AG.h; return h("div", { class: "ag-pair" }, [["m", d.mName, d.mCpt, d.m], ["f", d.fName, d.fCpt, d.f]].map(function (x) { return h("div", { class: "ag-pair-row" }, [ h("p", { class: "ag-pair-name" }, [h("span", { class: "ag-ink-" + x[0], text: x[1] }), AG.cpt(x[2])]), h("p", { class: "ag-num ag-pair-val", text: AG.money(x[3]) }) ]); })); }; document.addEventListener("click", function () { var open = document.querySelectorAll(".ag-cpt-wrap.is-open"); for (var i = 0; i < open.length; i++) { open[i].classList.remove("is-open"); open[i].firstChild.setAttribute("aria-expanded", "false"); } }); AG.stat = function (d, opts) { var h = AG.h, s = AG.side(d); var num = opts && opts.exact ? AG.pctExact(d.pct).replace("\u2212", "") : AG.pct(d.pct); return h("p", { class: "ag-stat" + (opts && opts.small ? " is-small" : "") }, [ h("span", { class: "ag-stat-num", text: num }), AG.tx("span", "shared.difference", { class: "ag-stat-cap" }), h("span", { class: "ag-sr", text: " (" + AG.t(s === "m" ? "shared.srHigherMale" : "shared.srHigherFemale") + ")" }) ]); }; AG.onVisible = function (el, fn) { if (!("IntersectionObserver" in window)) return fn(); var io = new IntersectionObserver(function (es) { if (es.some(function (e) { return e.isIntersecting; })) { io.disconnect(); fn(); } }, { threshold: 0.2 }); io.observe(el); }; AG.axisEnds = function (extraClass) { var h = AG.h; return h("div", { class: "ag-axis-cap " + (extraClass || "") }, [ h("span", { class: "ag-ink-f" }, [h("span", { class: "ag-arrow", "aria-hidden": "true", text: "\u2190" }), AG.tx("span", "shared.paysMoreFemale")]), h("span", { class: "ag-ink-m" }, [AG.tx("span", "shared.paysMoreMale"), h("span", { class: "ag-arrow", "aria-hidden": "true", text: "\u2192" })]) ]); }; AG.header = function (o) { return AG.h("div", { class: "ag-hd" }, [ AG.tx("h2", o.hed, { class: "ag-hed" }), o.dek ? AG.tx("p", o.dek, { class: "ag-dek" }) : null ]); }; AG.footer = function () { var h = AG.h; var about = h("div", { class: "ag-about", hidden: true, id: "ag-about-" + Math.random().toString(36).slice(2, 8) }, [ AG.tx("p", "shared.about1"), AG.tx("p", "shared.about2") ]); var btn = AG.tx("button", "shared.aboutButton", { class: "ag-about-btn", type: "button", "aria-expanded": "false", "aria-controls": about.id }); btn.addEventListener("click", function () { var open = about.hidden; about.hidden = !open; btn.setAttribute("aria-expanded", String(open)); }); return h("div", { class: "ag-ft" }, [ AG.tx("p", "shared.method", { class: "ag-method" }), h("div", { class: "ag-ft-row" }, [ AG.tx("p", "shared.source", { class: "ag-source" }), AG.tx("p", "shared.credit", { class: "ag-credit" }), h("div", { class: "ag-ft-end" }, [btn, AG.ta(h("span", { class: "ag-logo", role: "img" }), "aria-label", "shared.logoLabel")]) ]), about ]); }; AG.mount = function (root) { var name = root.getAttribute("data-ag"); var fn = AG.components[name]; if (!fn || !AG.data) return; root.setAttribute("data-ag-mounted", ""); if (root.parentElement) root.style.setProperty("--ag-host", getComputedStyle(root.parentElement).fontFamily); root.innerHTML = ""; fn(root); if (typeof CustomEvent === "function") root.dispatchEvent(new CustomEvent("ag:mounted", { bubbles: true })); }; AG.mountAll = function () { var run = function () { var roots = document.querySelectorAll(".ag-root[data-ag]:not([data-ag-mounted])"); for (var i = 0; i 0; }).length; var sorted = AG.data.slice().sort(function (a, b) { return a.pct - b.pct; }); var sel = null, entered = false, landed = false, pos = {}; root.appendChild(AG.header({ hed: "pattern.hed", dek: "pattern.dek" })); var findIn = AG.ta(h("input", { type: "search", "aria-label": "Find a procedure on the chart", autocomplete: "off" }), "placeholder", "pattern.findPlaceholder"); var hits = h("ul", { class: "ag-pt-hits", "aria-label": "Matching pairs" }); root.appendChild(h("div", { class: "ag-pt-find" }, [h("div", { class: "ag-find", html: AG.icons.search }, [findIn]), hits])); var wrap = h("div", { class: "ag-pt-svgwrap" }); var svg = h("svg", { role: "img", tabindex: "0", "aria-label": "Beeswarm chart. " + nM + " of 55 pairs pay more for the male procedure. Use arrow keys to step through pairs." }); wrap.appendChild(svg); root.appendChild(wrap); root.appendChild(AG.axisEnds("ag-pt-cap")); var card = h("div", { class: "ag-pt-card", "aria-live": "polite" }); root.appendChild(card); root.appendChild(h("div", { class: "ag-sr" }, [h("table", {}, [ h("caption", { text: "Table 3, facility payments, 2023" }), h("tr", {}, ["Male procedure", "Payment", "Female procedure", "Payment", "Percent difference"].map(function (t) { return h("th", { text: t }); })) ].concat(AG.data.map(function (d) { return h("tr", {}, [d.mName, AG.money(d.m), d.fName, AG.money(d.f), AG.pctExact(d.pct)].map(function (t) { return h("td", { text: t }); })); })))])); root.appendChild(AG.footer()); function drawCard() { card.innerHTML = ""; if (!sel) { card.appendChild(AG.tx("p", "pattern.emptyCard", { class: "ag-pt-empty" })); return; } var d = sel; card.appendChild(AG.pairRows(d)); card.appendChild(AG.stat(d, { small: true })); } var circles = {}; function layout() { var W = wrap.clientWidth; if (!W) return; var narrow = W < 520; var r = narrow ? 5.5 : 7, gap = 1.5, D = 2 * r + gap; var padL = r + 4, padR = r + 4; var sx = function (p) { return padL + ((p - LO) / (HI - LO)) * (W - padL - padR); }; var placed = []; AG.data.slice().sort(function (a, b) { return Math.abs(a.pct) - Math.abs(b.pct) || a.id - b.id; }).forEach(function (d) { var x = sx(d.pct), cands = [0]; placed.forEach(function (p) { var dx = Math.abs(x - p.x); if (dx < D) { var dy = Math.sqrt(D * D - dx * dx); cands.push(p.y + dy, p.y - dy); } }); cands.sort(function (a, b) { return Math.abs(a) - Math.abs(b); }); for (var i = 0; i = D * D - 0.01; }); if (ok) { placed.push({ x: x, y: y, d: d }); pos[d.id] = { x: x, y: y }; break; } } }); var maxY = Math.max.apply(null, placed.map(function (p) { return Math.abs(p.y); })); var annH = 8, axisH = 22; var cy = annH + maxY + r + 6; var H = cy + maxY + r + 6 + axisH; svg.setAttribute("width", W); svg.setAttribute("height", H); svg.setAttribute("viewBox", "0 0 " + W + " " + H); svg.style.width = W + "px"; svg.style.height = H + "px"; var old = svg.querySelector(".ag-pt-axes"); if (old) old.remove(); var axes = h("g", { class: "ag-pt-axes" }); TICKS.forEach(function (t) { var x = sx(t); axes.appendChild(h("line", { class: t === 0 ? "ag-pt-zero" : "ag-pt-grid", x1: x, x2: x, y1: annH - 4, y2: H - axisH + 2 })); axes.appendChild(h("text", { class: "ag-pt-tick", x: x, y: H - 6, "text-anchor": "middle", text: t === 0 ? "0" : (t < 0 ? "\u2212" : "") + Math.abs(t) + "%" })); }); svg.insertBefore(axes, svg.firstChild); var dots = svg.querySelector(".ag-pt-dots"); if (!dots) { dots = h("g", { class: "ag-pt-dots" }); svg.appendChild(dots); } AG.data.forEach(function (d, i) { var c = circles[d.id]; if (!c) { c = h("circle", { class: "ag-pt-dot is-" + AG.side(d), r: r, cx: 0, cy: 0, "data-id": d.id }); c.style.transform = "translate(" + sx(0) + "px," + cy + "px)"; c.style.opacity = "0"; circles[d.id] = c; dots.appendChild(c); } c.setAttribute("r", r); var place = function () { c.style.transform = "translate(" + pos[d.id].x + "px," + (cy + pos[d.id].y) + "px)"; c.style.opacity = ""; }; if (entered) { if (landed) c.style.transitionDelay = "0s"; place(); } c.__place = place; c.__at = SWEEP * (d.pct - sorted[0].pct) / (sorted[sorted.length - 1].pct - sorted[0].pct); }); svg.__cy = cy; } function enter() { entered = true; var reduced = AG.reduced(); AG.data.forEach(function (d) { var c = circles[d.id]; c.style.transitionDelay = reduced ? "0s" : Math.round(c.__at) + "ms"; c.__place(); }); setTimeout(function () { landed = true; for (var k in circles) circles[k].style.transitionDelay = "0s"; }, reduced ? 0 : SWEEP + 950); } function select(d) { sel = d; for (var k in circles) circles[k].classList.toggle("is-on", sel && +k === sel.id); svg.classList.toggle("ag-pt-dim", !!sel); if (sel) circles[sel.id].parentNode.appendChild(circles[sel.id]); drawCard(); } function nearest(evt) { var b = svg.getBoundingClientRect(), x = evt.clientX - b.left, y = evt.clientY - b.top, best = null, bd = 22 * 22; AG.data.forEach(function (d) { var p = pos[d.id]; if (!p) return; var dd = (p.x - x) * (p.x - x) + (svg.__cy + p.y - y) * (svg.__cy + p.y - y); if (dd < bd) { bd = dd; best = d; } }); return best; } svg.addEventListener("pointermove", function (e) { if (e.pointerType === "mouse") { var d = nearest(e); if (d && d !== sel) select(d); } }); svg.addEventListener("click", function (e) { var d = nearest(e); select(d || null); }); function outside(e) { if (!document.contains(root)) return document.removeEventListener("click", outside, true); if (!sel || (e.target.closest && e.target.closest(".ag-pt-svgwrap, .ag-pt-card, .ag-pt-find"))) return; select(null); } document.addEventListener("click", outside, true); svg.addEventListener("keydown", function (e) { var i = sel ? sorted.indexOf(sel) : -1; if (e.key === "ArrowRight" || e.key === "ArrowUp") { select(sorted[Math.min(sorted.length - 1, i + 1)]); e.preventDefault(); } else if (e.key === "ArrowLeft" || e.key === "ArrowDown") { select(sorted[Math.max(0, i -1; }) : []; for (var k in circles) { var hit = match.some(function (d) { return d.id === +k; }); circles[k].classList.toggle("is-hit", hit); if (hit) circles[k].parentNode.appendChild(circles[k]); } svg.classList.toggle("ag-pt-finding", !!q); if (match.length === 1) select(match[0]); hits.innerHTML = ""; if (!q) return; if (!match.length) { hits.appendChild(AG.tx("li", "shared.noMatches", { class: "ag-pt-none" })); return; } match.slice(0, 3).forEach(function (d) { var b = h("button", { type: "button", class: "ag-pt-hit" }, [ h("span", { class: "ag-ink-m", text: d.mName }), " vs. ", h("span", { class: "ag-ink-f", text: d.fName }) ]); b.addEventListener("click", function () { select(d); }); hits.appendChild(h("li", {}, [b])); }); if (match.length > 3) hits.appendChild(AG.tx("li", "pattern.moreHits", { class: "ag-pt-none" }, { n: match.length - 3 })); } findIn.addEventListener("input", find); drawCard(); layout(); if ("ResizeObserver" in window) { var lastW = 0; new ResizeObserver(function () { if (wrap.clientWidth !== lastW) { lastW = wrap.clientWidth; layout(); } }).observe(wrap); } AG.onVisible(wrap, function () { setTimeout(enter, 120); }); }; })(); window.AG.mountAll();

King, the director of reproductive bioethics at Harvard Medical School Center for Bioethics and a contributor on the study, believes that when the RVU system was created back in the 1990s, gynecological services were largely ignored, leaving the specialty undervalued from the start. While Medicare and Medicaid Services have undertaken some efforts to make RVUs more equitable across specialties over the years, that undervaluation has persisted. 

That problem may come down to how those values are determined in the first place — and who determines them. RVUs are set by a committee of doctors convened by the American Medical Association (AMA), with most of the seats allocated to members of major medical societies. The committee surveys different doctors on the time and skill required for procedures in their specialties. Based on these responses, the committee recommends values for each service to the federal government, which has historically accepted nearly 90 percent of them.

While the data quality of the underlying surveys has improved over the years, it is still not very high, said Dr. Miriam Laugesen, a tenured associate professor of health policy and management at Columbia University Mailman School of Public Health. Because the committee’s process isn’t transparent, it is often unclear what evidence its valuations rest on. This leads to distortions of all kinds, she said.

“It’s not a government process; It’s not a federal advisory committee,” Laugesen said. “It’s just a committee that was put together by the [AMA]. It’s pretty unusual in terms of how policy is made.”

In particular, King said that the surveys have a very low response rate from some specialties and are only sent to a small subset of doctors. She has never received a committee survey in the 17 years that she has practiced. 

The American College of Obstetricians and Gynecologists (ACOG) has a core seat on the committee that determines RVUs. But most ACOG members are general OB-GYNs, who split their time between obstetrics and gynecology and typically operate relatively rarely. The surgeons who perform the bulk of gynecologic operations are subspecialists – gynecologic oncologists, urogynecologists, and minimally invasive gynecologic surgeons — who complete an additional fellowship after residency. They mainly belong to their own societies and don’t have a seat at the table when RVUs are being determined. 

“From a purely cynical or economic standpoint, [ACOG] has no reason to advance billing for gynecology. It doesn’t represent a large portion of the practices of their members,” said King, adding that ACOG has been heroic in its efforts to obtain reimbursement equity for its own members. (One unintended possible result of that advocacy is that pushing for a smaller pay gap for services related to pregnancy has in turn sent the message that women’s bodies are literally worth less, and are less deserving of care when they’re not engaged in the god-given duty of reproduction.)

The result is that doctors in specialties like OB-GYN who operate infrequently are answering the surveys about complicated surgical procedures that gynecologic surgeons perform more frequently. King said that her surgical schedule aligned more closely with those of general surgeons. For example, she operates two to three times a week whereas, according to her, an average OB-GYN will likely operate once a month. 

“So they’re not the right people to be answering these surveys. They [the survey committee and ACOG] don’t target the surveys to people who operate a lot,” she said. 

Part of the problem with using surveys to determine a key foundation of medical reimbursements is that the data is self-reported by doctors. This is especially relevant when more objective avenues may be available. One of those avenues is the American College of Surgeons’ National Surgical Quality Improvement Program, which is an initiative that collects and manages key surgical data to track quality and improvement in surgical fields, including the actual time spent performing surgical procedures, making it a more definitive measure than self-reported surveys.

Dr. Shitanshu Uppal, a gynecologic oncologist and division chief for gynecology oncology services at the University of Michigan, and his colleagues analyzed 901,917 surgeries using both the National Surgical Quality Improvement Program as well as the self-reported surveys used to determine RVUs. They found that median RVUs per hour vary widely between specialties. Gynecology had the third-lowest median RVUs per hour of all the specialties studied. In effect, that means that gynecological surgeons are paid less for every hour that they work. 

The researchers also found that compared to the operating times logged for real surgeries in the Surgical Quality Improvement Program, surgeons in certain specialties tended to report longer procedure times in the self-reported surveys sent out by the RVUs committee. Specialties that reported longer operating times were more likely to be awarded higher RVUs, leading to greater hourly rates of reimbursement.

According to Uppal’s analysis, urologists — a profession most often associated with procedures on men because their work routinely concerns the prostate and the testicles — reported times that exceeded the baseline data by a median of 20 minutes. By contrast, estimates from gynecologists only exceeded the actual time by a median of five minutes, meaning that urologists tended to overestimate their time spent in surgery by four times as many minutes. Generally, urologists earn much more than general OB-GYNs, who in turn earn more than other subspecialties like gynecologic surgery. Despite having access to reliable electronic records of operating time, Uppal and his colleagues note, the AMA committee still continues to use self-reported operating times, which influences their RVU recommendations, ultimately cementing disparities in female-specific procedures. 

“The system that they have now developed over time,” King said, “now creates discrimination because of its complexity.” She added that this is how systemic discrimination is perpetuated, even if systems or rules appear seemingly neutral.

How low reimbursement rates make women’s lives worse

The US healthcare system has never been especially good at putting its money where its mouth is when it comes to women’s health. Experts have been sounding the alarm on sex-based disparities in medical billing for a long time — long enough that governing authorities like the committee responsible for RVUs and ACOG have had time to respond to the concerns. 

Over the years, the gap between male-specific procedure reimbursements and female-specific reimbursements has decreased slightly. But researchers of the Price and Prejudice study showed that between 2003 and 2023, there were no statistically significant improvements to the pay disparities. Comparing a smaller set of procedures across 1997, 2015, and 2023, they found that the gap had narrowed only minimally.

One common justification that ACOG provides for the pay gap is that obstetrics and gynecologic services see a higher-than-average share of patients on Medicaid, which pays doctors less than other insurers. King agreed this is a real factor, but it doesn’t explain why Medicare itself values procedures on women lower in the first place. And as her account of double discrimination makes clear, undervaluing gynecology ultimately affects women everywhere for the worse.

“I have patients who are waiting for surgery with me for a year at a time. I mean, that’s crazy.”

Dr. Louise King

Lower reimbursements in gynecologic surgery disproportionately affect female surgeons because they represent a majority of this specialty. It’s not just the surgeons’ salaries that are affected. Hospitals and facilities work on a revenue-based model — if gynecologic surgeries are not bringing in enough money, institutions tend to allocate fewer resources to those procedures. That, in turn, can limit access to operating rooms, surgical staff, and operating times. 

“I have patients who are waiting for surgery with me for a year at a time. I mean, that’s crazy,” King said. As a minimally invasive gynecologic surgeon, she surgically treats women with endometriosis, fibroids, cysts, or other such conditions.

It also affects the training that gynecologic surgeons receive. When there aren’t enough resources to operate regularly, opportunities to train residents are rarer than they should be. The result is that low reimbursement rates have contributed to a workforce of low-volume gynecologic surgeons who are sometimes not as well-trained as other surgeons who operate frequently.

The relationship between volume of surgeries performed and patient outcomes is well-documented in other fields. Research shows that surgeons who operate infrequently have worse outcomes, including more complications before, after, and during surgeries, compared to surgeons who operate regularly. 

Low-volume gynecologic surgeons — who perform a particular procedure less than 12 times a year — have significantly higher rates of causing bowel and urinary tract injuries in their patients. Especially in benign gynecological surgery (procedures not related to cancer), having surgeons who operate frequently also increases the number of minimally invasive procedures performed, which is related to better patient outcomes. 

Payment reform is an uphill battle, but not a lost cause

It takes multiple years and pressure from different entities to update or add new RVUs for procedures — but crucially, it is not impossible. The first few steps to creating a sustainable system might look like submitting gynecology-related procedure codes for reevaluation to the AMA committee or prompting a congressional report on the matter. 

For example, for years there has only been one billing code for endometriosis, regardless of the complexity of surgery or technique used. This disincentivizes surgeons from taking on complicated surgical cases of endometriosis because of the low reimbursement rate. Reevaluating that rate or diversifying the various surgical approaches that different cases require would help affected women get the care they deserve.

Medicare’s payment system also has what’s called a budget neutrality rule, which dictates that significantly increased payments for any given procedure must be offset by cuts elsewhere. The AMA itself believes that reforming this rule would make it easier to work toward reimbursement equity for female-specific procedures.  

Experts have suggested creating gynecology-specific conversion factors to bring parity to a system that naturally undervalues these procedures, while others think that eliminating sex-specific billing codes whenever possible is the right move. For example, the code for genitalia biopsies is different for men and women. This means that those procedures can be reimbursed differently even though they are essentially similar. Adopting one sex-neutral code for any genitalia biopsies would avoid this. While the reform required for this would be substantial, researchers believe that it would narrow the billing gap significantly.     

Authorities often justify lower RVUs for female-specific procedures by pointing to training: Gynecologists spend fewer years learning to operate than urologists and other higher-paid surgical specialists, according to King.

Historically, surgeons who operated on the female pelvis trained in ways that were more closely aligned with general surgeons than OB-GYNs. When obstetrics and gynecology merged into one specialty in the 1900s, the training for gynecologic surgery was truncated. 

“General OB-GYNs will train for four years and of that four years about 18 months is devoted to surgical training in gynecology,” said King, contrasting the new training period to those of general surgeons, which is in years. 

She believes that training periods should be increased for gynecologic surgeons. That change would secure better reimbursement for the speciality, while also producing better trained surgeons who would be more attuned to advances in minimally invasive surgery that will ultimately improve the outcomes for their female patients. In some cases, the experience gained during a two-year fellowship in gynecologic surgery was equivalent to 19 years in practice.  

In their initial work on double discrimination, Watson and King argued that failing to implement solutions for parity is tantamount to saying that female patients deserve less well-trained surgeons than male patients.  

As with most women’s health issues, it is unclear if this systemic disparity in medical reimbursement is the result of conscious misogyny or a by-product of ignorance. But that question of origins matters little when its consequences have been enshrined in medical policy, with lasting consequences for the practice of medicine more generally. We have allowed this wage gap to persist, even as many have sounded the alarm for decades. It is long past time to heed their warnings.

October 7, 2026, 5:50 pm ET: This story was originally published on October 2 and has been updated to include the sourcing on the RVU gap resulting from training for gynecologic surgery.  

You’re supposed to get one free doctor’s visit every year. So why are so many Americans being charged?

22 October 2026 at 12:11
an illustration of a woman in a doctor’s office. A doctor is waiving to her from the other side of an exam table covered in a giant bill.

After moving to West Virginia last year, Steve Kuo signed up for a new insurance plan that would cost him $500 a month. But there was one upside: He knew he was entitled to a free preventive visit. He wanted to take advantage of it, so he made an appointment at a clinic near his new home.

But then when he got there, they asked about his medical history and he mentioned prior kidney problems. When he received a bill a few weeks later, he had been charged twice for the same appointment: Once as that free preventive visit, once as an “office sick visit” because of the kidney conversation. He was flummoxed — and very annoyed, as he shared on social media. “No copayment means no copayment, exactly as stated in the insurance guidelines,” Kuo told me over email. “What is written and agreed upon should be honored.”

He is far from alone. On Reddit, I easily found more than a dozen examples in just the past year of people getting a surprise bill for what they thought was going to be a free visit. 

One woman posted a nearly $1,000 bill she’d received for what she thought was going to be a preventive gynecology visit. Another woman said that she ended up facing roughly $3,000 bills because she was given an ultrasound (which she said she didn’t request) at a preventive visit, and then her blood draw was sent to an out-of-network lab. Another person lamented that they had been billed $170 for an office visit because they had briefly mentioned back stiffness.

It’s not supposed to be like this. Americans don’t get much when it comes to our healthcare, but most of us are supposed to be entitled to at least one thing: Once every year, no matter your health insurance, you can go to the doctor with the goal of preventing future health problems by discussing important vaccinations, cancer screenings, and cardiovascular health screenings. The Affordable Care Act made that the law in 2010.

But more than 15 years later, people all over the country are walking into their doctor’s office, thinking they’re entitled to that one free visit every year, and walking out being billed for a sick visit, blood labs, and more. Researchers estimate that Americans spend tens of millions, maybe hundreds of millions of dollars every year on services that are supposed to be free under the ACA.

Dr. Yalda Jabbarpour, a family physician in the Washington, DC, area and medical director of the Robert Graham Center for Policy Studies, told me she still deals all the time with people’s confusion about what a preventive visit really means.

“Every single time I’m in the clinic, this issue comes up with a patient. And it’s sad that it comes up,” Jabbarpour told me. “In my mind, the blame is not to be put on the patient. The blame is not to be put on the physician. Really, this points to a bigger system issue that we need to solve.”

How could a seemingly simple promise of one free annual doctor’s visit result in a situation so convoluted that patients and doctors are still struggling with it nearly two decades later? And how might we fix it?

Patients are getting surprise bills from their doctors — and they’re pissed off

The goal of the ACA was to expand coverage and make sure health insurance would be comprehensive to actually help people stay healthy. As part of that project, the authors of the law added a mandate for insurers to cover those services, including an annual wellness exam. The problem is, they did not define what the parameters of that preventive visit actually were, said Alex Hoagland, a healthcare economist at the University of Toronto. 

“It didn’t establish a clear definition of…all the diagnosis codes and procedure codes and how frequently you get that combination within a year,” he said. “They don’t define what actually is preventive care and what’s not.”

Do’s and don’t’s for a preventive visit:

  • Topics that should be free to talk about: routine vaccinations, many cancer screenings, screenings for diabetes and cardiovascular health, contraception.
  • Topics that could lead to you getting charged: chronic pain, prior medical problems, other physical and mental health symptoms (including depression).
  • If you are a first-time visitor at a doctor’s office, you may also be charged a “new patient” fee.

That has left each insurer to define a preventive visit on their own — and that’s where the perverse incentives that leave patients in a lurch begin. Preventive visits are supposed to be reserved strictly for screenings and talking about other preventive measures you can take to protect your long-term health, but you may get billed for an “office visit” or a “sick visit” if you talk about any specific symptom you’re experiencing, the same as if you had come in because you had the flu. 

Health insurers have an incentive to keep the definition of preventive care as narrow as possible, so they have to pay fewer claims without any contribution from the patient. At the same time, doctors want to be paid for the actual services that they are providing. If somebody does bring up a bigger health problem during a preventive visit, then the doctor reasonably wants to be paid accordingly. 

“I know, particularly in the healthcare space, it’s really popular to blame one party or another, and here I don’t think it’s a matter of corporate greed or physician incompetence or whatever,” Hoagland said. “It’s just a natural mismatch of incentives.”

So the reality is that “one free doctor’s visit” sounds straightforward, but, in practice, it’s much more complicated. You as the patient might think of it as one visit, but in our fee-for-service healthcare system, where providers bill based on each specific thing they do, it’s not. The conversation about your vaccination may be free — but asking about your back pain is not. If you get blood tests ordered, that’s another line item. The list goes on. “It’s not like you walk into a doctor’s office and it’s just one thing that happens, right?” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University. “It’s multiple different things that are happening when you go into a doctor’s office.”

Part of the problem may be that it’s one free visit. We Americans are consumers at heart: Tell us we’re going to get something for free and we want to take advantage of it. But having just one free visit may also lead to people bringing a laundry list of questions to that preventive visit, because they think of it as their only chance to ask everything of their doctor. 

That makes it easy for the discussion to tip over into a sick visit — and not only does that lead to a surprise bill, it can also crowd out the conversation about prevention that the visit is supposed to be focused on.

“What ends up happening a lot…is that a patient comes in for their annual visit, and in their mind, that is their time to bring up every single thing that’s been happening during the year, because they see it as the free visit to bring up everything that’s happened during the year. For some patients, that takes up the entire visit,” Jabbarpour told me. “They leave, and it’s like, ‘Oh my god, we forgot to do all the screening things: the vaccinations, the cancer screenings, and the cardiovascular risk screening.’ And then something happens down the line because you never address those screenings.”

A 2021 study by Hoagland and Paul Shafer, both of Boston University at the time, estimated that Americans with employer-sponsored insurance had in 2018 alone paid between $75 million and $219 million in medical bills that should have been free. They were more likely to be charged for things like contraception or cholesterol and diabetes screenings, with individuals sometimes paying hundreds of dollars for those services.

Hoagland told me he had been billed for preventive visits because he has type 1 diabetes and the system automatically categorized his appointment as a diabetic visit. Earlier this year, he co-authored a study that found people with chronic conditions were more likely to be charged for preventive care. Corlette said that she too had recently been charged for what was supposed to be a preventive visit after she mentioned an issue as an aside. And these are folks who study health care for a living.

“It was literally maybe a 10-second conversation where I would ask the doctor a question about something,” she said. “And that triggered it.”

Colonoscopies are another dramatic example of how this issue plays out in real life; Corlette told me the procedure was one of the first services where this fuzzy line between prevention and treatment under the ACA became obvious. People go under for what is supposed to be a preventive colonoscopy. But then their doctor finds a polyp and decides to remove it — good clinical practice, but as a result, their patient could end up being charged thousands of dollars because the colonoscopy was no longer preventive once that polyp was snipped.

“All of a sudden, that would trigger what the patient thought was a preventive service into a cost-sharing obligation,” Corlette said. “Colonoscopies can be thousands of dollars. That was when we were first like, ‘Oh, yeah, this is a more complicated area than I think the lawmakers that drafted this provision originally envisioned.’”

How the US could fix our preventive visit headaches

The ACA’s preventive visit promise was clearly well-intentioned and it’s worth remembering that, if you look in the aggregate, more Americans are getting more free preventive care than they did before the law was passed. The problem, as much as anything, is expectations: People think they’re entitled to a free visit and are understandably frustrated when they get billed for it.

“The difference is before the Affordable Care Act, maybe they anticipated some kind of cost-sharing,” Hoagland said. “But after, they expect it to be free.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

It doesn’t have to be this way. Corlette’s team at Georgetown University recently released a proposal that Americans be entitled to three primary care and two urgent care visits every year with no cost-sharing. This approach has two virtues, she told me: It will help people feel like they are actually getting value from their insurance — the very complaint that Steve Kuo raised — and, because we know primary care helps prevent problems down the road, it should also improve people’s health in the long term. Take the pressure off that one free visit and let people see the doctor a few times a year without worrying about being charged.

“In employer-based insurance, a lot of people feel like, ‘What the hell am I getting for my premium each month?’” Corlette said. “We wanted people to feel like they’re getting good value, and we wanted to get to better population health.”

Hoagland also endorsed the idea of at least one free physician’s visit every year, no matter what’s discussed. In the long term, Jabbarpour said she’d like to see copays eliminated entirely for primary care. 

But any payment reforms are not going to happen immediately. What can we do right now?

For one, doctor offices could make an effort to be as transparent as possible. Jabbarpour’s MedStar system has started calling people a couple of days before their appointment with a brief script that tells the patient that they could be charged if the conversation with their doctor touches on additional medical problems. If your doctor’s office doesn’t proactively bring it up, ask when you schedule your appointment or when they call you to confirm it. Worst-case scenario, ask your provider what they consider preventive care when your visit begins. You might also want to educate yourself on what services are generally considered preventive and should be available for free: Your insurer may make that information available on their website, or KFF has a database you can peruse.

It’s not a perfect solution. “What ends up happening is patients come in, and they say, ‘I know I’m not supposed to talk to you about anything else, so I’m not going to tell you about anything else.’ And you don’t want that to happen,” Jabbarpour said. You should ask your doctor directly: What do you consider to be preventive care? Establish boundaries at the start. That way, you can at least be aware if you are going to get charged because the conversation crossed the line to discussing an active health problem.

And if you want to see the underlying laws change, start organizing. Contact your state and federal reps and ask them what they are doing to ensure this stops happening. Things could be different: Jabbarpour said she hopes to one day work in a health system where the cost of a single primary care visit isn’t so high-stakes, where doctors and their patients can manage their health according to their particular needs, rather than worry about how to bill for one specific conversation that covers the whole range of somebody’s health — like primary care is supposed to do.

“I think some patients can be managed by seeing us once every year, once every two years, and some patients need to see us monthly,” Jabbarpour told me. “To put all patients in the same box and say you can only see your primary care physician once a year if you want it paid for, it makes zero sense.”

This story was originally published in The Highlight. To get access to member-exclusive stories like this every month, become a Vox Member today.

❌